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Identification  of  novel  biomarkers  of  breast  and  prostate  cancers  to  supplement  current  
diagnostic,   prognostic   and   predictive   tools   is   an   important   clinical   need.      Interaction  
between  the  host’s   immune  system  and   tumours   is   reflected   in  detectable  changes   in  
profiles  of  proteins   in  blood  cells  and  therefore   these  cells  can  be  a  source   for  cancer  
biomarkers.  In  a  previous  investigation  conducted  in  our  laboratory,  a  panel  of  proteins  
differentially  expressed  in  white  blood  cells  (WBCs)  of  patients  with  primary  and  advanced  
breast   cancer   (BRCA   and   ABC   cohorts,   respectively)   was   identified   using   integrated  
approaches.  The  aim  of  the  present  study  was  to  assess  the  biomarker  potential  of  five  
proteins:  Serpin  B1,  Lipocalin  2,  Copine  3,   Integrin  a4  and  5LOX,  using  Western  blot,  
immunofluorescence,   flow   cytometry   and   ELISA   techniques.   Serpin   B1,   Lipocalin   2,  
5LOX  and  Copine  3  were  present  in  neutrophils,  whereas  Integrin  a4  was  detected  in  T-­
lymphocytes.  Significantly  higher  levels  of  Serpin  B1  and  Lipocalin  2,  and  lower  levels  of  
Integrin  a4  were  observed  in  WBCs  in  the  BRCA  cohort  compared  to  healthy  individuals,  
suggesting   their   utility   as   early   breast   cancer   biomarkers.   Levels   of   Serpin   B1   and  
Lipocalin  2  increased  and  Integrin  a4  decreased  as  the  disease  advanced,  indicating  their  
utility   as   biomarkers   of   poor   prognosis.   Lower   basal   levels   of   Serpin   B1   in   patients  
undergoing  chemotherapy  and  endocrine  treatment  correlated  with  complete  response  to  
treatment.  Additionally,  the  utility  of  BORIS  as  a  diagnostic  marker  was  investigated  in  
plasma  of  breast  cancer  patients  and  urinary  sediments  and  exosomes  of  prostate  cancer  
patients.  The  presence  of  BORIS  autoantibodies  was  demonstrated  in  plasma  of  breast  
cancer  patients.  The  highest  levels  of  BORIS  mRNA  were  detected  in  urine  of  prostate  
cancer  patient  with  the  advanced  disease.  This  indicates  potential  of  the  BORIS  for  breast  
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Chapter  1:  Introduction  
1.1  Cancer  
Breast  and  prostate  cancer  are   the   two  most  common   types  of  cancer   in  women  and  
men,  respectively.  Typically,  both  types  of  cancer  are  sex  hormone-­dependent  and  have  
underlying  biological   similarities.   The   sex   hormones  oestrogen  and  androgen  are   key  
drivers  of   both   prostate   and  breast   cancer.  Therefore,   the   inhibition   of   oestrogen  and  
androgen  receptors,  as  well  as  key  enzymes  involved  in  steroid  metabolism,  are  some  of  
the  therapeutic  strategies  that  can  be  used  to  combat  the  disease  (Risbridger  et  al.  2010).  
Cancer   is   a   disease   characterised   by   uncontrolled   cell   proliferation   caused   by   the  
accumulation  of  multiple  abnormalities  that  affect  cell  regulatory  mechanisms.  Mutations  
accumulate  during  the  life  cycle  of  a  cell.    Under  normal  physiological  conditions,  the  cell  
recognises   these   mutations   and   undergoes   programmed   cell   death   (apoptosis)   by   a  
number   of   pathways   (intrinsic,   extrinsic   and  cytotoxic  T-­lymphocyte).  However,  during  
oncogenesis,  a  cell  acquires  a  series  of  mutations  known  as  “driver  mutations”,  which  
confer   a   selective   growth   advantage.   To   date,   140   genes   that   can   promote   driver  
mutations  have  been  identified  (Vogelstein  et  al.  2013).  Following  these  driver  mutations,  
the  cell   transitions   from  normal  physiological,   to  precancerous  and  finally  a  cancerous  
cell.      Post   oncogenesis,   the   cell   will   acquire   numerous   other   mutations,   known   as  
“passenger  mutations”,  irrelevant  to  tumour  progression  .  
During  cancer  progression  and  therapy,  tumour  cells  adapt  to  their  microenvironment  in  
the  same  manner  in  which  species  evolve,  resulting  in  heterogeneity  between  cells  of  the  
same   tumour   type   and   subtypes.   This   process   impacts   patient   prognosis,   treatment  
response   and   can   explain   the   failure   of   many   prognostic   and   predictive   biomarkers  
(Gerlinger  et  al.  2014).  
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1.1.1  Breast  cancer    
1.1.2  Mammary  glands  under  normal  physiological  conditions    
The  mammary  glands  are   the  secretory  organs  unique   to   the  Mammalia  class.  Unlike  
most  organs  of   the  body   that   fully  develop  during  embryogenesis,  breast  development  
continues  through  puberty  reaching  maturity  by  the  end  of  pregnancy  and  the  lactation  
phase.    The  breast  is  a  modified  apocrine  gland  located  in  the  chest  wall,  composed  of  
glandular  (secretory)  and  adipose  (fatty)  tissue  supported  by  a  fibrous  connective  tissue  
framework  (Figure  1.1)  The  functional  unit  of  the  breast  is  the  terminal  duct  lobular  unit  
(TDLU).    The  mammary  epithelium   is  composed  of  basal  and   luminal  cells.  The  basal  
epithelium  consists  of  contractile  myoepithelial  cells.  These  cells  form  the  outer  layer  of  
the  organ  and  function  to  secrete  milk  from  the  lactating  gland.  The  luminal  epithelium  
generates   the   inner   layer  of   the  breast,  whilst  also   forming  ducts  and  secretory  alveoli  
(Prater  et  al.  2014).  
There   are   three   distinct   stages   of   breast   development–   embryonic,   pubertal   and  
reproductive.  The  mammary  gland  begins  to  form  at  4  weeks  of  gestation  when  ectoderm  
proliferates  to  form  the  mammary  or  milk  line.  Which  is  further  categorised  into  individual  
placodes  following  the  formation  of  mammary  buds,  culminating  in  the  formation  of  the  
primary  ductal  structure  and  terminal  end  buds  (TEB)  (Hennighausen  &  Robinson  2005).  
This  process  is  coordinated  under  the  same  signals  that  regulate  teeth,  sweat  glands  and  
hair  follicle  formation  (Robinson  2012).      
Following  birth,  mammary  development   is  suspended.  At  puberty,  under   the  control  of  
oestrogen  and  progesterone,  with  each  menstrual  cycle  the  breast  expands  considerably,  
involving  growth  and  branching  of  the  secondary  and  tertiary  ductal  structures.    
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The  major  part  of  breast  development  takes  place  during  pregnancy  and  lactation.  During  
this  stage,  under  the  regulation  of  prolactin  and  progesterone,  ducts  continue  proliferation  
forming  milk  secreting  structures  known  as  alveoli.  The  alveoli  join  up  to  form  lobules.  At  
the  end  of   lactation,   the  expanded  epithelium  undergoes  apoptosis  and  the  mammary  




Figure  1.1  Anatomy  of  Breast.  Front  view  and  side  view  of  normal  breast  tissue  showing  
ducts,  lobules,  fatty  tissue,  muscle  and  lymph  nodes.  (Source  https://cancer.osu.edu  Last  
accessed  9/02/2018).    
23  
  
1.1.3  Breast  cancer  epidemiology    
Breast  cancer  is  the  second  most  common  type  of  cancer  worldwide  in  women  after  lung  
cancer.  In  the  UK,  approximately  one  in  eight  women  are  diagnosed  with  breast  cancer  
and,  although  the  advances  in  diagnostics  and  treatment  are  reflected  in  the  increasing  
survival   after   diagnosis,   17,000   women   still   die   from   breast   cancer   every   year.   The  
incidence  of  breast  cancer  increases  with  age  and  generally  reaches  a  peak  in  the  50-­60  
age  group.  According  to  current  national  statistics,  the  five  years  survival  rate  for  stage  1  
breast  cancer  is  100%  and  22%  for  stage  4  metastatic  breast  cancer  (Cancer  Research  
UK,  2012).
  
1.1.4  Risk  factors  
The  origin  of  breast  cancer  is  not  known.  However,  many  risk  factors  have  been  identified.  
Less   than   10%   of   breast   cancers   can   be   attributed   to   an   inherited   genetic  mutation.  
Examples  include  the  BRCA1  and  BRCA2  genes  involved  in  DNA  repair.  Individuals  who  
inherit  mutant  alleles  of  BRCA1  and  BRCA2  possess  a  life-­time  risk  of  developing  breast  
and  to  a  lesser  extent  ovarian  cancer  (Weinberg  2014).  However,  the  mutations  in  these  
genes  only  account  for  40%  of  hereditary  breast  cancers.  Since  the  discovery  of  BRCA1  
and  BRCA2  more  than  15  years  ago,  understanding  in  how  cells  repair  DNA  damage  has  
helped  to  identify  other  genes  involved  in  the  repair  network.  Those  that  have  been  found  
associated  with  increased  cancer  risk  are  ATM,  CHEK2,  PALB2  and  BRIP1.  ATM  is  the  
serine/threonine   kinase   involved   in   DNA   repair   and   cell-­cycle   check   point   control  
(Renwick  et  al.  2006).  CHEK2  is  a  serine/threonine  kinase  that  activates  downstream  of  
ATM  and  mediates  cell   cycle  arrest   following  DNA  damage  and/or  phosphorylation  of  
BRCA1/p53   (Nevanlinna   &   Bartek   2006).   PALB2   modulates   the   recruitment   of  
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BRCA1/BRCA2  to  the  site  of  DNA  damage  (Nepomuceno  et  al.  2017).  BRIP1  has  a  role  
in  BRCA1  dependent  DNA  repair  (Seal  et  al.  2006).  
It  is  known  that  breast  cancer  is  sex  hormone  dependent.  In  postmenopausal  women,  the  
positive  correlation  between  circulating  oestrogen  levels  and  the  risk  of  breast  cancer  is  
well  established.  The  available  data  for  premenopausal  women  shows  a  similar  pattern,  
in  which  the  breast  cancer  risk  increases  with  increasing  sex  hormone  concentration  (Key  
2013).    
An  epidemiological  study  published  in  1969  reported  a  higher  incidence  of  breast  cancer  
among  nuns  (Fraumeni  et  al.  1969).  Since  then,  many  studies  have  demonstrated  that  
early   birth   and   increased   numbers   of   full-­term   pregnancies   significantly   decrease   a  
woman’s  risk  of  developing  breast  cancer  (Clavel-­Chapelon  &  Gerber  2002;;  Dall  et  al.  
2017).  
Older  studies  have  reported  an  early  menarche  and  late  menopause  as  an  important  risk  
factor  for  breast  cancer  (Apter  &  Vihko  1983).  However,  more  recent  findings  have  not  
shown  a  significant  correlation  (Opdahl  et  al.  2011).  
An  increase  in  BMI  has  been  reported  to  be  positively  associated  with  post-­menopausal  
breast  cancer  (Renehan  et  al.  2008;;  Magnusson  et  al.  1998;;  Huang  et  al.  1997).  Few  
mechanisms  have  been  suggested  of  how  obesity  affects  mammary  tumorigenesis.    One  
of   them   is   that   increased   levels   of   adipose   tissue   serve   as   an   additional   source   of  
oestrogen  through  increased  activity  of  the  enzyme  aromatase.    
An  alternative  explanation  suggests  that  hyperinsulinemia,  often  associated  with  obesity,  
can  stimulate  the  mammary  epithelium  via  insulin  like  growth  factor  (IGF-­1).  IGF-­1  is  a  
known  mitogen  for  a  wide  variety  of  cancer  cell  lines  (Yaginuma  et  al.  1997;;  Oku  et  al.  
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1991;;  Macaulay  1992)  and  has  been  targeted  by  monoclonal  antibodies  (mAb)  over  the  
past  decade.      
Studies  have  shown  that  women  who  exercise  3  times  a  week  have  30-­40%  reduced  risk  
of  developing  breast  cancer  (Brown  et  al.  2012).  Furthermore,   regular  physical  activity  
can   improve   disease   prognosis   and   lower   disease   reoccurrence   in   cancer   patients  
(Lahart  et  al.  2015).  The  positive  effects  of  exercise  are  linked  to  reduced  body  fat,  lower  
insulin  levels  and  sex  hormone  production.  In  addition,  physical  activity  reduces  cancer  
risk  by  improving  immune  system  function  (Dieli-­Conwright  et  al.  2016).  
  
1.1.5  Types  of  Breast  cancer  
Breast  cancer  originates  from  the  transformation  of  breast  epithelial  cells,  lining  milk  ducts  
and  lobules  of  the  breast.    While  still  restricted  to  the  to  the  duct  or  lobule,  breast  tumours  
classified  as  ductal  carcinoma  in  situ  (DCIS)  and  lobular  carcinoma  in  situ  (LCIS).  DCIS  
is  an  early  stage  breast  cancer  that  can  progress  to  invasive  ductal  carcinoma  (IDC)  in  
which  tumour  cells  migrate  to  the  other  parts  of  the  breast.  It   is  estimated  that  40%  of  
DCIS  will  progress  into  IDS  (Cowell  et  al.  2013).  However,  currently  it  is  not  possible  to  
predict  which  patient  is  at  risk  of  developing  IDC.  In  a  recent  study,  by  analysing  individual  
breast  cancer  cells  from  tissue  specimens  obtained  from  patients,  researches  attempted  
to  track  the  progression  of  DCIS  to  IDS.  Following  from  their  study,  researchers  came  up  
with  a  model,  in  which  clones  arise  from  a  single  cell  in  the  milk  duct  and  escape  from  it  






Figure  1.2  Schematic  model  of  the  transition  from  DCIS  to  invasive  stage  IDC.  DCIS  
arises  from  a  single  tumour  cell,  in  which  following  mutation  forms  different  clones  (purple  
and  yellow).  DCIS  sometime  progress  to  IDC  and  all  the  tumour  clones  present  in  DCIS  
also  present  on  IDC.  Adapted  from  (Casasent  et  al.  2018).    
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The   traditional   breast   cancer   classification   system   is   based   on   histopathological  
assessment   (type   and   grade   of   tumour),   expression   of   oestrogen   receptor   (ER),  
progesterone   receptor   (PR)   and   over-­expression   of   human   epidermal   growth   factor  
receptor   2   (HER2).   However,   histologically   identical   tumours   may   still   show   different  
clinical   behaviour   due   to   molecular   heterogeneity.   Therefore,   molecular   classification  
based  on  gene  expression  profile  and  proteomic  studies  have  been  introduced.  According  
to  the  genetic  profiling,  breast  cancer  is  classified  into  the  Luminal  A,  Luminal  B,  Basal-­
like,  Her2  positive  and  Normal-­like  (Perou  et  al.  2000).  However,  more  subtypes  have  
now  been  identified  based  on  the  molecular  analysis  of  2,000  breast  cancers  (Curtis  et  
al.  2012).  
Breast  cancers  with  positive  hormonal  status  (oestrogen  or  progesterone)  constitute  up  
to  65-­75  %  of  all  breast  cancers.  Those  that  express  oestrogen  or  progesterone,  but  not  
the  HER2  belong  to  the  Luminal  A  group.    Marker  of  proliferation  Ki67  is  a  differentiator  
between  Luminal  subtype  A  and  B  (Miller  et  al.  2014).  
Clinically   breast   cancer   is   classified   into   primary   breast   cancer   characterised  by   local  
occurrence  and  advanced  breast  cancer  spread  to  distant  organs.  It  is  known  that  30%  
of  patients  diagnosed  with  primary  breast  cancer  develop  metastatic  disease,  which   is  
the  main   reason   for   patient  mortality.   The  metastatic   spread  of   breast   cancer   cells   is  
achieved  by   two  main   routes;;   vascular   and   lymphatic.   Tumour   cells   acquire   changes  
according   to   their   metastatic   capacity   in   the   early   stages   of   tumorigenesis.   Regional  
lymph  nodes  are  often  the  first  sites  to  develop  metastases.  Bone  is  the  most  common  
site  of  metastasis  and  almost  80%  of  patients  with  advances  breast  cancer  develop  these  
lesions  (Siclari  et  al,  2006).
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1.1.6  Metastatic  breast  cancer  
Metastatic  invasion  accounts  for  90  %  of  cancer-­associated  mortality.  Furthermore,  the  
survival  rate  for  metastatic  disease  has  not  improved  in  the  past  30  years  (Tevaarwerk  et  
al.  2013).  Breast  cancer  can  relapse  in  two  forms;;  distant  metastasis  (bone,  brain,  liver,  
lung  and  distant   lymph  node),  which  happens   in  30   -­  60  %  of  cases  and   locoregional  
disease   (breast,   chest  wall  and   regional   lymph  nodes)  diagnosed   in   10  %  of   patients  
(Yates   et   al.   2017).   The   tumour   drained   lymph  nodes  are   the   first   sites   of  metastatic  
dissemination   in  breast  cancer.  About  30  -­  60  %  of  breast  cancer  patients  with   lymph  
node  metastasis  eventually  develop  distant  spread  (Redig  &  Mcallister  2013).    
Genome  profiles  of  metastatic  lesions  resemble  those  of  the  primary  tumour  with  some  
acquired  genomic  changes  that  are  not  present  in  primary  lesions  (Brastianos  et  al.  2015;;  
De  Mattos-­Arruda  et  al.  2014).    
The  process  of  metastases  known  as  metastatic  cascade  involves  a  sequence  of  steps;;  
local  invasion,  intravasation,  transport,  extravasation,  formation  of  micrometastases  and  
colonization  (Weinberg  2014).  The  first  step  of  local  invasion  is  associated  with  invasion  
of  the  tissue  surrounding  the  primary  tumour.  The  tumour  cells  then  enter  the  circulation  
and  disseminate  via  the  blood  stream  or  lymphatic  system  to  distant  organs  where  they  
undergo  cell  cycle  arrest  and  adhere  to  the  capillary  bed  to  consequently  extravasate  the  
bloodstream,  enter  the  hostile  tissue  and  colonise  it  (Figure  1.3).  Importantly,  in  order  to  
survive  during  all  those  steps,  malignant  cells  have  to  escape  apoptotic  signals  and  the  
host  immune  response  (Scully  et  al.  2012).    
The   “seed   and   soil”   theory   postulates   that   all   types   of   tumour   spread   in   a   certain  
organotrophic  manner   (Paget   1889).   PR-­   and   ER-­positive   tumour   subtypes   are  more  
likely  to  develop  secondary  lesions  in  bones,  whereas  HER2-­positive  have  a  tendency  to  
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spread  to  the  liver  and  lung  (Smid  et  al.  2008).  For  triple  negative  breast  cancer,  the  most  
common  sites  for  metastasis  are  the  brain  and  lungs  and  it  is  less  likely  to  spread  to  bone  





Figure  1.3  Major  steps  in  metastatic  dissemination  of  the  tumour.  The  first  step  is  
detachment  of   the   tumour  cells   from  the  primary  site.  The  tumour  cells   then  enter   the  
circulation  and  disseminate  via  the  blood  stream  or  lymphatic  system  to  distant  organs  
where   they  undergo  cell   cycle  arrest  and  adhere   to   the  capillary  bed   to  consequently  
extravasate   the   bloodstream,   enter   the   hostile   tissue   and   form   secondary   lesions.  
Adapted  from  (Guo  &  Giancotti  2004).
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1.1.7  Breast  cancer  diagnosis    
The  important  requirement  for  the  successful  breast  cancer  treatment  lies  is  in  its  earliest  
possible  detection.  Diagnosis  of  breast  cancer  involves  “triple  assessment”  and  includes  
physical  examination,  radiological  investigation  (mammography  or  ultrasonography)  and  
pathological   investigation.   Mammography   is   the   main   tool   in   the   diagnosis   of   breast  
cancer,  however,  as  with  most  medical  procedures,  it  has  limitations  and  as  a  result  about  
20  %  of  breast  cancers  are  not  detected  (National  Cancer  Institute,  2012).  On  other  hand,  
a  recent  study  on  breast  cancer  screening  reported  that  women  are  more  likely  to  have  
breast   cancer   that   is   overdiagnosed   than   have   earlier   detection   of   a   tumour   that   is  
destined  to  become  large.  The  same  study  reported  that  the  reduction  in  breast  cancer  
mortality  was   the  result  of   improved  systemic   treatment  and  not  due   to   the  screening  
programme  (Welch  et  al.  2016).    
Another   study   suggests   that   the   increased  detection   of   small   tumours   (<   2   cm)   is   of  
somewhat  limited  utility,  as  the  progression  from  small  to  large  tumour  (>  2  cm)  would  not  
necessarily  occur  during  the  lifetime  of  the  patient.    Furthermore,  small  tumours  that  are  
not   detected  by   screening  would   become  more   readily   detectible  within   19   years.      In  
contrast,   tumours  with  a   less   favourable  prognosis  are   rarely  diagnosed  early  as   they  
have   such   short   lead   times   (Lannin   &   Wang   2017).   Currently,   there   is   no   tool   to  
distinguish  primary  tumours  that  are  likely  to  become  metastatic  from  those  that  will  not  
likely  to  spread  during  the  lifetime  of  the  patient  (Weinberg  2014).
  
1.1.8  Treatment  
In   the   developed  world,   the  majority   of   breast  malignancies  are   diagnosed  during   the  
early   stages   by  mammogram.   Surgical   removal   of   early   stage   tumour(s)   followed   by  
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chemo-­  or   radiotherapy  has  been   the  gold  standard   for  breast  cancer   treatment.  Two  
main   treatment   options   for   breast   cancer   are   chemotherapy   and   endocrine   therapy.  
Cytotoxic   chemotherapy   after   surgery   is   recommended   for   patients  with   the   following  
parameters  ER-­;;  PR-­  and  HER2-­negative;;  HER2  positive,  larger  tumour  size  and  lymph  
node  positive  (McDonald  et  al.  2016).    
Cytotoxic  agents  used  in  standard  chemotherapy  include  anthracyclines,  taxanes  and  5-­
fluorourocyl.  Anthracyclines,  originally  derived   from  bacterium  Streptomyces  peucetius  
varcaesius   have   been   a   part   of   chemotherapy   since   their   discovery   in   1960.      These  
antitumour   antibiotics,   being   DNA   intercalators,   interfere   with   DNA   transcription   by  
binding   to   the   unwound   DNA   strand   and   preventing   cell   replication.   In   addition,   they  
produce   free   radicals   to   damage   tumour   cells.   One   of   the   major   side   effect   of  
anthracyclines   is   their   cardiotoxic   effect   caused   by   the   peroxidation   of   the   cardiac  
sarcoplasmic  reticulum  by  free  radicals.  This  in  turn  lead  to  cardiac  necrosis,  as  a  result  
of   cardiac   tissue   lacking   catalase,   the   enzyme   required   to   neutralise   free   radicals  
(Moudgil  &  Yeh  2016).  
Taxanes  are  naturally  occurring  compounds,  isolated  from  the  Pacific  yew  tree.  The  anti-­
tumour   effect   of   taxanes   occurs   due   to   their   ability   to   arrest   the   cell   cycle   during  
metaphase  by  the  activation  of  mitotic  checkpoints.  In  addition  to  anti-­cancer  treatment,  
taxanes  are  widely  used  in  cell  biology  to  induce  cell  death  (Weaver  2014).  
5   fluoroucyl   is  a  part  of  chemotherapy  agent  known  as  anti-­metabolite.      It   inhibits   the  
thymidylate   synthetase   to   create   shortage   of   thymine   required   for   DNA   replication  
(Longley  et  al.  2003).  
Patients  with  PR-­  or  ER-­positive  breast  cancer  receive  endocrine  treatment  agents  such  
as   oestrogen   receptor   modulators   and   aromatase   inhibitors.   Oestrogen   receptor  
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modulators  work  by  binding   to   the  oestrogen  receptor  to   interfere  with  DNA  synthesis.  
Among  them  is  Tamoxifen  prescribed  for  pre-­menopausal  women.  Aromatase  inhibitor  
drugs  inhibit  the  enzyme  “aromatase”  –  a  main  source  of  oestrogen  in  post-­menopausal  
women   (Miller   et   al.   2014).   Endocrine   treatment   is   prescribed   for   at   least   five   years.  
However,  targeted  endocrine  therapy  for  ER-­positive  breast  cancer  is  not  effective  in  all  
cases.  Many  patients  initially  benefit  from  it,  but  with  time  develop  drug  resistance  (Selli  
et  al.  2016).      
About  25  %  of  breast  cancers  are  characterised  by  the  overexpression  of  HER2  (ErbB1)  
protein.   HER2   is   the   transmembrane   glycoprotein   that   has   both   intracellular   receptor  
tyrosine  kinase  (TK)  domain  and  an  extracellular  ligand  binding  domain.  HER2  receptors  
are  activated  via  homodimerisation  or  heterodimerisation  with  its  family  members  HER1  
or  HER3.    Treatment  of  breast  cancers  overexpressing  HER2  involves  the  monoclonal  
antibody   Herceptin,   also   called   trastuzumab   in   combination   with   chemotherapy  
(Weinberg  2014).    
Triple  negative  breast  cancer  (TNBC)  are  tumours  characterised  by  the  absence  of  ER,  
PR   and   HER2.   These   tumours   are   biologically   aggressive   and   do   not   benefit   from  
hormonal   based   treatment.   Chemotherapy   following   surgery   remains   the   major  
therapeutic  option  for  the  treatment  of  TNBC  (Wahba  &  El-­Hadaad  2015).    
The  main  aim  of  treatment  for  patients  with  metastatic  disease  is  to  prolong  the  survival  
and  minimise  the  side  effects.  Treatment  options  for  metastatic  cancer  patients  depends  
on  the  site  of  the  metastatic  lesion  and  the  molecular  subtype  of  the  tumour,  as  it  has  
been  shown  to  be  associated  with  a  distinct  response  to  treatment  (Rouzier  et  al.  2005).  
Treatment  options  are  the  same  as  those  for  primary  tumours  and  include  chemotherapy,  
hormone   therapy   or   monoclonal   antibody   approaches   for   treatment   of   HER2-­positive  
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tumours  (Lambert  et  al.  2017).  Androgens,  oestrogen  and  progesterone  are  often  used  
for   the   third  or   fourth   line  of   treatment  of  metastatic  disease.  Medroxyprogesterone,  a  
synthetic  progesterone   is  administered   to  control   the  growth  of  breast  cancer  cells  by  
inhibiting   oestrogen   receptor   levels.   It   is   often   prescribed   to   patients   that   no   longer  
respond   to   tamoxifen.   High   doses   of   artificial   oestrogen,   diethylstilbestrol,   is   used   in  
patients  that  have  been  treated  with  antioestrogens.  As  the  growth  of  breast  cancer  cells,  
prolonged  period  of  time  deprived  from  oestrogen  shown  to  be  inhibited  by  the  high  dose  
of  oestrogen  (Osipo  et  al.  2003).  Despite  androgens  historically  being  used  as  treatment  
agents  for  metastatic  breast  cancer,  due  to  their  utility  in  suppressing  tumour  growth,  they  
have  since  been  rendered  obsolete.    
Surgery   is   the  primary   choice   of   treatment   for   locally   recurred  breast   cancer.  Reginal  
recurrence  after  mastectomy   is   treated  with  surgical  excision  of   regional   lymph  nodes  
followed  by  radiotherapy.  Patients  with  advanced  disease  at  their  first  presentation  with  
breast  cancer,  benefit  from  the  surgical  removal  of  the  primary  lesion.  Metastatectomy  
can  be  performed  for  the  pulmonary  and  liver  metastases,  however,  it  poses  great  risk  
for  the  patient.  
Radiation   therapy  (RT)   for   the   treatment  of  advanced  breast  cancer  has  been  used   in  
clinical  practice  since  1949.  It  is  based  on  the  use  of  high  energy  rays  to  kill  malignant  
cells  at  various  metastatic  locations.  This  type  of  cancer  treatment  reduces  local  relapse  
of   the   disease  by   70%.  Over   the   years  RT  has  been   improved   to   reduce  normal   cell  
toxicity  and  overall  treatment  time.  Local  RT  to  the  metastatic  lesion  is  the  treatment  of  
choice   for   locally   recurred   breast   cancer.   A   limited   number   of   bone   metastases   are  
treated  with   local  RT,  while  multiple   lesions  are   treated  with  systemic  RT.   In   the  case  
when  resection  of  liver  metastasis  is  not  possible,  RT  is  applied.  For  patients  with  brain  
metastasis,   surgery   is   an   option   if   the   disease   is   symptomatic,   as   it   can   eliminate  
35  
  
symptoms   of   intracranial   hypertension,   focal   neurological   deficit   and   improves   overall  
survival.  As  in  the  case  of  pulmonary  metastasis,   inaccessible  metastatic  brain  lesions  
can  be  treated  with  RT.        
Successful   treatment   of   patients   with   advanced   breast   cancer   heavily   depends   on  
accurate   staging   of   the   cancer.   In   order   to   stage   breast   cancer,   various   investigative  
techniques  are  used  with  the  focus  on  the  presence  of  metastatic  dissemination.  During  
the  course  of  treatment,  the  radiological  investigation  is  used  to  evaluate  the  progression  
of  the  disease  and  monitor  the  treatment  response.  Radiological  investigation  includes  X-­
ray,  CT  scan,  Ultrasound  scan,  MRI  scan  and  PET-­CT  scan.  These   investigations  are  
coupled  with  histopathological  examination  of   the  metastatic  specimen   to   improve   the  
accuracy  of  the  disease  staging.    
The  evolutionary  nature  of  cancer  makes  it  very  difficult  to  treat.  However,  this  problem  
is  not  only  attributed  to  cancer  treatment,  but  also  resistance  to  antibiotics  and  some  viral  
infections  such  as  human  immunodeficiency  virus  (HIV).  In  the  context  of  HIV  treatment,  
this  issue  is  successfully  addressed  through  a  combination  of  drugs,  in  conjunction  with  
anti-­HIV  vaccines,  are  now  used  to  combat  HIV  (Hammer  et  al.  1997;;  Gulick  et  al.  1997;;  
Ferguson  et  al.  2013).
  
1.1.9  Vaccines    
The  immune  response  against  cancer,  particularly  breast  cancer,  plays  an  important  role  
in   the   survival   of   diagnosed   patients.   Early   animal   studies   showed   that   the   immune  
system  recognises  tumours  and  elicits  an  immune  response  against  them  (Foley  1953).  
A  typical  tumour  contains  30  to  70  mutations,  these  mutations  are  foreign  to  the  host’s  
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immune   system  and   could   therefore   be   targeted  by   immunotherapy   (Vogelstein   et   al.  
2013).    
Selecting   a   target   for   vaccine   development   is   crucial,   however,   unlike   in   the   case   of  
cervical  cancer,  where  viral  aetiology  is  established,  there  is  no  single  cause  for  breast  
cancer.  There  are  different  subsets  of  breast  cancer  such  as  Luminal  A,  Luminal  B,  HER2  
and  basal  like  cancers,  which  makes  it  challenging  to  identify  a  common  vaccine  target.      
Currently  several  types  of  anti-­tumour  vaccines  are  being  tested  in  breast  cancer  patients  
(Parmiani   et   al.   2014).   Peptide-­based   vaccines   work   by   generating   a   cytotoxic   T-­
lymphocyte  response  against  the  tumour  cells.  One  such  example  is  the  vaccine  against  
Folate  receptor  (FR  alpha)  that  is  expressed  in  80%  of  TNBCs  and  negatively  correlated  
with   patient   survival   (Cheung   et   al.   2016).   HER2-­derived   peptide   vaccine   is   another  
example  of   the   therapeutic  strategy  against  HER2  positive  breast  cancer  being   tested  
showing  improved  patient  survival  (Clifton  et  al.  2016).    
Another  therapeutic  approach  is  the  use  of  DNA-­based  vaccines  to  combat  cancer.  For  
instance,  DNA  vaccine   INO-­1400  that  contains  a  plasmid  encoding   tumour  associated  
antigen,  human  telomerase  reverse  transcriptase  (hTERT),  expressed  in  85%  of  tumour  
cells.   The   result   of   INO-­1400   vaccination   is   the   expression   of   hTERT,   which   in   turn  
evokes   a   cytotoxic   T-­lymphocyte   immunological   response   against   malignant   cells  
expressing  hTERT.    
DNA  based  vaccines  are  also  used  to  develop  tailored  treatment  for  TNBC  patients.  In  
this  approach,  the  patient’s  own  cancer  cells  are  used  to  generate  plasmid  DNA  in  order  
to  boost  the  anti-­tumour  immune  response  by  propagating  isolated  T-­cells.    This  approach  
is  known  as  Adaptive  T  cell  transfer  therapy  (ATC)  and  is  currently  being  tested  (Moreno  
Ayala  et  al.  2017).    
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Emerging  data  suggest  the  potential  of  the  use  of  dendritic  cell-­based  vaccines  for  cancer  
treatment.  Dendritic   cells   (DCs)   are  a   population   of   leukocytes   that   play   a   role   in   the  
initiation  of  the  innate  immune  response.  Once  DCs  recognise  the  antigen,  they  migrate  
to  the  lymphoid  organs  where  they  interact  with  CD4+  and  CD8+  T  lymphocytes  resulting  
in  activation  of  T  cells.    Activated  T  cells  become  cytotoxic  T  cells  and  generate  an  antigen  
specific  immune  response  (Gelao  et  al.  2014).  DCs  are  present  in  the  infiltrate  of  breast  
tumours  and  have  been  found  to  provide  a  memory  response  to  tumour  antigens  (Lissoni  
et  al.  1999).  The  effectiveness  of  DCs  anticancer  vaccines  have  been  demonstrated  by  
animal   studies.   Immunisation   of   mice   with   tumour   antigen   loaded   DCs   have   been  
reported   to   provoke   a   cytotoxic  T   lymphocyte   immune   response   against   tumour   cells  
(Zheng  et  al.  2013).  
The  Boris  antigen  is  a  new  protein  that  is  now  being  targeted  for  developing  a  vaccine  
against  breast  cancer.  The  application  of  DCs  based  vaccines  against  Boris  is  currently  
under  investigation  (Mkrtichyan  et  al.  2011).  
A  major   limitation   of   immunotherapy   is   tumour-­associated   self-­tolerance  and  mutation  
(Cheng   et   al.   2004).   These   issues   are   being   addressed   by   the   use   of   multiple  
immunogenic   epitopes   to   reduce   tumour   immune   escape   variants   (Buonaguro   et   al.  
2011).  
  
1.1.10  Biomarkers  of  Breast  Cancer    
Biomarkers,   also   known   as   molecular   markers,   are   defined   by   the   National   Cancer  
Institute  as  a  substance  found  in  tissue,  blood  or  other  body  fluids  that  are  a  sign  of  cancer  
or  certain  noncancerous  conditions.  The  properties  of  a  good  cancer  biomarker  include  
high  presence  in  cancer  patients  and  absence  or  low  presence  in  healthy  individuals  and  
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easy  quantification  of  biological  samples   (Carlomagno  et  al.  2017).  Depending  on   the  
source  of  biomarkers  they  are  classified  as  humoral  or  cellular.  Currently,  biomarkers  play  
a   crucial   role   in   the   management   of   breast   cancer.   Depending   on   their   properties  
biomarkers  can  be  divided  into  three  groups;;  diagnostic,  prognostic  and  predictive.  
A  diagnostic  biomarker  allows  for  the  early  detection  of  cancer  in  a  noninvasive  way.  By  
the  time  of  diagnosis  breast  cancer  grows  to  its  critical  mass  which  makes  it  difficult  to  
treat.  Currently,  there  are  no  approved  biomarkers  to  be  used  for  early  detection  of  breast  
cancer.  Therefore,  there  is  the  need  to  identify  cancer  markers  to  assist  with  the  diagnosis  
of  disease  onset.    
The   purpose   of   prognostic   biomarkers   is   to   inform   about   disease   outcome,   such   as  
recurrence,  progression  or  death,  independent  of  the  treatment(s)  received.  For  instance,  
patients  with  “triple-­negative”  breast  cancer  have  a  significantly  lower  survival  rate  than  
other   breast   cancers.   As   the  main   cause   of   mortality   of   breast   cancer   is   metastatic  
dissemination,  new  markers  are  required  to  identify  the  likelihood  of  metastasis.  (Ballman  
2015).  However,  current  prognostic   tests   include   tumour  sampling  which  are  obtained  
through  biopsy,  yet  in  order  to  minimise  the  invasive  procedure  circulating  biomarkers  are  
urgently  needed.    
Predictive   biomarkers   provide   information   regarding   treatment   response   and   help   to  
identify  patients  that  are  likely  to  benefit  from  a  specific  treatment.  One  such  example  of  
an  important  predictive  biomarker  is  HER2,  the  overexpression  of  which  allows  clinicians  
to  determine  which  patients  would  benefit  from  monoclonal  antibody  therapies  (Duffy  et  
al.  2017).
  
1.1.10.1  Humoral  biomarkers  
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The   first   cancer   marker   was   discovered   in   1864   by   Bense   Jones,   who   identified   the  
presence  of  a  specific  immunoglobulin  in  the  urine  of  myeloma  patients.  Since  then,  many  
circulating  tumour  markers  have  been  identified  and  characterised.    
Presently   there   are   no   sensitive   and   specific   minimally   invasive   biomarkers   for   the  
detection  of  early  stage  breast  cancer.  Currently  available  serum  biomarkers  for  breast  
cancer  include  carcinoma  antigen  CA  15-­3  and  carcinoembryonic  antigen  (CEA)  which  
are  mainly  used  as  predictive  and  prognostic  biomarkers  in  patients  with  metastatic  breast  
cancer.  Unfortunately,  the  specificity  of  the  aforementioned  markers  is  low  as  elevated  
levels   of   both   proteins   have   also   been   found   in   patients   with   inflammatory   and  
autoimmune  diseases  as  well  as  in  smokers  and  the  elderly  (Lumachi  &  Basso  2004).  In  
a   recent   study   the   combined   use   of   CA   15-­3   with   two   novel   tumour   associated  
autoantibodies  was   investigated   in  order  to   increase  sensitivity   for  early  breast  cancer  
detection.  Predictive   accuracy  was  demonstrated   to   be   considerably   higher;;   however,  
most  of  the  serum  used  in  the  study  was  from  patients  with  advanced  disease  (Dong  et  
al.  2013).    
Epithelial   cells   are   protected   by   a   mucous   barrier   comprised   of   secreted   and  
transmembrane  mucins.  MUC1  is  a  transmembrane  protein  that  has  been  shown  to  be  
overexpressed  in  epithelial  cancer  cells.  Overexpression  can  lead  to  the  loss  of  epithelial  
polarity  and  activation  of  tyrosine  kinases  causing  downstream  signalling  and  cancer  cell  
survival  (Graham  et  al.  2014).  In  order  to  detect  the  MUC1  protein,  several  antibodies  are  
used,  such  as  CA15-­3  and  CA27.29.  Determining  the  concertation  of  CA15-­3  in  blood  is  
used  for  screening,  not  only  for  breast  cancer,  but  for  pancreatic,  lung,  ovarian,  colon  and  
liver  cancers.  In  breast  cancer,  CA15-­3  is  utilised  to  predict  the  relapse  of  disease    (Lee  
et  al.  2013).  A   recent  study   reported   that  serum   levels  of  CA15-­3  can  be  used  as  an  
independent  prognostic  factor  in  patients  with  advanced  breast  cancer  (Darlix  et  al.  2016).  
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In  another  study  on  the  correlation  of  the  molecular  subtype  of  tumour  and  CA15-­3  levels,  
researchers   found   that   the  high   levels  of   the  marker  was  strongly  associated  with  ER  
negative  status  (Shao  et  al.  2015).  According   to   the  current  guidance  of   the  American  
Society  of  Clinical  Oncologists,   the  use  of  CA15-­3   is  not   recommended  for  screening,  
diagnosis  or  staging  of  breast  cancer.  
CA27-­29  is  another  MUC1  marker,  also  known  as  breast  carcinoma-­associated  antigen  
(Rack  et  al.  2010).  Although,  elevated  levels  of  CA27-­29  are  present  in  serum  of  80  %  of  
breast  cancer  patients,  it  is  also  found  in  patients  with  benign  breast  conditions  as  well  
as  in  other  malignancies  (Beveridge  1999).  This  marker  has  similar  utility  to  CA15-­3.    
Another  widely  used  serum  marker  in  breast  cancer  is  the  oncofoetal  glycoprotein  CEA,  
the  first  discovered  in  human  colon  carcinoma  in  1965.  Various  studies  confirmed  that  
high  serum  concentration  of  CEA  in  breast  cancer  patients  correlates  with  metastasis  and  
poor  disease  outcome.  In  primary  breast  cancer,  high  pre-­treatment  levels  of  CEA  were  
found  to  be  useful  criteria  to  identify  node  negative  breast  cancer  patients  with  high  risk  
of   disease   recurrence   (Molina   et   al.   2010).   In   a   recent   study,   high   levels   of   CEA   in  
preoperative  primary  breast  cancer  was  detected  in  patients  with  HER2  positive  tumours  
(Shao   et   al.   2015).   Currently   CEA   is   recommended   to   be   used   in   clinical   settings   in  
combination   with   digital   imaging   to   assess   treatment   efficacy   (Harris   et   al.   2007).  
However,  it  is  not  specific  for  breast  cancer  as  elevation  of  CEA  has  also  been  detected  
in  other  malignancies  such  as  colon,  lung,  thyroid,  pancreas,  liver,  stomach,  ovary,  and  
bladder   (Thompson   et   al.   1991).   Further   work,   although   challenging,   is   necessary   to  
improve  the  limitations  for  early  breast  cancer  diagnosis.  
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Currently  few  promising  circulating  biomarkers  of  breast  cancer  are  in  the  development  
pipeline.   These   include  mammaglobin   and  MicroRNAs   (miR-­10b,   miR-­21,   miR-­125b,  
miR-­145,  miR-­155,  miR-­182)  (George  &  Mittal  2010;;  Mar-­Aguilar  et  al.  2013).    
Mammaglobin  is  a  14-­22  kDa  protein  found  in  the  plasma  of  over  70  %  of  breast  cancer  
patients  and  not  detected  in  patients  with  other  types  of  cancer.  To  investigate  the  levels  
of   this  protein,  an  ELISA  technique  was  applied  and  was  able   to  differentiate  between  
breast  cancer  patients  and  healthy  volunteers.  Furthermore,   it   showed  high  sensitivity  
and  specificity  of  the  potential  biomarker  (Bernstein  et  al.  2005).  
miRNAs  are  a  type  of  short  interfering  RNAs  that  function  in  post-­transcriptional  regulation  
of  gene  expression.  The  changes  in  miRNA  are  reported  to  be  strongly  associated  with  
cancer   development   and   progression   (Vasudevan   et   al.   2007;;   Alajez   et   al.   2011).  
Therefore,   the   potential   use  of  miRNA  as   circulating   cancer   biomarkers   is   currently   a  
popular  area  for  clinical  investigation.  For  instance,  increased  levels  of  miRNA-­10b  and  
miRNA-­373   is   found   in   the  plasma  of   lymph  node  positive  breast  cancer  patients  (W.  
Chen  et  al.  2013).  
  
1.1.10.2  Cellular  biomarkers    
The   cellular   markers   routinely   used   in   clinical   practice   are   oestrogen   receptor   (ER),  
progesterone   receptor   (PR)   and   HER2.   These   are   important   markers   of   treatment  
response  in  breast  cancer.  
Oestrogen  receptor  (ER)  is  a  member  of  the  nuclear  steroid  family  of  receptors  and  is  
controlled   by   the   female   sex   hormone   oestrogen.   ER  measurement   in   breast   cancer  
tumours   is   used   to   identify   patients   that   benefit   from   endocrine   treatments   such   as  
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tamoxifen   in  both   local  and  metastatic  diseases.  Clinically,  ER-­positive  breast   tumours  
indicate  a  more  favourable  prognosis  for  patients  (Lumachi  et  al.  2013).    
Progesterone  receptor  (PR)  is  nuclear  hormone  receptor  that  binds  to  progesterone.  PR  
status  is  analysed  in  local  and  metastasised  breast  cancer  lesion  to  identify  patients  that  
would  benefit  from  hormonal  treatment  and  in  determining  a  treatment  plan.    
HER2   is   a   protein   encoded   by   the  erbB  oncogene   and   is   a   truncated   version   of   the  
epidermal  growth  factor  receptor  (EGF).  Healthy  cells  require  growth  factors  in  order  to  
grow,  whereas   cancerous   cells   are   less   dependent   on   growth   factor   stimulation.   The  
oncogene  erbB  lacks  the  N-­terminal  and  this  mutation  causes  abhorrent  growth  signalling  
independent  of  ligand  binding  (Weinberg  2014).  The  presence  of  HER2  in  breast  cancers  
are  associated  with  poor  prognosis.  Overexpression  of  HER2  is  detected  in  15-­30  %  of  
invasive  breast  cancers   (Rimawi  et  al.  2015).  Detection  of  HER2   in  clinical  settings   is  
determined  by  IHC  and  fluorescence  in  situ  hybridisation  (FISH)  techniques  (Petroni  et  
al.  2016).  HER2  expression  patterns  are  evaluated  in  both  primary  and  metastatic  breast  
cancer  patients.  Determining  HER2  status  is  important  to  determine  patients  that  would  
benefit  from  anti-­HER2  monoclonal  antibody  therapy.  However,  anti-­HER2  treatment  is  
not  exclusive,  patients  with  HER2  positive  disease  also  benefit  from  anthracycline  based  
therapy.    
The  proliferation  marker  Ki67   is  another  prognostic  parameter   that   influence  treatment  
regimes  in  the  management  of  breast  cancer.  Ki67  is  the  nuclear  protein  that  has  a  role  
in  cell  proliferation.  Its  status  in  tumour  mass  is  evaluated  using  immunohistochemistry.  
Positive  staining  in  early  stage  breast  cancer  correlates  with  high  risk  of  breast  cancer  
recurrence  and  poor  survival  rates  in  both  node  negative  and  node  positive  patients  (de  
Azambuja   et   al.   2007).   Another   study   reported   that   Ki67   positive   cancer   significantly  
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correlates  with  shorter  overall  patient  survival  (Stuart-­Harris  et  al.  2008).  The  predictive  
value  of  Ki67  in  response  to  treatment  was  evaluated  in  several  recent  studies.  In  one  of  
them,  high  Ki67  was  indicative  of  improved  relapse-­free  survival  in  an  ER  positive  cohort  
treated  with  both  chemotherapy  and  endocrine   treatment  (Niikura  et  al.  2012).  For   the  
treatment  of  locally  advanced  breast  cancer,  chemotherapy  is  often  administered  before  
surgery.  In  this  cohort  of  patients,  high  pre-­treatment  Ki67  was  shown  to  be  predictive  of  
complete  response  to  chemotherapy  (Brown  et  al.  2014).  
Urokinase  plasminogen  activator  (uPA)  and  plasminogen  activator  inhibitor  1  (PaI-­1)  are  
a  class  of  plasminogen  activating  proteins.  High  levels  of  uPa  and  PaI-­1  in  tumour  tissues  
such  as  breast,  prostate,  endometrial,  colon,  lung  and  stomach  are  associated  with  poor  
disease  prognosis  (Stillfried  et  al.  2007).  UPa  is  protease  that  converts  the  plasminogen  
into  plasmin  and  PaI-­1  is  an  inhibitor  of  the  activity  of  uPa.  Both  uPa  and  PaI-­1  are  directly  
involved  in  metastasis  and  therefore  regarded  as  a  prognostic  marker  of  cancer.  Their  
elevated  levels  in  breast  cancer  tissue  is  associated  with  poor  prognosis  for  patients  with  
node  negative  disease  (Lampelj  et  al.  2015).  
Tumour  suppressor  protein  P53  is  a  nuclear  protein  involved  in  the  regulation  of  the  cell  
cycle.  Mutation  of  p53  is  frequently  observed  in  a  wide  variety  of  human  cancers.  In  breast  
cancer,  mutation  of  p53  is  a  strong  indicator  of  the  aggressiveness  of  the  tumour  and  is  
associated  with  poor  survival  probability  (LI  2008).  A  recent  study  shows  that  p53  status  
may  be  used  as  a  predictive   factor   for   the   response   to  chemotherapy,  as   it  has  been  
shown   that   cancer   cells   treated   with   chemotherapy   agents   undergo   p53   mediated  
apoptosis.   Reduced   levels   of   p53   could   be   a   marker   of   resistance   to   chemotherapy  
(Parrales  &  Iwakuma  2015).  
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Cyclin  E,  a  cell  cycle  regulator,   is  expressed   in   late  phases.  Deregulation  of  cell  cycle  
proteins  is  a  frequent  event  in  tumorigenesis.  Overexpression  of  Cyclin  E  is  associated  
with  poor  prognosis  and  disease  recurrence  (Bi  et  al.  2015).  
  
1.1.10.3  Monitoring  treatment  response  
Monitoring  treatment  response  is  crucial  in  the  management  of  metastatic  breast  cancer.  
It  helps  clinicians  to  identify  patients  that  benefit  from  the  treatment  received  and  those  
that  require  a  change  of  treatment.  Traditionally,  measurement  of  the  levels  of  CA15-­3  
and  CA  27.29  are  used  to  monitor  the  response  to  treatment  in  patients  with  advanced  
disease.   Elevation   in   the   levels   of   CA15-­3   and   CA   27.29   indicate   treatment   failure.  
However,   this  method   is  not   recommended   to  be  used  alone,  but   in  combination  with  
diagnostic  imaging  as  levels  of  CA15-­3  are  shown  to  rise  spuriously  in  the  first  4-­6  weeks  
of  treatment  (Graham  et  al.  2014).  
  
1.1.10.4  Multigene  prognostic  assays    
1.1.10.4.1  Oncotype  DX  
Oncotype  DX  is  a  21-­gene  assay  that  is  used  to  evaluate  breast  cancer  recurrence.  The  
test  includes  16  cancer  related  genes  and  5  reference  genes  from  primary  breast  cancer  
tissue.  The   result  of   the   test   is  a  score   from  0-­100   reflecting   the   likelihood  of  disease  
recurrence   within   10   years   (McVeigh   et   al.   2014).   This   assay   has   prognostic   and  
predictive   value   for   ER   positive   breast   cancer.   More   specifically,   the   test   provides  
information  whether  patient  will  benefit  from  chemotherapy.  
45  
  
1.1.10.4.2  MammaPrint  assay  
The  MammaPrint  assay   is  a  prognostic  microarray-­based  multigene  assay   for  patients  
younger  than  61  years  of  age  with  stage  I-­II  node  negative  or  I-­III  node  positive  breast  
cancer   (Mook   et   al.   2009).   The   assay  measures   the  mRNA   expression   of   70   genes  
involved  in  the  regulation  of  cell  proliferation  in  order  to  identify  patients  with  a  very  good  
or  very  poor  prognosis.  Originally  the  test  required  freshly  frozen  tissue  (within  an  hour  
from  the  surgery),  however,  recently  the  assay  was  improved  to  allow  the  use  of  formalin  
fixed  paraffin  embedded  tissue  (Mittempergher  et  al.  2011).  
1.1.10.4.3  Genomic  grade  index  
The  genomic  grade  index  is  a  microarray  test  that  measures  the  expression  of  97  genes  
to  establish  the  molecular  grade  of  the  tumour.  The  assay  is  based  on  the  comparison  of  
gene  expression  profiles  of  grade  I  and  grade  III  tumours  (Gyorffy  et  al.  2015).    
The  breast  cancer  index  is  an  RT-­PCR  based  test  that  is  designed  to  predict  early  and  
distant   disease   recurrence   in  ER  positive   node  negative   breast   cancer.   In   addition,   it  
helps  identify  patients  who  would  benefit  from  extended  endocrine  therapy  (Sgroi  et  al.  
2013).  
1.1.10.4.4  EndoPredict  assay  
The  EndoPredict  assay  is  an  RT-­PCR  assay  based  on  measurement  of  the  expression  
of  eight  cancer  and  three  control  genes.  The  test  is  used  to  predict  disease  recurrence  in  





Liquid  biopsy  is  an  approach,  alternative  to  tissue  biopsy,  that  involves  analyses  of  tumour  
tissue  material  found  in  blood  and  other  body  fluids.  The  test  is  based  on  the  knowledge  
that  during  tumorigenesis  tumour  components  are  shed  into  the  circulation.  The  notion  of  
liquid  biopsy  is  not  new,  it  was  first  established  to  detect  foetal  DNA  in  maternal  blood  (Lo  
et  al.  1997).  Recently  though  many  techniques  have  been  developed  to  study  circulating  
tumour  cells,  cancer  stem  cells  and  circulating  tumour  DNA.  Cancer  is  caused  by  a  series  
of  mutations  in  oncogenes  that  affect  the  function  of  certain  pathways  potentially  taking  
several  decades  to  develop.  Therefore,  the  majority  of  cancers  are  not  detected  in  the  
first  90%  of   the  “cancer   lifetime”  (Vogelstein  et  al.  2013).  As  most  of   the  cancer  driver  
genes  and  pathways  affected  by  them  are  well  studied,  liquid  biopsy  may  serve  as  a  tool  
for  early  diagnosis  (Heitzer  et  al.  2017).
1.1.10.5.1  Circulating  tumour  cells    
Circulating  tumour  cells  (CTC)  are  released  by  tumours  into  the  circulation.  The  presence  
of  the  CTC  in  the  blood  of  cancer  patients  was  first  reported  in  1869  by  Thomas  Ashforth  
(Ferreira  et  al.  2016).  Advanced  tumours  release  millions  of  cells  into  the  circulation  each  
day,  but   these  cells  have  short  half-­lives  (Vogelstein  et  al.  2013).  Therefore,   the  main  
challenge  in  the  field  of  CTC  research  lies  in  the  low  number  of  CTC  found  in  the  blood  
of  cancer  patients  (one  CTC  is  detected  among  millions  of  healthy  blood  cells)  (Nelson  
2010).  CTCs  have  distinct  physiological  characteristics  that  help  to  distinguish  them  from  
normal   blood   cells.   Like  most   epithelial   cells   they   are   of   large   size,   different   density,  
charge  and  express  epithelial  cell  surface  markers  not  present  on  leukocytes  (Yu  et  al.  
2011).  Based  on   these  properties,  various  strategies  have  been  developed   to  capture  
CTCs  (Andreopoulou  et  al.  2012;;  Campton  et  al.  2015;;  Sollier  et  al.  2014).  The  prognostic  
value  of  CTCs  in  the  circulation  of  breast  cancer  patients  has  been  studied  extensively.  
Numerous  studies  have   reported   the  correlation  between  a  high  CTC  count  and  poor  
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prognosis  for  breast  cancer  patients  (Botteri  et  al.  2010;;  Zhao  et  al.  2011;;  Munzone  et  al.  
2012).  In  a  recent  study  on  how  ER  positive  cancer  cells  acquire  resistance  to  endocrine  
treatment,  a  population  of  ER  negative  CTCs  were  reported  in  ER  positive  tumours,  which  
might   be   able   to   escape   hormonal   treatment   (Babayan   et   al.   2013).   Furthermore,   a  
special  test  based  on  the  detection  of  the  panel  of  CTC  was  developed  to  identify  patients  
with  advanced  disease  that  resist  endocrine  treatment  (Paoletti  et  al.  2015)
1.1.10.5.2  Cancer  stem  cells  
Cancer  stem  cells  were   first   identified   in  human  breast  cancers   in  2003   (Al-­Hajj  et  al.  
2003).  The  discovery  of  cancer  stem  cells  (CSC)  changed  the  way  researchers  look  at  
the  mechanism  of   tumorigenesis.  According   to   the  CSC  hypothesis,  cancers  originate  
from  progenitor  cells,  or  CSC.  Organ  specific  stem  cells  are  characterised  by  their  ability  
to  self-­renew  and  differentiate  into  cell  types  that  form  the  organ.  The  ability  of  female  
breast  tissue  to  expand  during  puberty  and  pregnancy  suggests  the  presence  of  cells  with  
proliferative  properties  that  are  typically  attributed  to  stem  cells.  It  is  believed  that  CSC  
are  shed  by  the  primary  tumour  and  metastatic  lesion  into  the  circulation  and  therefore,  
considered   as   important   prognostic   biomarkers   to   study   disease   progression.   For  
example,  in  metastatic  breast  cancer  the  baseline  CSC  count  of  >5  was  identified  as  a  
risk  factor  for  disease  progression  as  well  as  an  indicator  of  poor  survival  (Lv  et  al.  2016).  
Similarly,   in  patients  with  primary  breast  cancer,  the  detection  of  CSC  before  and  after  
chemotherapy   indicated   an   increased   risk   of   disease   recurrence   and   worse   patients  
survival  (Rack  et  al.  2014).  CSCs  are  detected  through  the  use  of  epithelial  markers  such  
as  cytokeratins  that  are  not  expressed  in  blood  cells  (Alix-­Panabieres  &  Pantel  2014).    




Circulating  tumour  DNA  (ctDNA)  are  derived  from  the  dying  tumour  cells  that  release  their  
DNA  fragments  into  the  blood  of  cancer  patients.  Despite  their  short  half-­lives  they  are  
more  abundant  in  blood  than  CTCs  (Cai  et  al.  2015).  The  detection  of  ctDNA  was  reported  
in  75  %  of  metastatic  breast  cancer  patients  and  50  %  of  patients  with  a    primary  tumour  
(Bettegowda  et  al.  2014).  The  increased  level  of  ctDNA  in  patients  with  metastatic  disease  
was   found   to   be   associated   with   progressiveness   of   the   disease.   Furthermore,   the  
changes  in  ctDNA  levels  in  the  response  to  treatment  were  found  to  be  indicative  of  the  
changes  in  tumour  mass  (Dawson  et  al.  2013).  In  addition,  sequencing  of  ctDNA  reflects  
the  specific  mutation  acquired  by   the   tumour   in   response   to   treatment   (Murtaza  et  al.  
2013).  A  recent  study  reported   that  ctDNA  is  detectable   in  50  %  of  patients  with  early  
stage  breast  adenocarcinoma  (Bettegowda  et  al.  2014).
  
1.1.10.6  Proteomics  in  biomarker  discovery  
Proteomic   approaches   are   regarded   as   a   powerful   and   popular   tool   to   study  
tumorigenesis.  Although  using  genomic  approaches  have   resulted   in   the   discovery   of  
several  cancer  related  genes,  in  order  to  learn  about  their  function  proteomics  is  required.  
Furthermore,  mRNA  based  studies  whilst  being  informative  do  not  always  correlate  with  
the  corresponding  protein  concentration  (Schwanhüusser  et  al.  2011).  Proteins  are  highly  
dynamic   molecules   that   are   regulated   by   various   processes   such   as   proteolytic  
degradation,   post-­translational   modification   and   composition   of   complex   structures.  
Therefore,  studying  proteomic  profiles  of  different  specimens  from  cancer  patients  is  a  
frequently  used  tool  to  identify  cancer  biomarkers  for  disease  progression  and  treatment  
monitoring.  Moreover,  proteomics  is  a  more  favourable  technique  then  genomics  as  it  can  
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be  applied  to  diagnostic  and  prognostic  purposes  within  clinical  settings  (Sallam  2015).  
Proteins  can  be  detected  by  various  assays  such  as  western  blot  and  ELISA.  
The  ultimate  goal  in  biomarker  discovery  is  the  development  of  blood-­based  assays,  as  
blood  reflects  information  regarding  all  physiological  and  biological  processes  in  the  body.    
Since  the  invention  of  mass  spectrometry  (MS)  more  than  15  years  ago,  many  potential  
candidate   cancer   biomarkers   have   been   identified.   However,   to   date   only   15  
plasma/serum  biomarkers  have  been  approved  by   the  United  States  FDA   (Table  1.1)  
Although  the  discovery  of  novel  biomarkers  is  not  problematic,  it  is  the  validation  process  
where   obstacles   occur   (Makawita   &   Diamandis   2010).   The   most   commonly   used  
proteomic   techniques   are   tissue   protein  microarray,   2D-­gel   electrophoresis   and  mass  
spectrometry.    
  
1.1.10.7  Mass  spectrometry  overview  
Mass  spectrometry  is  a  technique  used  to  detect,  identify  and  quantify  molecules  based  
on  their  mass-­to-­charge  ratio.  The  technique  was  originally  developed  almost  100  years  
ago   to   measure   masses   of   charged   atoms   and   separate   elemental   isotopes,   which  
contributed  to  the  development  of  the  nuclear  bomb  during  WWII  (Griffiths  2008).  Later  
MS  was  applied  to  study  protein  structures.  
MS  has  become  a  method  of   choice   for   cancer   biomarker  discovery,  as   it   is   used   to  
identify  unknown  compounds  within  complex  samples.  The  first  step  of  MS  analysis  is  the  
generation  of  ions  from  the  studied  substance  by  electron  ionisation.  These  ions  are  then  
fragmented  and  separated  according  to  their  mass/charge  ratio.  The  data  is  displayed  in  
the  form  of  a  plot  of  ion  abundance  versus  mass/charge  ratio.  The  identified  mass  is  then  
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compared   with   a   known   substance   using   a   database   thus   allowing   for   protein  
identification.      
To   ionise   proteins   different   ion   sources   are   used.      MALDI   (Matrix   Assisted   Laser  
Desorption/Ionisation)   is   the   ionisation   technique   used   to   analyse   DNA,   proteins   and  
sugars,  where  the  sample  is  mixed  with  a  laser  absorbing  matrix  to  create  ions.  SELDI  
(surface  enhanced  laser  desorption  ionisation)  is  a  variant  of  MALDI  that  relies  on  the  use  
of  a  ProteinChip  coated  with  specific  matrices  (hydrophobic,  cationic  or  anionic)  that  can  
trap  proteins  selectively.  To  avoid  unspecific  binding,   the  chip   is  washed  after   (Vertes  
2008).   LS-­MS/MS   method   is   the   combination   of   mass   spectrometry   and   liquid  
chromatography.  This   technique  offers  higher  accuracy   in  analysis  of   larger  biological  
molecules.  
  
1.1.10.8  2D-­polyacrylamide  gel  electrophoresis  (2D-­PAGE)  
2D-­PAGE  is  a  key  technique  in  comparative  proteomic  research,  the  use  of  which  allows  
thousands  of   proteins   to   be   separated   in   a  single   gel   resulting   in   the  generation  of   a  
protein  profile.  This  technique  is  used  to  find  differentially  expressed  protein  in  samples  
healthy  versus  diseased  individuals.  The  technique  involves  two  steps  to  separate  cell  
lysate   according   to   two   protein   properties;;   molecular   mass   and   charge.   In   the   first  
dimension,   proteins   are   solubilised   in   urea   and   are   separated   on   the   basis   of   their  
isoelectric  point  focusing  on  a  pH  gradient.  Proteins  migrate  until  they  have  no  net  charge  
(Saraswathy   et   al.   2011).   In   the   second   dimension,   proteins   are   loaded   onto   a  
polyacrylamide  gel  containing  sodium  dodecyl  sulphate  (SDS)  under  an  electric  field.  The  
proteins   are   denatured  and   due   to   the   presence   of   SDS   become   negatively   charged  
allowing   them   to   migrate   under   the   electric   field   according   to   the   molecular   weight  
51  
  
(O’Farrell  1975).  The  result  is  proteins  are  separated  in  distinct  regions  on  the  acrylamide  
gel,   which   is   then   stained.   Following   staining,   proteins   can   be   excised   from   the   gel,  
digested  with  proteases  and  identified  using  mass  spectrometry.  
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Table  1.1   list  of  United  States  Food  and  Drug  Administration  approved  plasma/serum  
biomarkers  (Chambers  et  al.  2014).  
Biomarker   Cancer   Sample   Year  
Pro2PSA   Prostate   Serum   2012  
ROMA(HE4+CA-­125)   Ovarian   Serum   2011  
OVA1  (multiple  proteins)   Ovarian   Serum   2009  
Fibrin  degradation  product   Colorectal   Serum   2005  
AFP-­L3%   Hepatocellular   Serum   2005  
CA19-­9   Pancreatic   Serum/Plasma   2002  
CA-­125   Ovarian   Serum/Plasma   1997  
CA15-­3   Breast   Serum/Plasma   1997  
CA27.29   Breast   Serum   1997  
Free  PSA   Prostate   Serum   1997  
Thyroglobulin   Thyroid   Serum/Plasma   1997  
a-­fetoprotein   Testicular   Serum/Plasma   1992  
Total  PSA   Prostate   Serum   1986  
Carcinoembryonic  antigen   Not  specified   Serum/Plasma   1985  
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1.1.10.9  Biomarker  development  pipeline  
The   biomarker   development   pipeline   represents   a   sequence   of   phases   that   include  
biomarker  discovery,  verification  and  validation  before  approval  for  use  in  clinical  settings  
(Figure  1.4).  In  the  discovery  phase,  a  list  of  potential  protein  biomarkers  is  generated  
using   mass-­spectrometry   based   experiments   performing   sample   fractionation   (gel  
electrophoresis,   iso-­electric   focusing  and   liquid  chromatography).  The   result   is   tens   to  
hundreds  of  differentially  expressed  proteins  that  are  discovered.  In  a  review  focused  on  
existing   biomarker   discoveries,   a   list   of   1261   putative   proteins   cancer   markers   was  
generated,  showing  that  there  is  no  shortage  of  proteins  in  the  discovery  phase  (Polanski  
&   Anderson   2007).   However,   there   is   discrepancy   between   biomarker   discovery   and  
clinical  validation.    
In  the  qualification  step,  given  the  high  number  of  discovered  candidate  biomarkers,  these  
have   to   be   filtered   to   select   for   the   most   promising   targets.   In   the   verification   and  
validation  phase  the  selected  biomarkers  undergo  quantification  using  various  techniques  
such  as  RT-­QPCR  and  protein  assays  to  exclude  false-­positive  candidates.  As  a  result,  
the  number  of   target  proteins   is  dramatically  decreased.  The  pre-­clinical  steps   involve  
expression  and  purification  of   protein   biomarkers   to   develop  antibodies   against   them.  
Finally,  in  the  clinical  stage  also  known  as  clinical  trials,  candidate  biomarkers  undergo  
validation  on  a  large  number  of  clinical  samples.  In  the  outcome  at  this  stage  surrogate  
and  clinical  endpoint  are  evaluated.  The  clinical  endpoint  reflects  on  how  patients  feel,  
function   or   how   long   a   patient   survives,   whilst   the   surrogate   endpoint   is   a   biomarker  






Figure  1.4  Main  stages  of  the  biomarker  development  pipeline.    The  discovery  
phase  involves  MS  experiment  to  generate  a  list  of  potential  biomarkers  which  are  then  




1.2  Cancer  and  immunity  
1.2.1  Relationship  between  cancer  and  inflammation.  
The   relationship   between   the   development   of   cancer   and   inflammation   was   first  
suggested  by  Dr  Rudolph  Virchow  in  1863.  He  identified  leukocytes  in  cancerous  tissues  
and  discovered  the  link  between  inflammation  and  cancer.  In  another  publication  in  1986,  
Harold  Dvorak  described   tumours  as  wounds   that  do  not  heal   (Flier  et  al.  1986).  The  
researcher   found  that   the  same  processes  are  required   for  wound-­healing  and  cancer  
progression.  Cancerous  cells  release  growth  factors  and  cytokines  in  the  same  way  as  
wounded  cells  do  to  recruit  leukocytes  and  initiate  an  inflammatory  response  that  includes  
proliferation  of  epithelial  cells  and  formation  of  blood  vessels  near  the  wound  (Weinberg  
2014).   A   recent   study   by   Feng   and   co-­workers   looking   into   parallels   between  
tumorigenesis  and  wound  inflammation  using  live  imaging  techniques  also  revealed  the  
same  pattern  of  leukocyte  recruitment  in  both  processes  (Feng  et  al.  2010).
  
1.2.2  Neutrophils  
Neutrophils,  also  referred  to  as  polymorphonuclear  leukocytes  are  the  most  common  type  
of  white  blood  cells,  comprising  50-­70  %  of  all  leukocytes.  They  represent  the  first  line  of  
immune  defence  against  invading  pathogens  and  along  with  other  leucocytes  they  are  
directed  to  repair  sites  of  damaged  tissues.  Neutrophils  functions  by  releasing  enzymes,  
anti-­bacterial   agents   and   cytokines.   In   the   blood   of   healthy   individual   these  
haematopoietic  cells  exist  in  a  non-­active  state,  ensuring  that  their  intracellular  content  is  
not  released  to  damage  host  tissue  (Wright  et  al.  2010).  
Neutrophils  develop   in   the  bone  marrow.  During   infection,   resting  neutrophils  become  
activated   (a   process   referred   to   as   priming)   and   recruited   to   the   site   of   infection   by  
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selectin-­  mediated   rolling,   integrin-­  mediated  adhesion  and   transmigration   through   the  
vessel  wall.  At  the  site  of  inflammation  neutrophils  release  cytokines  and  chemokines  to  
recruit   other   immune   cells,   engulf   pathogens   via   phagocytosis   and   form   neutrophil  
extracellular   traps   (NETs)   in   order   to   prevent   bacterial   spread.   In   the   absence   of  
inflammation,  neutrophils  die  apoptosis  (Figure  1.5)  (Geering  &  Simon  2011;;  Amulic  et  






Figure  1.5  Neutrophil  functions.  After  migrating  to  the  site  of  inflammation,  neutrophils  
phagocytose  and  digest  the  invading  microbes;;  release  NETs,  which  trap  bacteria;;  and  
produce   cytokines,   which   contribute   to   the   inflammatory   reaction.   Once   infection   is  
cleared,  neutrophils  die  by  apoptosis  and  promote  a  program  to  resolve   inflammation.  
Inset,  the  destruction  of  the  pathogens  inside  the  phagosome  occurs  by  ROS  generated  
by  the  NADPH  oxidase,  as  well  as  granule  enzymes  released  from  intracellular  granules.  
Illustration  is  taken  from  (Mócsai  2013).
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1.2.2.1  Role  of  neutrophils  in  cancer  
In  addition  to  their  antimicrobial  function,  a  new  role  for  neutrophils  as  modulators  of  anti-­
tumour   immunity   has   been   proposed   (Mantovani   et   al.   2011)   It   is   recognised   that  
leukocyte  infiltration  is  one  of  the  main  characteristics  of  a  wide  variety  of  human  tumours.  
Tumour  associated  neutrophils,  referred  to  as  TANs,  are  known  to  be  present  in  tumour  
leukocyte   infiltrate   and   it   has   been   shown   that   cancerous   cells   themselves   attract  
neutrophils  by  secreting  one  of  the  major  neutrophil  attractants,  interleukin  8  (Figure  1.7)  
(Gregory  &  Houghton  2011).  It  has  been  established  that  many  tumour  cell  lines  including  
breast,  colon,  cervical,   lung,  brain,  ovarian  display  elevated   levels  of   interleukin  8  (Xie  
2001).  
Recent  clinical  studies  indicate  that  high  levels  of  neutrophils  in  tumours  correlate  with  
poor   disease   outcome.   For   example,   the   presences   of   TAN   in   metastatic   renal   cell  
carcinoma  is  associated  with  poor  patient  survival  (Jensen  et  al.  2009).  Furthermore,  it  
has  been   revealed   that  an  elevated  count  of  neutrophils   in  whole  blood,   indicating  an  
acute   inflammation,   is   also   reported   in   cancer   patients   and   together   with   a   reduced  
number   of   lymphocytes   is   associated   with   poor   survival   in   patients   with   metastatic  
melanoma  and  metastatic  renal  cancer  (Schmidt  et  al.  2005;;  Negrier  et  al.  2002).  More  
recently,  the  neutrophil  to  lymphocyte  ratio  (LNR)  has  been  introduced  as  a  prognostic  
marker  for  colorectal  cancer  and  non-­small  cell  lung  cancer  (Tomita  et  al.  2011).  
How   neutrophils   contribute   to   carcinogenesis   has   only   been   partially   explained.   ROS  
released   by   neutrophils   are   thought   to   induce   DNA   damage   at   the   sites   of   chronic  
inflammation   (Güngör   et   al.   2010).   Neutrophils   have   four   types   of   granules   in   their  
cytoplasm  containing  different  proteinases  that  participate  in  normal  cell  proliferation.  A  
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growing  body  of  evidence  suggests  that  products  derived  from  neutrophils  have  roles  in  
tumour  cell  proliferation,  angiogenesis  and  metastasis  (Figure  1.6)  (Houghton  2010).  The  
ability  of  proteinases   to  activate  gene  expression   is  well  documented   in   the   literature.  
Furthermore,   tumour   invasion   involves  proteolytic   cascades  and  a   positive   correlation  
between  the  aggressiveness  of  tumour  and  the  secretion  of  various  proteases  has  been  
found.  Due  to  their  wide  variety  of  functions,  extracellular  proteases  and  their  inhibitors  
have  great  potential  as  clinical  biomarkers  for  predicting  outcome  disease  outcome  (Roy  





Figure  1.6  Schematic  representation  of  tumour  dissemination  and  the  supporting  
role  of  proteases  in  this  process.  In  order  to  spread,  tumour  cells  must  leave  the  actual  
tumour  and  enter  the  bloodstream  or  lymphatic  system.  For  this  purpose,  they  use  certain  
enzymes  (proteases),  that  break  down  the  tissue  surrounding  the  tumour  (Rakash  2012).  
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Angiogenesis  is  the  formation  of  new  blood  vessels  from  the  existing  vascular  beds  that  
occurs  normally  in  the  human  body  during  embryogenesis.  In  adults,  the  process  of  the  
formation  of  new  blood  vessels  is  restricted  to  physiological  situations,  such  as  wound  
healing  and  female  reproductive  cycling.  During  the  menstrual  cycle,  angiogenesis  occurs  
in  order   to  support   the  growth  of   the  endothelium  and  neutrophils  are   found  to  be   the  
source   for  pro-­angiogenic  vascular  endothelium  growth   factor   (VEGF)   in   these  tissues  
(Mueller  et  al.  2000).  
During  tumour  progression  the  formation  of  new  capillaries  is  continued  in  order  to  supply  
growing   tumour   cells   with   oxygen   and   nutrition   and   the   positive   correlation   between  
intensity  of  angiogenesis  and  tumour  invasiveness  has  been  reported  (Folkman  2006).  
Recent  studies  investigating  the  role  of  neutrophils  in  angiogenesis  suggest  the  existence  
of  an  angiogenic  subtype  of  neutrophils  that  is  distinct  from  inflammatory  neutrophils.  Pro-­
angiogenic  neutrophils  are  thought  to  be  recruited  to  the  site  of  malignancy  via  interleukin  
8   (also   known   as  CXCL)  where   they,   together   with   tumour   associated  macrophages,  
release  Oncostatin  M  and  metalloproteinase  9  (MMP-­9)  that  induce  VEGF  to  promote  the  





Figure      1.7    Mechanism  of  neutrophil  recruitment  to  tumours.      Tumour  cells  produce  
chemokines  (CXCL1,CXCL2    etc.),  which  are  chemoattractants  for  neutrophils    .  the  cell    
then   migrate      out   of   the   blood   circulation   into   the   tumour.   Where   they   produce  













Figure  1.8  Angiogenic  function  of  neutrophils.  Neutrophils  are  recruited  by  malignant  
cells   via   the   secretion   of   Interleukin   8   (CXCL).  Once   inside   the   tumour,   they   release  
factors   such  as  Oncostatin  M  and  MMP-­9   to   activate   the   production   of  VEGF  by   the  
tumour  in  order  to  promote  angiogenesis  (Tazzyman  et  al.  2009).
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1.2.3.  Discovery  of  novel  white  blood  cells-­based  cancer  biomarkers  
Previous  studies  have  found  that  peripheral  blood  cells  are  a  valuable  source  for  breast  
cancer   biomarkers,   as   cancer   provokes   an   immune   response   reflecting   in   detectable  
changes  in  circulating  blood  cells.  Blood  biomarkers  have  a  high  potential  for  early  cancer  
diagnosis  and  prognosis,  and  could  be  used  to  aid  or  even  replace  mammography  (Aarøe  
et  al.  2010).  
It  is  recognised  that  cancer  cells  interact  with  the  host  immune  system  and  it  is  reflected  
in   changes   in   gene   expression   profiles   in   peripheral   blood   cells.   A   wide   range   of  
techniques   including   microarrays   and   proteomic   methods   were   used   for   biomarker  
discovery  in  the  blood  of  cancer  patients.  For  example,  it  was  suggested  that  whole  blood  
can  be  used  as  a  diagnostic   tool   for  detection  of  cancer  during  early  stages.   In   these  
studies  the  cancer-­related  gene  expression  patterns  in  the  blood  of  breast  cancer  patients  
were   analysed   and   groups   of   genes   with   altered   expression   in   cancer   patients   were  
discovered   (Lönneborg   et   al.   2009;;   Aarøe   et   al.   2010).   These   genes  were   related   to  
various   functional   processes   such   as   defence   response,   translation,   and   metabolic  
processes  (e.g.  lipid  and  steroid  metabolism).  
In  agreement  with  the  above  study,  work  conducted  previously  within  the  Klenova  group  
has   demonstrated   that   white   blood   cells   (WBCs)   are   a   potential   source   for   cancer  
biomarkers  (D’Arcy  et  al.  2008).  A  number  of  candidate  blood-­based  biomarkers  were  
identified   to   be   used   for   early   breast   cancer   diagnosis,   prognosis   and   treatment  
monitoring.   In   these   studies,   proteomic   approaches   were   applied;;   they   included   two  
approaches   (1)   2D   gel   electrophoresis   followed   by   mass   spectrometry   and   (2)   the  
proteome-­wide  profiling  of  membrane  fractions  of  WBCs  using  the  Orbitrap  Velos  mass  
spectrometer.  The  protein  profiles  of  WBCs  from  breast  cancer  patients  were  analysed  
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and  compared  to  those  of  healthy  donors.  As  a  result,  a  panel  of  candidate  proteins  were  
selected  based  on  various  criteria  for  further  investigation.  Among  those  criteria  were  the  
proteins   role   in   the   tumour   immune   response,   increase  or   decrease   in   protein   levels,  
presence  in  WBCs  in  healthy  donors  and  others  (Many,  J.,  PhD  thesis,  2015).  
To  identify  the  differences  between  different  grades  and  stages,  samples  were  chosen  in  
patients  with   either  Grade1-­Stage1   tumours   (favourable   prognosis)   or  Grade3-­Stage3  
tumours  (less  favourable  prognosis).  We  reasoned  that  by  choosing  samples  with  these  
characteristics   the   differences   in   proteome   would   be   significant.   Orbitrap   LFQ   mass  
spectrometer  was  used   to  generate  proteome  profiles  of  WBCs.  Protein  profiles  were  
then  compared  between  different  patients’  cohorts.  The  pipeline  of  biomarkers  discovery  
is  presented  in  Figure  1.9.  After  a  rigorous  process  of  shortlisting  fifteen  candidates  were  




Figure  1.9  Workflow  of  proteomics  biomarker  development  pipeline.  To  identify  the  
differences  between  different  grades  and  stages,  samples  were  chosen  in  patients  with  
either  Grade1-­Stage1  tumours  (favourable  prognosis)  or  Grade3-­Stage3  tumours  (less  
favourable  prognosis).  We  reasoned  that  by  choosing  samples  with  these  characteristics  
the  differences  in  proteome  would  be  significant.  Orbitrap  LTQ  mass  spectrometer  was  
used   to   generate   proteome   profiles   of   WBCs.   Protein   profiles   were   then   compared  
between   different   patients’   cohorts.   After   a   rigorous   process   of   shortlisting   fifteen  
candidates  were  selected  for  further  validation  (see  Table  1.2  for  details).
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Table   1.2  Short   listed  biomarker   candidates   identified   in   the  previous  study   for  
further  validation   (Mani,  PhD   thesis,  2015):  Genes  common   from  different  datasets  
comparing  healthy  donors,  primary  breast  cancer  patients  and  metastatic  breast  cancer  
patients  were  obtained.  The  overlapping  genes  were  further  shortlisted  based  on  several  
criteria;;  normal  presence  in  WBC,  correlation  with  clinical  response/data,  relative  levels  
to   healthy   donor,   function   in   immune   response   and   association   with   cancer   through  
literature  search  to  give  a  15  panel  gene  list  to  be  further  validated.  Red  coloured  cells  
indicate  overexpression;;  green   indicates  underexpression;;  pink  overexpression  only   in  
low  grade  breast  cancer.The  presence  in  metastatic  breast  cancer  cohort  is  denoted  by  
‘X’  and  the  fold  change  is  not  included  since  the  initial  analysis  did  not  include  comparison  
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Our   current   laboratory   studies   analysing  protein   profiles   of  WBCs   from  breast   cancer  
patients  show  promising  results  for  five  of  the  identified  proteins.  Their  use  for  early  breast  
cancer  diagnosis,  prognosis  and  treatment  monitoring  is  currently  being  investigated.    
1.2.3.1  Biological  function  of  Serpin  B1    
One  of  the  short-­listed  candidate  biomarker  is  Serpin  B1,  a  member  of  serpin  family  of  
proteinase  inhibitors  that  maintain  homeostasis  by  neutralising  overexpressed  protease  
activity.  Serpins,   the   largest   family   of   protease   inhibitors   that   include   several   hundred  
members  was  first  described  in  1980.  These  proteins  are  encoded  by  genes  located  on  
10  different   chromosomes  and   characterised  by   the   absence  of   the  N-­terminal   signal  
peptide  required   for   the  secretion  pathway  and  therefore  reside   intracellularly.  Despite  
their  exclusively  cytoplasmic  distribution,  extracellular   localization  of  serpins  has  been  
reported.   For   instance,   SerpinB5   was   found   in   secretory   vesicles   at   the   cell   surface  
(Pemberton   et   al.   1997).   Although,   the   exact   mechanism   remains   unknown,   a   study  
aiming   to   investigate   the  secretion  of  serpin  by  blood  monocytes   revealed  alternative,  
endoplasmic  reticulum  ER-­Golgy-­independent  pathway  (Ritchie  &  Booth  1998).  Serpin  
exist  in  two  forms,  a  native  metastable  form  that  changes  into  a  relaxed  stable  form  after  
binding   to   the  protease     (Gatto  et  al.  2013).  The   interaction  of  serpins  with  proteases  
happens  through  inhibitory  and  substrate  pathways  and  results  in  protease  degradation.  
Proteases   play   roles   in   the   regulation   of   a   variety   of   biological   processes   including  
angiogenesis,  apoptosis,  cell  migration  and  blood  coagulation  (Mangan  et  al.  2008).    The  
prevention  of  unwanted  proteolytic  activity  of  proteases  is  regulated  by  inhibitors  such  as  
the  serine  protease  family  (Bots  &  Medema  2008).      
The  Serpin  B1  protein   is  expressed   in   the  cytoplasm  of  granulocytes,  monocytes  and  
macrophages   where   it   inhibits   several   target   molecules;;   neutrophil   elastase   (NE),  
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cathepsin   G,   proteinase-­3   and   regulates   NET-­osis.   NE   is   secreted   by   activated  
neutrophils   during   inflammatory   processes   with   a   role   in   the   degradation   of   foreign  
organic  molecules  phagocytised  by  neutrophils.   It  has  been   reported   that  NE   induces  
lung  tumour  growth  and  proliferation  (Houghton  et  al.  2010).    
Serpin  B1  has  been  shown  to  be  associated  with  tumour  progression.  Increased  levels  of  
this  protein  are  reported  in  62.5  %  of  invasive  oral  squamous  cell  carcinomas  (Tseng  et  
al.  2009).  In  our  study,  we  observed  elevated  levels  of  Serpin  B1  in  leukocytes  of  breast  
cancer   patients.   One   can   hypothesise   that   in   order   to   initiate   the  metastatic   process  
cancer   cells  must   degrade   the  extracellular  matrix   (ECM)  barrier.   This   is  achieved  by  
overexpression   of   several   families   of   proteases   including   serine   proteases   and  
metalloproteinases  (Roy  &  Walsh  2014).  
1.2.3.2  Biological  function  of  Lipocalin  2  
Lipocalin  2  (LCN2),  also  referred  to  as  neutrophil  gelatines  associated  Lipocalin  (NGAL)  
belongs  to  the  family  of  small  proteins  characterised  by  their  ability  to  bind  and  transport  
lipophilic  molecules  such  as  retinols,  steroids  and   iron.     The  LCN2  gene   is   located  at  
9qN34  and   contains   7   exons.  Recently,   several   new  properties   attributed   to   Lipocalin  
have  been  reported  such  as  prostaglandin  synthesis,  protease  inhibition  and  modulation  
of  cell  growth.  The  expression  of  NGAL   is   induced  by  cytokines  and  was   found   to  be  
upregulated  under  inflammatory  conditions  (Bauer  et  al.  2008).  
NGAL  is  secreted  by  neutrophils  in  few  conformations,  as  a  monomer  or  as  a  complex  
with   matrix-­metalloproteinese-­9   (MMP-­9).   This   enzyme   belongs   to   the   family   of   zinc-­
dependent  endopeptidases  comprising  of  23  members  with  different  substrate  specificity  
and  tissue  specific  expression  patterns  (Roy  &  Walsh  2014).  MMPs  have  various  roles  in  
the   regulation   of   signalling   pathways   that   control   cell   growth,   inflammation   and  
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angiogenesis.  In  cancer  MMPs  are  thought  to  have  multiple  functions.    The  central  roles  
are  promotion  of  cancer  cell  invasiveness  via  degradation  of  the  ECM  and  the  support  of  
angiogenesis  via  liberation  of  VEGF  (Bergers  et  al.  2000).  Recent  studies  investigating  
the  prognostic  utility  of  MMPs  in  breast  cancer  patients  revealed  that  MMP-­9  expression  
in  breast  tumours  is  highly  associated  with  higher  tumour  grade  and  ER-­negative  status  
(McGowan  &  Duffy  2008).  
The  role  of  Lipocalin  2  in  the  regulation  of  the  innate  immune  response  is  attributed  to  its  
iron-­binding  property.  Iron  is  necessary  for  all   living  organism.  During  infection,  cells  of  
the   innate   immune  response  stimulate   the  secretion  of  Lipocalin  2   in  order   to   limit   the  
availability  of  this  nutrient  resulting  in  inhibition  of  bacterial  activity  (Reilly  et  al.  2012).  
Heightened   expression   of   Lipocalin   2   has   been   reported   in   many   epithelial   cancers  
including  breast  carcinomas.  For  example,  Lipocalin  2  was  found  to  be  up-­regulated  in  
the  plasma  of  a  mouse  model  of  breast  cancer  (Pitteri  et  al.  2008).   In  human  studies,  
Bauer  et  al.  examined  the  localization  of  NGAL  in  tumours  of  208  primary  breast  cancer  
patients   using   an   immunostaining   technique   and   compared   the   results   with   clinical  
outcome.  The  researchers  detected  strong  correlation  between  cytoplasmic  location  of  
NGAL   and  HER2   overexpression,   lymph  node  metastasis   and   decrease   disease-­free  
survival  (Bauer  et  al.  2008).
  
1.2.3.3  Biological  role  of  Copine  3  (CPNE3)  
Another   protein   identified   by   previous   work   within   the   Klenova   group   is   CPNE3-­   a  
calcium-­dependant   phospholipid-­binding   protein   that   exists   in   the   cytosol   of   human  
neutrophils.   This  protein  belongs   to   a   group  of   proteins   characterised  by   two   calcium  
binding  C-­2  domains  at  the  N-­terminus  and  an  A-­domain  at  the  C-­terminus.  The  A-­domain  
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shared   distant   similarity   with   the   A-­domain   of   certain   integrins   which   can   bind   other  
proteins   in   a   Ca2+   and   Mg2+   dependent   manner   which   are   involved   in   cell   migration  
(Perestenko  et  al.  2010).  Proteins  that  exhibit  C2  domains  that  are  required  for  calcium  
dependent  binding  to  phospholipids  include  enzymes  such  protein  kinases.  Interestingly  
some   studies   based  on  phosphorylation   experiments   have  demonstrated   that  CPNE3  
may   function   as   a   protein   kinase   (Caudell   et   al.   2000).   CPNE3   was   found   to   be  
ubiquitously  expressed  in  mammalian  tissues.    
In  primary  breast  cancer,  elevated  levels  of  CPNE3  was  found  to  correlate  with  levels  of  
HER-­2  and  suggested   that  Copine-­3  has  a  role   in   the  regulation  of  HER-­2  dependant  
tumour   progression.   The   exact   mechanism   of   the   regulation   is   unknown,   however,  
bioinformatics   analysis   suggested   that   CPNE3   does   not   bind   HER-­2   directly.  
Furthermore,   CPNE3   expression   was   detected   in   prostate   and   ovarian   tumours  
suggesting  its  more  general  role  in  carcinogenesis  (C  Heinrich  et  al.  2010).  
Abnormally   low   expression   of   CPNE3   has   been   reported   in   the   peripheral   blood   of  
patients  with   stable   coronary   artery   disease  and  has  been  proposed   to   be  used  as   a  
genetic  marker  on  the  risk  of  recurrence  of  the  disease  (Tan  et  al.  2018).  For  patients  with  
acute  myeloid  leukaemia  high  levels  of  CPNE3  in  monocytes  were  identified  as  poor  a  
prognostic  factor  as  it  was  found  to  correlate  with  shorter  overall  survival  (Lin  Fu  et  al.  
2017).  
1.2.3.4  Biological  role  of  Integrin  a4  
Integrins  are  the  family  of  24  heterodimeric  adhesion  receptors  required  for  the  interaction  
of  cells  with  the  extracellular  matrix  (ECM),  cell  migration,  growth  and  differentiation.  As  
a  result,   integrins  play  an  essential  role  in  physiological  as  well  as  pathological  events  
such  as  inflammation  and  tumourigenesis.  Each  integrin  is  a  heterodimer  composed  of  a  
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and  b   subunits  specific   for   the   interaction  with  proteins  of   the  ECM,  namely  collagen,  
fibronectin  and  laminin  (Hinton  et  al.  2008).    
Integrin  signalling  is  bidirectional  allowing  for  a  diverse  cellular  outcome.  The  inside-­out  
signalling  is  directed  by  binding  of  intracellular  activators  such  as  talin  and  kindlins  to  the  
“tail”  of  the  receptor,  which  in  turn  allows  the  cell  to  bind  to  the  ECM  proteins  and  facilitates  
cell  adhesion  and  migration.  The  outside-­in  signalling  enables  binding  of  the  extracellular  
ligands  to  the  “head”  of  the  receptor,  allowing  the  transmission  of  the  signal  into  the  cell  
(Figure   1.10).   The   combination   of   both   types   of   signalling   contribute   to   the   broad  
repertoire   of   the   integrin  molecules   function   and   their   ability   to   control   the   variety   of  
processes  such  as  cell  proliferation  and  survival  (Shattil  et  al.  2010).  Several  studies  have  
demonstrated   the  crucial   role  of   integrin  signalling   in  each  step  of  metastatic  cascade  
(Akalu  et  al.  2005;;  Parise  et  al.  2000;;  Gilcrease  2007).    
Integrin   a4,   also   known   as   CD49d,   is   a   cellular   adhesion   receptor   involved   in   the  
migration  of  lymphocytes  from  blood  to  the  sites  of  infected  tissues.  CD49d  is  an  a  chain  
of   very-­late   antigen   (VLA)-­4   that   forms   a   heterodimer  with   integrin  b1   and  b7   and   is  
involved  in  cell  adhesion  to  fibronectin.  This  receptor  is  primarily  expressed  on  T-­  and  B-­
lymphocytes,  but  not  on  neutrophils.    
The  altered  expression  of  integrin  4  in  human  cancers  has  been  associated  with  tumour  
progression  (Rincon  et  al.  1992;;  Holzmann  et  al.  1998).  For  instance,  low  levels  of  integrin  
alpha4   have   been   reported   in   gastric   carcinoma   cells.   In   this   study,   following  
overexpression  of  the  gene,  the  reduction  of  the  invasiveness  of  the  gastric  cancer  cells  
was  observed.  As  the  mechanism  of  downregulation,  transcriptional  silencing  of  Integrin  
a4   by   DNA   methylation   was   identified   (Park   et   al.   2004).   Another   study   reported  
hypermethylation  of  the  Integrin  a4  gene  as  a  poor  prognostic  factor  in  breast  cancer,  as  
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Figure   1.10   Structure   of   Integrin.   Integrins   are   heterodimeric   adhesive   receptors  
designed   to  act   as   bidirectional   signalling  molecules.   They  are   composed  of  a   and  b  
subunits.  N-­terminal  (“head”),  the  ligand  binding  site  is  presented  by  b-­propeller  and  bA  
domain.  C-­terminal  cytoplasmic  domain  (“tail”)    (Shattil  et  al.  2010).
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1.2.3.5  Biological  role  of  Lipoxygenase  5  (5LOX)  
Leukotrienes  are  pro-­inflammatory  regulators,  their  name  originates  from  the  cells  which  
they  are  derived,  namely  leukocytes  (macrophages,  neutrophils  and  eosinophils).  5LOX  
is  a  member  of  a  large  family  of  enzymes  required  for  the  biosynthesis  of  leukotrienes.  
5LOX  has  two  structural  domains,  a  C-­terminal  a-­helix  containing  the  catalytic  site  and  
an   N-­terminal   b   barrel   that   facilities   calcium   dependent   activation   of   the   enzyme  
(Rådmark  &  Samuelsson  2010).  The  5LOX  enzyme  is  usually  located  in  the  cytoplasm  
as   soluble   protein,   yet   in   the   presence   of   calcium   it   translocates   to   the   nucleus   or  
endoplasmic  reticulum,  where  with  the  help  of  its  activating  protein  FLAP  it  catalyses  the  
oxygenation   of   arachidonic   acid   and   therefore,   synthesis   of   leukotrienes   (Tuncer   &  
Banerjee  2015).  Furthermore,  independently  from  calcium  activation,  different  forms  of  
cell  stress  such  as  oxidative  stress  or  osmotic  shock  lead  to  the  activation  of  5LOX  and  
the  production  of  leukotrienes  (Werz  et  al.  2002).    
Leukotrienes   function   as   anti-­inflammatory   molecules.   It   is   known   that   chronic  
inflammation  is  a  risk  factor  for  carcinogenesis.  The  expression  of  5LOX  has  been  shown  
to  increase  within  the  tumour  microenvironment  (Wang  &  Dubois  2010).  The  role  of  5LOX  
in  the  growth  of  several  tumour  types,  including  pancreatic,  colorectal,  prostate  and  breast  
cancer  has  been  reported  (Harris  2009).    It  is  believed  to  be  produced  by  cancerous  cells  
as  well  as  tumour  associated  macrophages  (TAM)  and  its  abhorrent  expression  shown  
to  contribute  to  the  survival  and  proliferation  of  malignant  cells  (Rådmark  &  Samuelsson  
2010).  Furthermore,  the  expression  of  5LOX  correlates  with  density  of  TAM  in  hypoxic  
areas  of  ovarian  tumours  (Wen  et  al.  2015).    
Due   to   its   heightened  expression   in   tumours,   5LOX  become  an  attractive   therapeutic  
target  in  research.  For  instance,  in  a  study  on  chronic  myeloid  leukaemia,  this  enzyme  
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was  identified  as  a  critical  regulator  of  leukaemia  stem  cells  (LSCs)  and  its  inhibition  was  
shown  to  cause  impairment  of  LSCs  (Chen  et  al.  2009).  Study  on  the  genetic  deletion  of  
5LOX  in  mast  cells  of  mice  xenografted  with  human  colon  cancer  showed  a  significant  
reduction  of  the  tumour  mass  (Cheon  et  al.  2011).    Whereas,  in  lung  cancer  models,  mice  
globally   deficient   in   5LOX   exhibited   increased   tumour   volume   and   liver   metastases  
(Poczobutt  et  al.  2016).  Furthermore,  5LOX  is  proposed  to  be  a  potential  serum  protein  
marker  for  breast  cancer,  as  elevated  levels  have  been  reported  in  the  serum  of  breast  
cancer  patients  (Kumar  et  al.  2016).  
1.2.4  Autoantibodies  in  the  plasma  of  cancer  patients  
Although  little  is  known  about  the  origin  of  the  immune  response,  it  is  now  recognised  that  
cancer  patients  produce  autoantibodies  to  cancer  proteins,  particularly  in  breast  cancer  
(Carney  et  al,  2013).  Many  studies  have  begun  to  emerge,  showing   that  autoantibody  
production   takes  place  many  years  before   the  diagnosis  of  cancer  and   therefore,  can  
serve  as  an  early  marker  for  cancer  (Frenkel  et  al.  1998).  
For  years  autoantibodies  (AAb)  were  considered  to  be  a  by-­product  associated  with  the  
breakdown  or  release  of  tumour  proteins.  Nowadays  the  production  of  AAb  is  believed  to  
be  triggered  by  the  overexpression  of  self-­antigen  on  the  surface  of  malignant  cells  and  
the  inflammatory  reaction  within  tumours.  Leukocyte  infiltration  detected  in  different  types  
of  tumour  support  the  above  hypothesis  (Madrid  &  Maroun  2011).  
Although  autoantibodies  have  showed  promising  results  as  novel  diagnostic  biomarkers  
for   the  early  detection  of  many  cancers,  the   low  sensitivity  and  specificity  have   limited  
their   clinical   application   (Zhong  et   al.  2008).   The  presence  of   p53  autoantibodies  has  
been  observed  in  only  15%  of  patients  with  breast  cancer  and  has  been  associated  with  
other  diseases  as  well  (Lenner  et  al.  1999;;  Kulić  et  al.  2010).  
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Since  a  single  biomarker  lacks  sensitivity  and  specificity,  recent  studies  now  concentrate  
on  identification  of  a  panel  of  autoantibodies  to  increase  the  reliability  and  accuracy  of  
diagnosis  (Chapman  et  al.,  2007;;  Desmetz  et  al,  2011;;  Dong  et  al.,  2013).
1.3  Prostate  cancer  
With  more  than  670,000  diagnosed  cases  per  year  prostate  cancer  is  the  second  most  
common  type  of  cancer  in  men  worldwide  (Van  Hemelrijck  et  al.  2012).    Early  detection  
of  the  disease  during  stage  1  allows  for  almost  100%  survival.  However,  once  the  cancer  
has  metastasised  outside  the  prostate  gland,  the  survival  rate  falls  significantly  It  is  most  
commonly  diagnosed  in  men  aged  65  and  above  which  account  for  75%  of  diagnosed  
cases.   Men   under   50   years   of   age   represent   1%   of   the   prostate   cancer   diagnoses  
(Crawford  et  al.  2017).
1.3.1  The  prostate  gland  under  normal  physiological  conditions      
The  prostate  gland  is  part  of  the  male  reproductive  and  urinary  system  (Figure  1.11).  This  
pyramid-­shaped  organ  is  located  at  the  base  of  the  bladder.  In  younger  men,  the  gland  is  
approximately   the   size   of   a  walnut,   however,   the   organ  enlarges  with   age.  The  main  
purpose  of   the  prostate  gland   is   the  secretion  of  alkaline   fluid   that   represents  20%  of  
seminal   liquid.   The  prostate   gland   is   divided   into   a   right   and  a   left   lobe   composed  of  








13.2  Diagnosis  and  treatment  
During  early  stages  prostate  cancer  is  asymptomatic,  however,  at  the  later  stage  painful  
urination,  blood  in  urine  or  seminal  fluid  and  thigh  pain  is  reported  by  patients.  The  risk  of  
developing  prostate  cancer   increases  with  age.  The   incidences  of  prostate  cancer  are  
highest  in  African-­American  populations  and  lowest  in  Asian  populations  (Kinseth  et  al.  
2014;;  Kimura  2012).    
Diagnostic  tools  for  prostate  cancer  include  prostate  specific  antigen  (PSA)  test,  digital  
rectal  examination  (DRE),  biopsy  and  Magnetic  Resonance  Imaging  (MRI)  (Lavery  et  al.  
2016).  Staging  and  grading  of  the  tumour  are  important  predictors  for  disease  outcome.  
Staging   of   the   disease   is   evaluated   by  measuring   tumour   size/volume   and  malignant  
potential  of  the  cancer.  It  involves  DRE  or  MRI  scanning  and  categorised  into  4  stages.  
Grading  of  the  prostate  tumour  is  performed  using  Gleason  Grading  System  based  on  
the  microscopic  examination  of  the  biopsy  specimen.    According  to  this  method  low-­grade  
tumours  are  associated  with  small  and  uniformly  packed  glands.  High-­grade  tumours  are  
characterised  by  loose  glandular  architecture  and  more  spread  out  cells.    
Although  both  grading  and  staging  of  prostate  cancer  are  very  important  determinants  for  
prostate  cancer  management,  they  are  associated  with  invasive  and  painful  procedures  
and  are  not  accurate  in  early  detection  of  the  disease.      
Management  of  prostate  cancer  depends  on  the  stage  of  the  disease.  For  stages  I-­III  of  
prostate  cancer  patients,  treatment  involves  radical  prostatectomy  and  radiotherapy.  For  
the   advanced,   stage   four   patients   endocrine   therapy   and   chemical   castration   are   the  
choice  of  treatment  (Trewartha  &  Carter  2013).  Endocrine  therapy  also  called  androgen  
deprivation  therapy  for  the  treatment  of  advanced  prostate  cancer  was  introduced    in  1941  
(Huggins  &  Hodges  1941).  The  basis  of  the  treatment  is  to  deprive  prostate  cancer  cells  
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from  androgens.  Testosterone  is  the  major  androgen,  in  the  prostate  it  is  converted  into  
dihydrotestosterone  (DHT)  by  the  enzyme  5a-­reductase.  DHT  has  a  higher  affinity  to  the  
androgen  receptor  and  greater  stimulation  of  prostate  tumour  growth  than  testosterone.  
The  5a-­reductase   inhibitor   is   often   used   as   a   treatment   option   to   reduce   the   level   of  
circulating  DHT.  The  vast  majority  of  cancers  respond  to  androgen  deprivation  therapy.  
Although,  endocrine  treatment  improves  survival,   it   is  not  curative  and  has  an  adverse  
effect  on  quality  of  life  (Tammela  2012).
1.3.3  Established  and  emerging  biomarkers  of  prostate  cancer  
The  most  commonly  used  serum  biomarker  for  detection  of  prostate  cancer  is  prostate  
specific  antigen  (PSA)  (Gaudreau  et  al.  2016).  The  discovery  of  PSA  in  the  late  1970’s  
has  revolutionised  management  of  the  disease  and  saved  many  lives  (Ablin  1972).  PSA  
is   produced  by   prostate   epithelial   cells   and   found   in   semen.  PSA   is   a   33   kDa   serine  
protease,  a  member  of  the  Kallikrein  family  of  proteins.    
At   low   levels,   it   is   present   in   the   serum   of   healthy  men,   however   in   the   presence   of  
prostate  cancer  it  levels  are  found  to  be  elevated.  Other  factors  such  as  age,  ethnicity,  
obesity  and  some  medication  are  reported  to  affect  levels  of  PSA.  Those  factors  result  in  
over   diagnosis   of   the   disease  and   lead   to  unnecessary  biopsy   investigation   and  over  
treatment  causing  distress  among  patients  (Adhyam  &  Gupta  2012).    
A  major  challenge  in  the  management  of  prostate  cancer  revolves  around  the  failure  of  
existing   diagnostic   tools   such  as  PSA   to   distinguish   between  benign  hyperplasia   and  





1.3.4  Urine  based  biomarkers  of  prostate  cancer  
Urine   represents   a   cost-­effective   and   non-­invasive   source   for   prostate   cancer   (PCa)  
biomarkers.  Urinary  cancer  markers  include  DNA-­,  RNA-­  and  protein-­based  biomarkers.    
Epigenetic  modifications,  such  as  DNA  hypermethylation  occurs  under  the  influence  of  
stress  and  dietary  factors  and  leads  to  increased  risk  of  cancer  formation  (Estelle  ret  al,  
2001;;  Jones  et  al,  2002).  This  event  happens  in  the  early  stage  of  carcinogenesis  and  
therefore,   can   serve   as   a   biomarker   for   early   cancer   detection.   Currently,   the  
hypermethylation   of   over   40   genes   have   been   investigated.   One   of   the   best   studied  
examples   is   the   hypermethylation   of   glutathione  S-­transferase   P1   (GSTP1)   which   is  
present  in  90%  of  the  PCa  and  in  78%  of  the  corresponding  urine  sediments  (Goessl  et  
al.   2001).      Another   example   is   the   tumour   suppressor   gene   Ras-­association   domain  
family  protein  isoform  A  (RASSF1A),   in  which  silencing  is  observed  in  70%  of  prostate  
tumours  (Kuzmin  et  al.  2002).    
Properties   of   several   potential   protein-­based   biomarkers   currently   being   investigated.    
Among  them  the  serum/urine    PSA  ratio  for  early  diagnosis  of  prostate  cancer,  Annexin  
A3   (ANXA3)   calcium-­binding   protein   production   of   which   is   decreased   in   malignant  
prostate  tissue  and  the  role  of  increased  levels  of  MMP9  (Irani  et  al.,  2005;;  Bolduc  et  al.,  
2007;;  Schostak  et  al.,  2009;;    Roy  et  al.,  2008).    
PCA3   is   a   commercially   available   RNA-­based   prostate   cancer   test,   discovered   by  
comparative  gene  expression  methodologies  (Bussemakers  et  al.  1999).    
The   expression   of   miRNA   is   highly   dysregulated   in   prostate   cancer   tissue,   however,  
diagnostic  properties  of  urinary  miRNA  failed  to  show  an  improvement  in  prostate  cancer  
detection  (Kalogirou  et  al.,  2013;;  Stephan  et  al,  2015).  
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1.3.5  Exosomal  biomarkers    
Exosomes   are   the   small   vesicles   released   by   various   cell   types   into   extracellular  
microenvironment   by   the   endocytic   recycling   pathway   (Figure   1.12)   (Lee  et   al.   2012).  
Exosomes   contain   proteins,   lipids,  mRNA   and  microRNA  molecules   and   carry   tissue  
specific   information.   Exosomes   function   in   cellular   communication   by  merging   with   a  
recipient  cell  and  releasing  their  contents  resulting  in  altered  cellular  function.  
Proteomic  studies  on  exosome  composition  reported  variation  depending  on  the  cell  type  
origin  (Mathivanan  et  al.  2010).  The  content  of  exosomes  can  reveal  information  about  a  
host  cell  and  underlying  pathophysiological  conditions  such  as  cancer  and  inflammation.  
Furthermore,  exosomes  can  be  isolated  from  all  body  fluids  such  as  blood,  urine,  sweat  
and  tears.  These  characteristics  of  exosomes  make  them  an  ideal  source  of  biomarker(s)    
with  diagnostic  and  prognostic  value  (Rak  2013).  Numerous  studies  analysing  exosomal  
content  revealed  that  exosomes  derived  from  the  fluids  of  cancer  patients  have  different  
protein,  DNA  and  RNA  expression  levels  and  profiles  (Balaj  et  al.  2011;;  Simpson  et  al.  
2012).    To  study  exosomes,  common  markers  such  as  CD9,  CD63,  Alix  and  TSG101  are  
used  (Willms  et  al.  2016).    
In  the  recent  study,  prostate  cancer  biomarkers,  PCA3  and  TMPRSS2-­ERG  have  been  
detected  in  exosomes  isolated  from  urine  of  prostate  cancer  patients  (Nilsson  et  al.  2009).  
Furthermore,   high   levels   of   plasma-­derived   exosomal   survivin   have   been   reported   in  
prostate  cancer  patients,  showing  potential  as  an  early  disease  biomarker  (Khan  et  al.  
2012).  Another  study  on  circulating  exosomal  miRNAs  revealed  the  association  between  




Figure  1.12  A  Synthesis  of  exosomes.  Firstly,  the  exosomal  vesicle  is  formed  at  the  
plasma  membrane  in  the  form  of  an  early  endosome,  which  then  matures  into  the  late  
endosome   or   multivesicular   bodies   (MVBs).   Next,   MVBs   merge   with   the   plasma  
membrane  and  release  exosomes  into  the  extracellular  space.  B  Structure  of  exosomes  
showing  common  membrane  exosomal  markers  CD9/CD63  in  addition  to  the  intracellular  
markers  Alix  and  Tsg101  (Lee  et  al.  2012).
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1.3.6  Brother  Of  the  Regulator  of  Imprinting  Sites  –  BORIS  
In  a  previous  study,  BORIS-­  cancer  testis  antigen  (CTA)  was  detected  in  the  leukocytes  
of  breast  cancer  patients,  while  in  normal  healthy  conditions  it  is  not  present  in  peripheral  
blood   (D’Arcy   et   al.   2008;;   Martin-­Kleiner   2012).   To   date   BORIS   is   the   only   known  
paralogue  of   the  CTCF  highly  conserved  zinc-­finger  protein  expressed   in  all  cell   types  
(Klenova,  et  al.,  2002).    For  its  involvement  in  diverse  regulatory  functions,  including  gene  
expression   through   organisation   of   chromatin   structure   and   14,000-­25,000   identified  
potential  binding  sites  CTCF  has  been  named  “master  waiver”  of  the  genome  (Phillips  &  
Corces  2009;;  Klenova  et  al.  2002).  
Although,  BORIS  and  CTCF  have  a  highly  conserved  DNA  binding  domain,  suggesting  
binding  to  the  same  sites,  they  are  expressed  in  a  different  manner,  often  as  antagonists  
resulting  in  opposite  function.  As  mentioned  before,  CTCF’s  expression  is  ubiquitous  and  
in  cancer  it  appears  to  function  as  a  tumour  suppressor  gene.  BORIS  on  the  other  hand,  
as  a  member  of  cancer  testis  genes,  is  normally  present  in  male  germ  line  cells  and  not  
in   other   somatic   cells;;   also   it   is   reported   to   be   detected   in   human   oocytes   and   in  
embryonic  stem  cells  (Martin-­Kleiner  2012).  Despite  some  controversy  in  the  literature,  
BORIS  has  been  shown  to  be  abhorrently  expressed  in  the  majority  of  human  tumours  
and  cancer  cell  lines.  For  example,  Khomanskikh  and  co-­workers  reported  the  presence  
of   BORIS   in   melanoma   (Kholmanskikh   et   al.,   2008).   In   another   study,   expression   of  
BORIS  was  detected  in  ovarian  cancer  (Woloszynska-­Read  et  al.  2007).  
Although   the   functional   role   of   BORIS   in   cancer   cell   lines   is   not   known,   it   has   been  
suggested   that   overexpression   of   BORIS   in   tissues   other   than   testis   could   indicate  
tumorigenesis  (Klenova  et  al,  2002).  In  line  with  the  above  view,  recent  reports  indicate  
that  BORIS  is  responsible  for  the  activation  of  other  CTAs  in  tumours    (Kosaka-­Suzuki  et  
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al.  2011;;  Kang  et  al.  2007).  Furthermore,  there  is  evidence  that  BORIS  can  deregulate  
the  expression  of  tumour  suppressor  genes,  such  as  CTCF  and  retinoblastoma-­related  
protein   Rb2/130   (Fiorentino   et   al.   2011).   Taken   together,   these   reports   reveal  
considerably  broader  roles  of  BORIS.  
CTAs,   including  BORIS,   for   their   exclusive   expression   in   spermatocytes   and   frequent  
overexpression   in   tumours   are   considered   to   be   an   attractive   target   for   cancer  
immunotherapy  and  BORIS  antitumour  vaccines  based  on  the  deletion  of  the  ZF-­region  
of  BORIS  have  been  tested  in  mice  with  different  malignancies  (Loukinov  et  al.  2006).
1.4  Aims  of  the  study  
The  main  aim  of  the  present  study  is  to  further  validate  the  utility  of  Serpin  B1,  Lipocalin  
2,  Copine  3,  Integrin  a4  and  5LOX  as  biomarkers  for  early  cancer  diagnosis,  prognosis  
and  treatment  monitoring.  The  hypothesis  is  that  the  levels  of  these  proteins  will  change  
depending  on  the  clinical  information  (Figure  1.12).  To  test  this  hypothesis  the  following  
objectives  were  studied:  
1.   Validation   of   novel   cancer   biomarkers   identified   from   blood   of   breast   cancer  
patients   using   RT-­qPCR,   Western   blot   analysis,   Immunofluorescent   staining,  
enzyme-­linked  immunosorbent  assay  (ELISA)  and  FACS  techniques.    
2.   Correlate  the  finding  from  the  above  objective  with  clinical  outcome  data  to  identify  
possible  diagnostic,  prognostic  and  predictive  factors.    
The   secondary   aim   of   this   study   was   to   investigate   the   property   of   BORIS   in   urine  
sediment   as   a   biomarker   of   prostate   cancer   and   anti-­BORIS   autoantibody   (AAb)   in  




Figure   1.12   The   rationale   of   the   study.   Growing   tumour(s)   interact   with   the   hosts  
immune   system,   which   is   reflected   in   changes   in   both   gene   and   protein   expression  
profiles  within  white  blood  cells.  These  changes  appear  to  be  present  before  a  tumour  is  













Chapter  2  Materials  and  methods
2.1  Participants  
2.1.1  Samples  from  prostate  cancer  patients  
The  total  of  67  cDNA  samples  from  urine  sediment  and  urinary  exosomes  from  prostate  
cancer  patients  was  received  from  the  University  of  East  Anglia  (Pellegrini  et  al.  2017).  
Patients  were  with  different  parameters  of   the  disease:  HG-­PIN-­  atypia,  P-­  prostatitis,  
CBN-­  PSA   normal   to   age  and   clinical   benign;;  CB<1-­  PSA<1   clinically   benign,  Sneg-­    
raised   PSA   negative   biopsy;;  L-­   Low   risk   PSA<10,   IL   –   intermediate   risk   PSA>10;;   I  
Intermediate  risk  PSA<20,  HL-­High  risk,  PSA>20;;Hh  High  risk,  PSA<100,  Hhh-­High  risk,  
PSA>100.  
2.1.2  Blood  samples  from  breast  cancer  patients  
The   ethical   approval   for   this   study  was   obtained   from  NRES  Essex  Research   Ethics  
Committee  [MH  363  (AM03)]  and  the  Research  &  Development  Department  of  Colchester  
Hospitals   University   NHS   Foundation  Trust.  Women   diagnosed  with   advanced  breast  
cancer  who  were  about  to  undergo  chemotherapy  or  endocrine  treatment  in  Colchester  
General  Hospital  were  recruited  to  participate  in  this  study.  Written  consent  was  obtained  
from  all  participants.  Patients  commencing  chemotherapy  have  six  cycles  of  treatment.  
The  blood  was  taken  from  those  patients  six  times;;  at  the  start  of  the  treatment  (baseline)  
and  before  every  subsequent  cycle.  Patients  undergoing  endocrine  treatment  had  their  
blood  taken  three  times;;  at  the  beginning  of  the  treatment,  after  six  weeks  and  after  twelve  
weeks.  Clinical  response  of  these  patients  to  the  treatment  was  assessed  by  the  clinician  
after  each  treatment.    
The  efficacy  of   the   treatment   is  evaluated  using  Response  Evaluation  Criteria   In  Solid  
Tumour  (RECIST).    This  procedure  is  based  on  the  monitoring  of  the  changes  in  tumour  
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size  after  each  treatment  and  assessment  of  disease  progression  (Litière  et  al.  2017).  
According  to  RECIST,  the  clinical  response  is  categorised  into  four  groups:    
-­  CR  (complete  response)  -­  disappearance  of  all  lesions  
-­  PR  (partial  response)  –  reduction  of  the  lesion  diameter  by  30%  
-­  SD  (stable  disease)  –  no  significant  change  of  the  size  of  the  lesion.    
-­  PD  (progressive  disease)  –  the  appearance  of  new  lesions  and  an  enlargement  of  the  
existing  one  by  at  least  20%  
2.2  Cell  culture  
2.2.1  Cell  lines    
Cell   lines   used   in   the   present   study   include   human   embryonic   kidney   cell   line   293T,  
human   breast   cancer   cell   line   MCF7,   human   leukaemia   cell   line   K562,   human   B  
lymphocyte  cell  line  Raji  and  human  T  lymphocyte  cell  line  Jurkat.  
2.2.2  Media  and  cell  growth  conditions  
The   growth   medium   used   for   293T   cells   was   DMEM   (Dulbecco’s   Modified   Eagles  
Medium)   with   L-­Gutamine,   glucose,   Pyridoxine-­HCl,   NaHCO3   (PAA-­GE   Healthcare)  
supplemented  with  10%  of  FBS  (Biosera)  and  50µg/ml  gentamicin  (Life  Technologies-­
Invitrogen).  All  cells  were  maintained  at  37°C  and  5%  CO2.  
The  MCF7,  K562,  Raji  and  Jurkat  T  cell  lines  were  cultured  in  RPMI  1640  (Roswell  Park  
Memorial  Institute  medium  1640  (1X)  with  L-­Glutamine)  medium  (PAA-­GE  Healthcare)  
supplemented  with  10%  of  fetal  bovine  serum  (FBS)  (Biosera)  and  50µg/ml  gentamicin  






Table  2.1  Cell  lines  used  in  the  present  study.  
  
Cell  line   Description   Reason  for  choosing  
293T   Human  embryonic  kidney  cell  
line  
Highly  transfectable  cells    
MCF7   Human  breast  cancer  cell  line   Used   for   overexpression   of  
BORIS  
K562   Human  leukaemia  cell  line   Cell  line  positive  for  CD15  
Raji   Human  B  lymphocyte  cell  line   Cell  line  positive  for  CD43  and  
CD21      
Jurkat   Human  T  lymphocyte  cell  line   Cell  line  negative  for  CD43  
  
2.2.3  Trypsinization  
All  cell  lines  used  in  this  study  grow  as  an  adherent  monolayer  and  require  passaging  
when  they  are  approximately  70-­80%  confluent.  To  trypsinize,  the  spent  media  was  
removed,  and  cells  were  washed  with  2ml  of  warm  EDTA  (1X).  Cells  were  detached  by  
adding  1ml  of  warm  10%  trypsin  (Sigma)/EDTA  (PAA-­GE  Healthcare)  to  the  cell  
monolayer  and  incubating  the  flasks  in  the  incubator  for  2-­10  minutes  (min).  After  
examining  the  cells  under  the  microscope,  the  trypsin/EDTA  in  the  flask  was  diluted  ten  
times  with  warm  complete  media.  The  media  was  carefully  pipetted  to  collect  all  the  
cells  stuck  to  the  flask.  The  cell  suspension  was  then  centrifuged  at  2000  rpm  for  5  min  
and  the  supernatant  was  aspirated  off.  The  cell  pellet  obtained  was  re-­suspended  in  
fresh  complete  media  and  one-­tenth  of  this  final  cell  suspension  was  transferred  to  the  
original  flask  for  future  culture  and  the  rest  was  used  for  other  experiments  as  described  
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in  the  following  sections.  The  cells  were  maintained  in  culture  for  up  to  one  month  after  
which  they  were  replaced  with  a  fresh  stock.  
2.2.4  Counting  and  seeding  of  cells  
For  counting,  10µl  of  the  final  cell  suspension  was  obtained  as  described  in  2.1.3.1  and  
cell  number  was  counted  using  a  haemocytometer.  Average  of  number  of  cells  present  
in  the  four  corner  squares  multiplied  by  104  is  equal  to  the  concentration  of  cells  per  ml.  
The  cells  were  diluted  to  the  required  concentration  (normally  between  1.0x105-­1.5x105  
cells/ml)  using  appropriate  media  and  were  seeded  in  a  12-­  or  6-­well  plates  or  flasks  as  
per  the  experimental  set  up.    
2.2.5  Freezing  and  defrosting  cell  stocks  was  followed  by  standard  procedure  
Cells  were  trypsinized  as  described  in  Section  counted  and  0.8ml  of  cell  suspension  
(concentration:  1x106  cells/ml)  were  diluted  with  0.8ml  of  freezing  mix  composed  of  20%  
Dimethyl  Sulfoxide  (DMSO)  (Sigma)  and  80%  FBS.  The  cell  mix  was  stored  at  -­80°C  
freezer  in  a  cryotube  wrapped  in  insulating  material  to  prevent  rapid  cooling  and  after  a  
week  it  was  moved  to  liquid  nitrogen  container  for  longer  storage.  
To  defrost  cells,  the  cryogenic  tubes  were  removed  from  liquid  nitrogen  on  dry  ice  and  
rapidly  defrosted  under  warm  water.  The  defrosted  cell  suspension  was  added  slowly  
into  10ml  of  pre-­warmed  growth  media  followed  by  centrifugation  at  2000  rpm  for  5  min.  
The  supernatant  was  discarded  and  the  cell  pellet  was  re-­suspended  in  9ml  of  RPMI  
1640  complete  medium  and  transferred  into  a  small  flask.  The  flask  was  maintained  at  
37°C  in  the  presence  of  5%  CO2  until  the  cells  were  confluent  enough  to  passage.  
2.2.6  Preparation  of  cell  lysates  for  SDS  page  
Cells   were   grown   in   an   adherent  monolayer.   Pre-­warmed   2mL  of   Trypsin/EDTA  was  
added  to  the  cells  to  dislodge  them  and  neutralised  by  the  addition  of  9mL  of  pre-­warmed  
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culture  medium.  Cells  were   counted  using  haemocytometer,   required  number   of   cells  
were   centrifuged   at   2000rpm   for   3   minutes   and   the   obtained   cell   pellet   was   lysed  
immediately  using  SDS  lysis  buffer  at  the  ratio  of  1x10  of  cells  per  20  µL  of  lysis  buffer  
(Table  2.1).  
2.3  Collection  of  blood  samples  and  blood  procession  
The  blood  samples  were  collected  from  two  cohorts  of  breast  cancer  patients  (primary  
and  advanced)   treated  at  Colchester  General  Hospital   (Essex  United  Kingdom).  As   a  
control  blood  samples  from  healthy  individuals,  not  diagnosed  with  cancer  were  collected.  
All  blood  samples  were  obtained  with  previous  written  consent.    
The   blood   was   processed   by   buoyancy   density   method   (D'Arcy   et   al.,   2006).   The  
experiment   involved   separating   the   blood   constituents   namely   cells   (erythrocytes,  
leukocytes,   platelets)   and   plasma.   Erythrocytes   (RBCs)   were   discarded,   but   the  
leukocytes   (WBCs)   were   used   for   experiments   and   plasma   was   stored   at   -­80°C.  
Histopaque  1119-­1  (Sigma)  and  Red  Cell  Lysis  Buffer  (Roche)  were  stored  at  4°C.  Blood,  
Histopaque  and  Red  Cell  Lysis  Buffer  must  be  at  room  temperature  prior  to  fractionation  
and   HBSS   should   be   kept   on   ice   before   use.   Blood   samples   were   stored   in   an  
Ethylenediaminetetraacetic  acid  (EDTA)  tube.  Each  tube  contained  5  mL  of  blood.  Blood  
was  mixed  well  before  the  experiment.    
Histopaque1119-­1(equal  to  the  volume  of  blood  i.e.  5  mL)  was  taken  in  a  15mL  falcon  
tube.  The  blood  was  then  carefully  layered  onto  the  Histopaque  by  gentle  pipetting  by  the  
side  of   the   tube  taking  care   to  avoid  mixing  with   the  Histopaque.   It  was  centrifuged  at  
1900  rpm   for  30  minutes  at   room   temperature   (18-­22°)  without  using   the  brake  of   the  
centrifuge.    
The  sample  got  separated  into  varying  bands  based  on  their  densities  (Figure  2.1).  The  
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top  layer  was  the  plasma  fraction,  which  was  separated  and  stored  at  -­80°C  after  adding  
EDTA   (2   mM)   and   Triton   (0.5%)   to   it.   The   buffy   layer   containing   leukocytes   was  
transferred  to  a  new  falcon  tube  and  the  erythrocyte  layer  was  discarded.  Cold  HBSS  was  
then  added  to  the  leukocyte  fraction  to  give  a  final  volume  of  12  mL  and  was  centrifuged  
at  1400  rpm  for  5  minutes  at  4°C  to  obtain  a  pellet.  The  supernatant  was  removed  leaving  
2  mL  of  HBSS  (to  prevent  disturbing  the  pellet)  and  cold  HBSS  was  again  added  to  get  a  
final  volume  of  10  mL.  It  was  again  centrifuged  at  1400  rpm  for  5  minutes  at  4°C.  The  
pellet  obtained  may  contain  erythrocytes,  which  were  lysed  using  1-­2  mL  of  red  cell  lysis  
buffer.  After  centrifuging  at  1400  rpm  for  5  minutes  at  4°C  and  removing  the  supernatant,  
a  white  blood  cells  pellet  was  obtained.  This  was  again  washed  with  10  mL  cold  HBSS  
and  centrifuged.  Leukocyte  pellet  thus  obtained  was  re-­suspended  by  adding  500μl  of  
cold  HBSS.  The  WBC  were  counted  using  a  haemocytometer.    
Cell  suspension  was  divided  into  five  fractions  each  of  which  was  used  for  the  following  
tests:   1)   Cell   smears   (3x104cells   per   well   of   a   chamber   slide),   2)   RNA   analysis  
(2x106cells),  3)  Western  Blot  analysis  (2x106  cells)  and  4)  ELISA  (1x107cells).  These  cell  
suspension  fractions  were  centrifuged,  and  the  pellets  were  obtained.  Cell  pellet  for  RNA  
was   re-­suspended   in  20  μl  cold  HBSS  and  100  μl  RNA-­later  solution  was  added  and  
stored  at  -­80°C.  Cell  pellet  for  Western  blot  was  lysed  using  200  μl  of  SDS  lysis  buffer  
(0.1M  Tris  pH6.8,  7M  urea,  10%  mercaptoethanol,  phenol   red  dye  and  4%  SDS)  and  
stored  at  -­20°C  or  -­80°C.  The  remaining  two  cell  pellets  were  stored  at  -­80°C.    
The  slide  was  coated  with  2  μl   leukocyte  suspension  per  well.  Once  the  smears  were  
dried,  they  were  fixed  with  100%  methanol  (pre-­cooled  to  -­20°C)  for  5  minutes.  Fixing  the  
cells   was   essential   to  maintain   the   cellular   architecture   and   avoid   loss   of   cells   in   the  
subsequent  washing  steps  during  staining.  Fixed  smears  were  washed  twice  with  cold  1  
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X  PBS.  Slides  were  dried,  put  into  a  cardboard  folder  and  stored  at  -­80°C.  The  smears  
can  be  stored  at  4°C  after  adding  400  μl  1X  PBS,  which   is  supplemented  with  0.01%  
Sodium  Azide.  Sodium  Azide  is  a  preservative  as  it  has  a  bactericidal  property.  
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Table  2.2  Reagents  and  buffers  used  for  blood  processing.  Reagents  used  for  white  
blood  cells  isolation.  
Histopaque  1119-­1  (Sigma)     
Triton  0.5%final     
HBSS  (Hank’s  Balanced  Salt  Solution)     
EDTA  0.5M  (Sigma)     
Red  cell  lysis  buffer     
SDS  lysis  buffer   0.1   M   Tris   pH   6.8,   7M   urea,   1%   b-­
mercapthoethanol,   phenol   red   dye,  
4%SDS  
RNA  later  (Qiagen)     
Methanol  100%     
Buffer  1  for  ELISA   25mM   Tris/Hepes   pH   8.0,   2mM   EDTA,  
0.5%Tween  20,  1mM  PMSF  
Buffer  2  for  ELISA   25mM   Tris/Hepes   pH   8.0,   2mM   EDTA,  
0.5%Tween  20,  0.5M  NaCl,  1mM  PMSF  
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2.4  Methods  for  protein  extraction  and  analysis  
  2.4.1  Preparation  of  White  Blood  Cell  Lysates  and  Western  Blot  
Total  cell  lysates  were  prepared  from  2x106  whole  white  blood  cells  in  SDS  lysis  buffer.  
The  composition  of  resolving  (8.1%)  and  stacking  (4%)  gel  is  given  in  Table  2.2.  Each  gel  
contained  one  well  with  cell   lysate   from  healthy  donor  2  as   the  control  and   remaining  
wells  with  white  blood  cells  lysates  from  breast  cancer  patients.    White  blood  cell  lysates  
were   loaded  onto   the  casted  polyacrylamide  gel  and  were   resolved   in   the  gel   running  
buffer   (see   Table   2.3.1)   for   2   hrs   under   40mA/125V.   A   pre-­stained   standard   protein  
marker  containing  proteins  of  known  molecular  weight  ranging  from  6kDa  to  175kDa  (New  
England  Biolabs)  was  always  run  parallel  to  the  protein  samples  to  be  analysed.    
The  resolved  proteins  from  the  SDS-­PAGE  gel  were  transferred  onto  the  Polyvinylidene  
difluoride  (PVDF)  membrane  (Immobilion  P  Millipore  Inc.)  using  a  semi-­dry  electro  blotting  
apparatus  (Bio  Rad)  in  the  following  manner.  Prior  to  the  transfer,  the  gel  was  incubated  
in  gel  running  buffer  with  1%  methanol  for  15  min  and  the  membrane  was  hydrated  in  
absolute   methanol   for   10   seconds   and   immediately   washed   with   RO   H2O.   A   stack  
consisting  of  5  pieces  of  Whatman  papers  soaked   in   transfer  buffer   (see  Table  2.5A)  
followed  by  the  membrane,  then  the  gel  and  finally  5  more  pieces  of  soaked  Whatman  
papers   on   the   top  was   prepared  and  placed   carefully   on   the   surface  of   the   semi-­dry  
electro  blotter.  Bubbles  were  removed  from  the  stack  by  gently  rolling  a  glass  rod  over  it  
and   the   apparatus   was   set   for   transfer   for   2   hrs   at   100mA/35V.   After   transfer,   the  
membrane  was  washed  with  20%  methanol,   rinsed   thoroughly  with  RO  H2O  and  was  
incubated  in  blocking  buffer  (see  Table  2.5A)  for  at  least  40  min  at  room  temperature  (RT)  
or   overnight   at   4°C.   After   the   blocking   step,   the   membrane   was   washed   once   with  
washing   buffer   (see   Table   2.5A)   and   was   then   incubated   with   the   primary   antibody  
prepared   in   blocking  buffer   (antibody   against   the   protein   of   interest)   for   2   hrs   at   RT.  
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Membrane  was  washed  thrice  with  washing  buffer  (5  min  each  wash)  before  incubating  
with  the  secondary  antibody  (prepared  in  blocking  buffer)  for  another  2  hrs  at  RT.  In  this  
study,  all  the  secondary  antibodies  used  were  conjugated  with  horse  radish  peroxidise  
(HRP).  Signal  detection  was  performed  using  Luminata  Forte  (Millipore).    
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Table  2.3  Composition  of  buffers  used  for  western  blot  analysis.  
Buffer   Composition  
Resolving  buffer   2M  Tris/HCl,  0.2%SDS  (pH8.9)  
Stacking  buffer   0.1MTris/HCl,  0.1%SDS  (pH6.8)  
Running  buffer   0.025M   Tris/HCl,   0.192M   Glycine,  
0.1%SDS  
Transfer  buffer   20mM   Na2PO4,   2%   Methanol,  
0.05%SDS  
Blocking  buffer   0.1%   Tween,   5%   dry   skimmed   milk  
powder,  1xPBS  
Washing  buffer   0.1%  Tween,  1xPBS  
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2.4.2  Immunofluorescent  staining  (IF)  of  fixed  White  Blood  Cells    
Antigen   retrieval  was  performed   in  a   citrate  buffer   (10mM,  6.0pH)   on   full   power   for  1  
minute   to   retrieve   the   antigens.   Endogenous   peroxidise   activity   was   blocked   by  
incubating  the  slides  in  3%  in  H2O2  for  15  minutes.  The  slides  were  then  permeabilised  
in  PBSx1-­0.26%  Triton  for  20  minutes  at  room  temperature  and  blocked  with  serum  from  
the  same  species  as  the  secondary  antibody  in  the  following  buffer:  PBS,  0.05%  Tween,  
2%  serum,  1%BSA  for  30  minutes  minimum.  Serpin  B1  and  Lipocalin  2  expression  was  
detected  by  incubating  the  slides  with  goat  anti-­rabbit  Serpin  B1  diluted  in  PBSx1,  0.05%  
Tween,  1%  BSA  (1:200  dilution,  Abcam)  for  2  hours  at  RT  and  washed  with  PBSx3.  Slides  
were   then   incubated   in   the   dark   for   1   hour  with   anti-­IGg-­FITC   conjugated   secondary  
antibody   diluted   in   the   same   buffer   as   primary   (1:400   dilution),   washed   PBS   3x   and  
mounted   on   the   microscope   slides   with   Fluoro-­Gel   mounting   media   containing   DAPI  
(Interchim)  to  identify  the  nuclei.  Negative  controls  were  prepared  by  incubation  of  slides  
with   secondary   antibody   only.     Images   were   taken   using   Confocal   Laser   Scanning  
Microscopy  (BioRad  Hercules).  
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2.4  Antibodies  used  in  immunological  techniques  and  their  application  
Primary  
antibodies  





Abcam   WB,  IF,  FACS   Anti-­rabbit  HRP   Abcam  
Goat   anti-­rabbit  





Sigma   WB,  IF,  FACS   Anti-­rabbit  HRP   Abcam  
Goat   anti-­rabbit  
IgG   FITC  
labelled  
Abcam  
Anti-­Boris              
Rabbit   anti  
Copine  3  
Abcam   WB,  IF   Anti-­rabbit  HRP   Abcam  









Abcam   WB,  IF,  FACS   Anti-­rabbit  HRP   Abcam  




Abcam   WB,  IF,  FACS   Anti-­rabbit  HRP   Abcam  




2.4.3  Protein  quantification  ImageJ  analysis  WB  
The  image  obtained  from  the  PVDF  membrane  was  then  analysed  with  ImageJ  analysis  
software  which  can  be  downloaded  freely.  The  software  analyses  the  band  intensity  and  
gives  values.  The  target  protein  molecule  was  normalised  between  samples  using   the  
signal  obtained  from  b-­Actin  antibody  probing.  Protein  density  values  from  different  gels  
were  normalised  based  on  the  value  obtained  from  a  common  sample  used.  
2.4.4  Flow  cytometry  
Freshly   isolated  WBCs  were   stained   for   20  minutes  with   pre-­labelled   neutrophils   cell  
surface   markers   (CD15/CD66b)   at   room   temperature.   Cells   were   washed   with   the  
staining   buffer   (PBS/Serum/BSA)   and   fixed  with   cold   4%   formaldehyde   on   ice   for   20  
minutes.  Cells  were  permeabilised  in  0.25%  tween/PBS  for  20  minutes  on  ice,  washed  
twice  with  the  staining  buffer  and  incubated  with  antibody  against  Serpin  B1,  Lipocalin  2,  
Integrin  a4,  Lipoxygenase   (1:200)  o/n  at  4°C.  The  cells  were   then  stained  with  FITC-­
labelled  anti-­rabbit  secondary  IgG  antibody  (1:400)  for  45  minutes  in  the  dark  to  detect  
protein   of   interest   and  analysed  using   flow   cytometer   (BD  Accuri  C6).   For   a   negative  
control,  cells  were  stained  with  an  isotype  control  antibody.  
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Table  2.5  Antibody  used  for  the  FACS  experiment.  
Primary  antibody   Supplier  
APC   conjugated   anti-­
human  CD3  
BioLegend  
APC   mouse   IgM   Isotype  
control  
BioLegend  
PE  anti-­human  CD4     BioLegend  
PE   mouse   IgM   Isotype  
control  
BioLegend  
APC  anti-­human  CD15     BioLegend  
PE  anti-­human  CD66b   BioLegend  
  
2.4.5  Enzyme-­linked  immunosorbent  assay  (ELISA)  
Preparation  of  cell  lysates  
The  human  embryonic  kidney  cell   line  293T  was  used  for  this  experiment.  The  growth  
medium  used  for  293T  cells  was  DMEM  (Dulbecco’s  Modified  Eagles  Medium)  with  L-­
Gutamine,  glucose,  Pyridoxine-­HCl,  NaHCO3  (PAA-­GE  Healthcare)  supplemented  with  
10%  of  FBS  (Biosera)  and  50µg/ml  gentamicin  (Life  Technologies-­Invitrogen).  All  cells  
were  maintained  at  37°C  and  5%  CO2.  
Transfection   protocol   was   followed   as   per   the   instruction  manual.   1.2x105   cells   were  
seeded   in   a   12-­well   plate   approximately   20  hours   (hrs)   before   transfection.   The   cells  
should   be   about   60-­80%   confluent   at   the   time   of   transfection.   The   old   medium   was  
aspirated  from  the  wells  and  fresh  growth  medium  containing  serum  and  antibiotics  was  
added   just  before   transfection.  Cells  were   transfected  with  1µg  of  pCMV6  BORIS  and  
pCI-­CTCF   plasmid   constructs   using   4µl   of   jetPRIME   transfection   reagent   and   were  
incubated   at   standard   growth   conditions   (37°C,   5%  CO2).   Fresh   growth  medium  was  
added   to   the  wells  after  6  hrs  of   transfection.  The  cells  were  collected  after  48  hrs  of  
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transfection   and   lysed   with   equal   volumes   of   Buffer1   and   Buffer2   (Table   2.3.1).   Halt  
protease  inhibitor  (2%)  from  Thermo  Scientific  was  added,  cells  were  incubated  on  ice  for  
20  minutes  and  centrifuged  at  13000rpm  at  4°C  for  15  minutes.  The  resulted  supernatant  
was  used  for  the  ELISA  experiment.    
  
Table  2.6  Plasmids  used  in  DNA  transfection  experiments.  
Plasmid   Description   Source  
pCMV6-­BORIS   pCMV6-­XL4   vector   cloned   with  
BORIS  cDNA  
Loukinov   et   al.,  
2002)  
pCI-­CTCF   pCI   vector   cloned   with   His-­
tagged  CTCF  cDNA  
(Farrar  et  al.,  2010)  
  
2.4.5.1  In  -­house  ELISA  
ELISA  was  performed  using  QED’s  GEMâELISA  Kit.  Antigen  (lysate   from   transfected  
293T  cells)  was  bound  to  the  wells  of  ELISA  plates  in  50  μL/well  of  coating  buffer.  Antigen  
coated  plates  were  sealed  with  plastic  wrap  and  incubated  overnight  at  room  temperature.  
The  next  day,  the  coating  buffer  was  removed  by  inverting  the  plates  and  the  wells  were  
blocked  for  30  minutes  with  200  μL/well  of  1X  blocking  solution,  prepared  by  diluting  10X  
blocking  solution  in  distilled  water.  The  blocking  solution  was  removed  by  inverting  the  
plates.  Pure  plasma  samples  were  added  and  incubated  for  1  hour  with  gentle  agitation.  
Plates  were  washed  3  times  with  1X  washing  buffer  (prepared  by  diluting  10X  wash  buffer  
in  distilled  water)  by  filling  all  wells  and  then  inverting  the  plates.  Secondary  antibody,  was  
diluted  an  antibody  diluent   (1:15000  mouse  monoclonal  secondary  antibody   to  human  
IgG  HRP  ab99765).  Diluted  secondary  antibody  was  added  to  each  well  for  30  minutes  
at   room   temperature  with  gentle  agitation.  Plates  were  washed  3   times  with  1X  wash  
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buffer.  100  μL/well  of  substrate  solution  were  added  and  plates  were   incubated  for  30  
minutes  at  room  temperature.  Optical  density  readings  were  taken  at  single  wavelength  




Figure  2.1  Schematic  representation  of  the  ELISA  technique  used  to  measure  the  
levels  of  BORIS  in  plasma  of  breast  cancer  patients.  The  main  steps  of  the  protocol.  
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2.4.5.2  ELISA  commercial  kits  
Cell   lysates  were  prepared  from  10x106  white  blood  cells  in  equal  volumes  of  Buffer  1  
and  Buffer  2  (Table  2.3.1).  Halt  protease  inhibitor  (2%)  from  Thermo  Scientific  was  added,  
cells  were   incubated  on   ice   for  20  minutes  and  centrifuged  at  13000rpm  at  4°C  for  15  
minutes.  The  resulted  supernatant  was  used  for  the  ELISA  experiment.    
ELISA  was  performed  with  Lipocalin2/NGAL  Human  ELISA  kit  (Abcam,  Cambridge,  UK),  
Human   SERPINB1   ELISA   kit   and   Human   INTEGRIN   a4   ELISA   kit   (Neo-­Biotech  
according  to  the  manufacturer’s  recommendation.    
The   assays   for   Serpin   B1   and   Integrin  a4   employ   the   quantitative   sandwich   enzyme  
immunoassay  technique.  Antibody  specific  for  Integrin  a4  and  Serpin  B1  have  been  pre-­
coated  onto   a  microplate.   In   the   first   step   of   the   experiment,   100µL  of   standards   and  
samples  were  pipetted  into  the  wells  and  incubated  for  2  hours  at  37°C.  After  the  plate  
was  inverted  to  remove  any  unbound  substances  and  100  µl  of  biotin-­conjugated  antibody  
specific  to  the  protein  of  interest  were  added  to  the  wells  following  1-­hour  incubation  at  
37°C.   in   the   next   step   of   the   experiment,   antibodies   were   aspirated,   and   wells   were  
washed  3x  with  wash  buffer  provided  in  the  kit.  After  washing,  100  µL  of  avidin  conjugated  
Horseradish  Peroxidase  (HRP)  was  added  to  the  wells  followed  by  1-­hour  incubation  at  
37°C.  following  3x  wash  with  wash  buffer,  a  90µL  of  TMB  substrate  solution  was  added  
to   each   well   and   incubated   for   30   minutes   at   37°C.   The   colour   developed   was   in  
proportion  to  the  amount  of  protein  of  interest  present  in  the  sample.  In  the  final  step,  the  
colour  development  was  stopped  by  addition  of  50µL  of  Stop  Solution  and  optical  density  
was  determined  using  microplate  reader  set  to  450  nm.    
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Human   Lipocalin-­2   ELISA   Kit   (Abcam)   employs   sandwich   (quantitative)   assay.   To  
perform  the  assay,  50µL  of  samples  and  standards  were  added  to  the  pre-­coated  wells,  
followed  by  the  addition  of  50µL  of  antibody  mix  (capture  antibody  and  detector  antibody).  
After  1-­hour   incubation  at   room  temperature  on  a  shaker,  the  wells  were  washed  with  
3x350  µL  1x  wash  buffer   to  remove  unbound  material.  After,  100µL  of  TBM  Substrate  
was  added  to  each  well  and  incubated  for  10  minutes  in  the  dark  on  a  shaker.  To  stop  
the  reaction,  100µL  of  Stop  Solution  was  added,  and  the  optical  density  was  measured  
at  a  single  wavelength  of  450nm.    
2.5  RNA  extraction  and  quality  control  
2.5.1  RNA  extraction  
In  the  presented  study,  total  RNA  was  extracted  from  blood  of  healthy  donors  and  MCF7  
cell  line  transfected  with  pCMV6  BORIS  plasmid  to  serve  as  negative  and  positive  control  
for  RT-­qPCR  reaction  respectively.  RNA  was  extracted  using  Trisure  (Bioline).  All  purified  
RNA  samples  were  subjected  to  treatment  with  DNase  to  remove  contaminating  DNA.  
For  this  purpose,  TURBO  DNA-­free™  Kit  (Ambion)  was  used  and  the  enzyme  reaction  
was   prepared   according   to   manufacturer’s   instructions.   For   up   to   10µg   of   RNA,   0.1  
volume  of  10x  TURBO  DNase  buffer  and  1µl  of  TURBO  DNase  were  added   in  a  50µl  
reaction.   The   reaction   mix   was   incubated   at   37°C   for   30   min.   Enzyme   was   then  
inactivated  by  incubating  the  reaction  with  0.1  volume  of  DNase  inactivation  reagent  for  
5min  at  RT  and  finally  the  contents  of  the  tube  were  centrifuged  at  10300  rpm  for  2  min.  
DNA-­free  RNA  was  transferred  to  a  fresh  tube  and  stored  at  -­80°C.    
2.5.2  RNA  quality  control  
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After  extraction,  the  concentration  of  total  RNAs  was  determined  using  NanoDrop®  ND-­
1000  UV/VIS  Spectrophotometer.  Although,  the  procedure  for  quantification  of  RNA  using  
Nanodrop  gives  some  idea  about  the  contaminants  present  in  the  RNA,  it  is  not  a  reliable  
method  to  assess  the  integrity  of  RNA  and  to  identify  any  genomic  DNA  contamination  
present  in  the  RNA  sample.  To  assess  the  integrity  of  total  RNA  isolated  from  white  blood  
cells  and  MCF7  breast  cancer  cell  line  Agilent  Bioanalyser  2100  was  used.  
Quantification  of  RNA  using  Nanodrop®  ND-­1000  UV/VIS  Spectrophotometer    
Purified   RNA   samples   were   quantified   using   NanoDrop®   ND-­1000   UV/VIS  
Spectrophotometer   (LabTech   International   Ltd,   UK)   following   the   manufacturer’s  
guidelines.   The   nucleic   acid   concentration   was   determined   by   Beer’s   law   and   the  
absorbance   was   measured   at   260,   280   and   230nm.   The   ratios   of   260nm/280nm   and  
260nm/230nm  were  obtained  to  assess  the  purity  of  RNA.  Both  ratios  had  to  be  above  
1.8  to  be  considered  pure.  Although  Nanodrop  measurements  indicate  the  purity  of  RNA  
it  does  not  indicate  the  integrity  of  RNA  or  indicate  presence  of  DNA  in  the  RNA  sample.    
Analysis  of  RNA  quality  using  Agilent  2100  Bioanalyzer    
Quality   of   all  RNA  samples  was  assessed  using  Agilent   2100  Bioanalyzer   instrument  
according  to   the  manufacturer’s   instruction.  The  Agilent  Bioanalyzer  performs  capillary  
electrophoresis  to  analyse  RNA,  DNA  and  proteins.  It  is  a  very  efficient  method  used  to  
perform   absolute   RNA   quality   control   before   downstream   applications   such   as   gene  
expression  analysis  or  microarrays.  All  the  reagents  of  Agilent  RNA  6000  Nano  kit  were  
incubated  at  RT  for  30  minutes  before   the  start  of   the  procedure.  The  Gel  matrix  was  
filtered  through  the  column  provided  in  the  kit.  The  gel-­dye  mix  was  prepared  by  mixing  
1μl   of   the  RNA   6000  Nano  Dye  with   65μl   of   the   Agilent   RNA   6000  Nano  Gel  matrix  
according  to  the  manufacturer  ‘s  instructions.  The  6000  NanoChip  was  primed  by  placing  
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a  9μl  of  this  mixture  into  the  specified  well  on  the  NanoChip.  The  gel  was  dispersed  across  
the  chip  with  a  help  of  a  plunger.  The  RNA  samples  were  denatured  for  2minutes  at  +70°C  
and   loaded   into   the  NanoChip  alongside  5μl  of   the  RNA  Nano  Marker.  The  NanoChip  
was  then  vortexed  for  60  seconds  at  2499xg  on  a  vortex  mixer  and  applied  for  analysis  
by  the  Bioanalyser.  To  start  the  experiment,  Eukaryote  Total  RNA  assay  was  selected  on  
the  program  and  run.  After  the  run  was  complete  the  data  was  saved  as  a  pdf  file  and  the  
RNA  quality  was  assessed  from  the  electropherograms  obtained.  Only  RNA  of  acceptable  
quality  was  used  in  downstream  applications.  
2.5.3  Synthesis  of  cDNA  and  RT-­qPCR  
RNA  prepared  and  analysed  as  described  above  was  reverse-­transcribed  to  cDNA  using  
VERSO  cDNA  Synthesis  kit  (Thermo  Fisher)  according  to  the  manufacturer’s  instructions.  
Real  time  qPCR  was  performed  in  LightCycler®96  Roche  using  the  SensiMixPlus  SYBR  
kit  (Quantance).  To  analyse  the  results,  comparative  CT  method  was  used.  First  the  levels  
of  BORIS  mRNA  in  samples  from  urinary  sediment  were  analysed  using  SYBR  qPCR.  
Next,   the   levels  of  BORIS  mRNA  were  evaluated   in   total  urinary  exosomal  mRNA.  To  
detect   all   the   23   known   mRNA   variants   of  BORIS  its   expression   was   analysed   by  
quantitative   RT-­PCR   with   two   sets   of   primers   encompassing   1–2   and   3–4   exon  
boundaries,   respectively.   For   this   experiment   TaqMan   gene   expression   assays  (Life  
Technologies,  Applied  Biosystems,  Carlsbad,  CA)  was  used.  The  amplification  reaction  
was   performed   using   the   TaqMan   Universal   PCR   master   Mix   (Life   Technologies,  
Invitrogen,   Carlsbad,   CA).   All   samples  were   run   in   duplicate   in   96-­well   plates   on   the  
LightCycler  detection  system  (Roche).  Normalization  was  carried  out  using  GapDH  as  
internal  control  gene.  TaqMan  gene  expression  assay   IDs   for  each  set  of  primers  and  
probe   were:   Hs00966555_g1   (BORIS  E1–E2);;   Hs00966548_g1   (BORIS  E3–E4)  
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(Zampieri   et   al.   2014).   The   qPCR   conditions   used  were   as   follows:   95.0°C   for   3  min  
followed  by  40  cycles  of  95°C  for  5  sec,  60°C  for  10  sec,  72°C  for  20  sec.  
2.6  Statistical  tests  
Data  was  plotted  using  the  GraphPadPrism  (version  4)  software  (San  Diego,  CA).  Since  
the   data  obtained   in   the   present   study   is   not   normally   distributed   statistical   difference  
between   groups  was   analysed   by   non-­parametric   Kruskal-­Wallis   analysis   for  multiple  
groups.  




3.  1  Validation  results  for  Serpin  B1    
One  of  the  short-­listed  candidate  biomarkers  selected  for  validation  in  this  study  is  Serpin  
B1  -­  a  member  of  the  serpin  family  of  proteinase  inhibitors  that  maintain  homeostasis  by  
neutralising  proteinase  activity.  Serpins  are  the  largest  family  of  proteinase  inhibitors  that  
include  more  than  1000  members,  with  roles  in  the  regulation  of  a  variety  of  biological  
processes   including   angiogenesis,   apoptosis,   cell   migration   and   blood   coagulation  
(Mangan  et  al.  2008).  It  is  highly  conserved  in  all  vertebrates  (Kaiserman  &  Bird  2005).  
Serpin  B1   inhibits   three  serine  proteases:  neutrophil  elastase  (NE),  proteinase  3(PR3)  
and  cathepsin  G  (CG)-­  major  components  of  neutrophil  azurophilic  granules    secreted  by  
activated  neutrophils  during  the  inflammatory  processes  (Korkmaz  et  al.  2010).  The  main  
role   of   these  proteases   is   degradation   of   foreign   organic  molecules   phagocytosed  by  
neutrophils.   However,   their   abhorrent   activity   has   been   associated   with   cancer  
progression.  One   of   the   proposed  mechanism   of   the   action   is   that   the   increased  NE  
activity  induces  the  expression  of  matrix  metalloprotease-­2  (MMP)-­important  component  
for  the  degradation  of  the  extracellular  matrix  barrier  by  the  cancer  cells  and  the  initiation  
of  metastatic  event  (Roy  &  Walsh  2014).  The  study  investigating  the  role  of  Serpin  B1  in  
the  regulation  of  this  event  in  hepatocellular  sarcoma  (HCC)  reported  that  knockdown  of  
Serpin  B1  gene  resulted  in  the  increase  in  the  levels  of  active  MMP2  and  promotion  of  
invasiveness  of  HCC  cells  (Cui  et  al.  2014).  
Existing  reports  suggest  the  crucial  role  of  Serpin  B1  for  the  sustaining  of  the  sufficient  
neutrophil   reserve   in   bone  marrow.   It   is   demonstrated  by   the   findings   that  Serpin  B1  
deficient   mice   are   shown   to   have   a   considerable   reduction   in   the   neutrophils.   The  
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availability  of  the  bone  marrow  reserve  of  mature  neutrophils  is  essential  for  host  defense  
against  infection  (C.  Benarafa  et  al.  2011).    
The  altered  expression  of  Serpin  B1  has  been  reported  in  variety  of  tumour  tissues  and  
shown   to  be  associated  with   tumour  progression.  For   instance,  elevated   levels  of   this  
protein  were   found   in  62.5%  of   invasive  oral  squamous  cell   carcinomas   (Tseng  et  al.  
2009).  In  breast  cancer  tissue,  upregulation  of  Serpin  B1  was  found  to  be  associated  with  
prolonged  relapse-­free  survival  of  breast  cancer  patients  (Sheng  et  al.  2015).    
  In  our  previous  proteomic  study  Serpin  B1  was  found  to  be  overexpressed  in  WBCs  of  
breast  cancer  patients  by  both  highthroughput  proteomics  (fold  change  +1.46)  and  2D  
gel  electrophoresis  (fold  change  +1.46).    
Given   the   evident   important   role   of   Serpin   B1   for   the   neutrophil   function   and   innate  
immune  response  and  the  fact  that  in  the  previous  proteomic  studies  in  the  laboratory  it  
was  identified  as  best  candidate  biomarker,  in  the  present  study  the  utility  of  this  protein  
as  novel  WBCs-­based  breast  cancer  biomarker  was  being  investigated.      
  
Objectives  of  the  present  study:  
Validation   of   novel   cancer   biomarkers   identified   from   breast   and   prostate   tissue  
specimens  is  one  of  the  overarching  aims  of  this  study.  In  this  Chapter  we  will  focus  on  
validation  of  Serpin  B1.  The  rationale  behind  this  investigation  is  illustrated  in  Figure  3.1.  
Two  Objectives  will  be  pursued  in  this  Chapter,  which  are  as  follows:          
1.   Assess   the  expression  patterns  of  Serpin  B1   the  white  blood  cells   (WBC)   from  
large   cohorts   of   breast   cancer   patients   and   healthy   donors   using   a   range   of  
different            techniques.  They  will   include  Western   blot   analysis,   enzyme-­linked  
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immunosorbent  assay  (ELISA),  immunofluorescence  and  fluorescence-­activated  
cell  sorting  (FACS)  analyses.    
2.    Correlate  findings  from  Objective  1  with  clinical  outcome  data  to  identify  possible  




3.2.1  Serpin  B1  expression  in  the  WBCs  of  obtained  from  blood  of  healthy  donors.    
Based   on   previous   findings,   showing   that   Serpin   B1   has   potential   as   breast   cancer  
biomarker,  here   its  utility  was  evaluated  using  Western  blot.  Levels  of  Serpin  B1  were  
investigated   in  white  blood  cells   (WBC)  purified   from  blood  samples  obtained   from  11  
healthy  donors.  The  results  showed  that  in  most  of  the  samples,  levels  of  Serpin  B1  in  
healthy   donors   are   lower   in   comparison   with   breast   cancer   patients   (Figure   3.2,   top  
panel).  However,  in  some  cases  we  observed  elevated  levels  of  the  protein  of  interest.  
For  example,  in  the  sample  corresponding  to  healthy  donor  45,  levels  of  the  protein  of  
interest  were  considerably  higher  than  in  other  healthy  donor  samples.  Interestingly,  this  
individual  has  a  family  history  of  both,  breast  and  prostate  cancer  (Table  3.1).  In  sample  
11,  levels  of  Serpin  B1  also  appeared  to  be  higher  than  in  the  rest  of  the  samples  and  
correlates  with  a  familial  history  of  breast  cancer.  Thus,  we  can  propose  that  high  levels  




Table  3.1  Healthy  donors  Information    
  
HD1   No  history  of  cancer  
HD2   No  history  of  cancer  
HD5   Yes,  prostate  
HD11   Yes,  breast  
HD45   Yes,  breast  and  prostate  cancer  
HD46   Yes,  uterine  and  skin  cancer  
HD47   Yes,  colon  
HD48   No  history  of  cancer  
HD49   Yes,  gastric  
HD50   No  history  of  cancer  
HD51   Yes,  breast  and  lung  cancer  
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3.2.2   Western   blot   analysis   of   Serpin   B1   expression   in   the   WBCs   from   breast  
cancer  patients  with  different  stages  of  breast  cancer  
Following  from  the  analysis  of  Serpin  B1  in  healthy  donors,  the  levels  of  Serpin  B1  were  
evaluated  in  four  different  categories  of  breast  cancer  patients  and  compared  with  healthy  
donors.  This  was  achieved  by  evaluating  the  levels  of  this  protein  in  WBCs  obtained  from  
blood  samples  from  39  participants  comprising  the  primary  breast  cancer  cohort  further  
stratified  into  two  groups  with  different  stages  of  lymph  node  metastasis,  node  negative  
and  node  positive;;  and  32  of  advanced  breast  cancer  patients  (a  cohort  of  breast  cancer  
patients  treated  for  secondary  metastases).    
Our  results  revealed  that  overall  levels  of  Serpin  B1  are  higher  in  WBCs  of  patients  with  
breast  cancer  in  comparison  with  healthy  individuals  and  the  highest  in  the  WBC  from  
participants  with  advanced  breast  cancer  (representative  examples  are  shown  in  Figure  
3.2,  middle   and   bottom   panels).      Following   the   analysis   of   the   images   of   the   bands,  
densitometry  was  performed  on  the  blots  using  Image  J  software  and  the  results  were  
plotted  on  a  graph  using  GraphPad  Prism  6  software.  As  shown  in  Figure  3.3,  levels  of  
Serpin  B1  are  overall  higher   in   the  combined  primary  breast  cancer  cohorts,  although  
lymph  node  positive  samples  had  more  Serpin  B1   than  node  negative  samples.     The  
highest   levels   of  Serpin  B1  was  detected   in   the   advanced  breast   cancer   cohorts   (the  
obtained  values  are  given  in  the  table  3.1).  Statistical  analysis  of  the  above  data  revealed  
significant  difference   in   the   levels  of  Serpin  B1  between  all  breast  cancer  cohorts  and  
healthy  donors.    
The  analysis  of  Serpin  B1  levels  between  two  breast  cancer  cohorts  revealed  that  it   is  
higher  in  advanced  cohort  than  in  primary  one.  The  Kruskal-­Wallis  test  of  the  data  showed  
that  the  difference  is  statistically  significant.  In  primary  breast  cancer  cohort  Serpin  B1  
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levels  were  higher  in  node  positive  group  than  in  node  negative,  however,  these  results  
were   not   statistically   significant.   Comparison   of   the   node   positive   group   from   primary  
breast  cancer  cohort  and  advanced  breast  cancer  cohort  showed  that  Serpin  B1  levels  
are  significantly  higher  in  advanced  cohort.  The  difference  in  Serpin  B1  levels  between  






Figure  3.2  Representative  western  blot  assays  demonstrating  Serpin  B1  levels  in  
WBCs   from   healthy   donors   and   breast   cancer   patients   with   different   disease  
conditions.   WBCs   were   isolated   from   blood   of   cancer   patients.   Cell   lysates   were  
prepared  from  2x106  cells.  The  samples  were  separated  using  SDS-­PAGE,  blotted  and  
probed  with  anti-­Serpin  B1  antibody.  The  same  membrane  was  then  re-­probed  with  anti-­  
























Figure  3.3  Serpin  B1  levels  in  WBCs  of  breast  cancer  patients  with  different  disease  
states.   The  WBCs   samples   were   prepared   and   analyzed   by  Western   blot   assay   as  
described  in  the  text  and  Figure  3.2.  Band  corresponding  to  the  proteins  of  interest  were  
visualized  using  Image  Analyzer.  Densitometry  was  performed  on  the  blots  using  Image  
J  software.  The  ratios  of   the   intensity  of  the  Serpin  B1  bands  over   the   intensity  of   the  
corresponding  β-­actin  bands  were  determined.    The  sample  from  Healthy  Donor  2  (HD2)  
was  used  in  all  Western  assays  to  cross  compare  data  from  different  gels.  The  results  
plotted   on   a   graph   using   GraphPad   Prism   6   software.   Statistical   difference   between  
groups  was  determined  by  non-­parametric  Kruskal-­Wallis  test.	  ∗∗ P ≤ 0.01;	  ∗∗∗  P ≤ 0.001  
Keys  describing  the  participants’  cohorts:  
HD:  healthy  donors;;  
BRCA:    all  participants  from  the  primary  breast  cancer  cohort;;  
BRCA  node  -­:    primary  breast  cancer  cohort,  lymph  node  metastasis  negative;;  
BRCA  +:  primary  breast  cancer  cohort,  lymph  node  positive;;  




3.2.3   Western   blot   analysis   of   Serpin   B1   expression   in   WBCs   of   patients   with  
advanced  disease.  
To   assist   the   assessment   of   the   breast   cancer   treatment   efficacy,   several   approved  
tumour  markers  such  as  CA15-­3  and  CEA  are  used.  However,  the  serum  levels  of  above  
markers   are   not   always   elevated   in   patients   with   advanced   disease   (Brooks   2009).  
Therefore,   there   is   a   need   for   more   reliable   non-­invasive   biomarkers   for   treatment  
monitoring  and  disease  progression  that  can  assist  or  replace  the  radiological  tests.  
This  part  of  the  study  was  designed  to  evaluate  the  potential  of  Serpin  B1  as  a  novel  white  
blood   cell-­based   biomarker   for   treatment   monitoring   in   patients   with   metastatic  
(advanced)  breast  cancer.  The  aim  of  this  part  of  the  study  was  to  assess  the  changes  in  
the   levels  of  Serpin  B1   in  blood  of  breast  cancer  patients  with  metastatic  disease  and  
correlate  them  with  clinical  data  provided  by  the  hospital  in  order  to  determine  the  clinical  
value  of  Serpin  B1  as  a  novel  white  blood  cells-­based  biomarker  for  treatment  monitoring.  
According  to  RECIST,  the  clinical  response  is  categorised  into  four  groups:    
-­  CR  (complete  response)  -­  disappearance  of  all  lesions  
-­  PR  (partial  response)  –  reduction  of  the  lesion  diameter  by  30%  
-­  SD  (stable  disease)  –  no  significant  change  of  the  size  of  the  lesion.    
-­  PD  (progressive  disease)  –  the  appearance  of  new  lesions  and  an  enlargement  of  the  
existing  one  by  at  least  20%  
Information  regarding  participants  taken  part  in  this  part  of  the  study  is  given  in  “Materials  
and  Methods”  section  2.1.2.  Fractionation  of  blood  and  separation  of  white  blood  cells  
was   performed   as   described   in   “Materials   and   Methods”   section   2.5.   Western   blot  
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analysis  was  performed  to  analyse  changes  in  Serpin  B1  expression  during  the  treatment  
as  described  in  “Materials  and  Methods”  section  2.6.  
3.2.3.1  Western  blot  analysis  of  Serpin  B1  expression  in  WBCs  from  breast  cancer  
patients  with  metastatic  disease  during  chemotherapy  treatment  in  correlation  with  
survival.  
Next,  we  analysed  whether  Serpin  B1  can  serve  as  a  marker   for   the   response   to   the  
treatment.  In  order  to  achieve  this,  expression  of  Serpin  B1  was  assessed  in  WBCs  of  
breast  cancer  patients  with  metastatic  disease  during  chemotherapy  treatment.  Patients  
with  invasive  breast  cancer  had  undergone  six  rounds  of  chemotherapy  treatment.  The  
level   of  Serpin  B1   in  WBCs  was  evaluated   in  WBCs  obtained   from  30  breast   cancer  
patients   prior   the   first   (baseline),   third   (middle)   and   sixth   (final)   treatments.   Upon  
evaluation,  four  different  patterns  of  Serpin  B1  levels  in  the  response  to  chemotherapy  
treatment  were  observed  and  results  were  divided  into  four  groups  of  response  (Figure  
3.4).  
  In  the  first  group,  we  observed  a  gradual  decrease  in  the  level  of  Serpin  B1  in  response  
to  treatment.  This  group  comprised  of  8  patients  with  the  majority  of  the  patients.  One  
patients  only  had  1  month  survival  and  one  48  months.  The  rest  of  the  patients  form  this  
group  had  survival  time  between  12  and  23  months.  In  the  second  group,  we  observed  
increase  of  Serpin  B1  levels  in  the  middle  of  the  treatment  and  decrease  in  the  end.  The  
observed  pattern  correlates  with  survival  time  between  9  and  48  months.  Decline  in  the  
level  of  Serpin  B1  expression  in  the  middle  of  the  treatment  and  slight  rise  at  the  end,  
was  detected   in   the   third   group   comprised  of   13   patients.   This   pattern   in   changes   in  
protein  expression  associates  with  variable  survival  time  from  3  to  26  months  and  one  
alive  patient.  In  the  final  fourth  group,  we  observed  gradual  rise  of  the  levels  of  Serpin  B1  
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expression  during  the  course  of  treatment.  This  group  consist  of  two  patients  with  7  and  




Figure  3.4  Western  blot  analysis  of  the  correlation  between  changes  in  the  levels  
of  Serpin  B1  during  the  chemotherapy  treatment  and  survival  of  the  patients.  WBCs  
were  extracted  from  blood  of  breast  cancer  patients  prior  the  treatment-­baseline,  in  the  
middle  and  at  the  final  stage;;  cell  lysates  were  prepared  from  2x106  cells.  Samples  were  
separated  using  SDS-­PAGE,  blotted  and  probed  with  anti-­Serpin  B1  antibody.  The  same  
membrane   was   then   re-­probed   with   anti-­β-­Actin   antibody   (loading   control).   Bands  
corresponding  to  the  proteins  of  interest  were  visualised  using  Image  Analyser.  The  ratios  
of   the   intensity  of   the  Serpin  B1  bands  over  the   intensity  of   the  corresponding  β-­Actin  
bands  were  determined  as  a  control  healthy  donor  2  was  used  in  all  the  westerns  and  the  
results  plotted  on  a  graph  using  GraphPad  Prism  5  software.
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3.2.3.2  Western  blot  analysis  of  Serpin  B1  expression  in  WBCs  from  breast  cancer  
patients   with   metastatic   (advanced)   disease   during   endocrine   treatment   in  
correlation  with  survival.  
Ten   patients   with   advanced   estrogen   receptor   (ER)   and   progesterone   receptor   (PR)  
positive   breast   cancer   had   undergone   three   round   of   endocrine   treatment   involving  
different  types  of  drugs.  After  each  step  of  treatment,  the  level  of  Serpin  B1  was  measured  
and   three   different   expression   patterns   were   observed   in   the   response   to   treatment  
(Figure  3.5).  
In   the   first   group,   we   observed   a   gradual   decrease   of   the   level   of   Serpin   B1   in   the  
response  to  treatment.  The  detected  pattern  of  Serpin  B1  expression  correlates  with  more  
favourable  prognosis,  longer  survival  of  the  patients  (24  months  and  one  patient  alive).  
In   the   second   group,   we   observed   increase   of   Serpin   B1   levels   in   the  middle   of   the  
treatment   and   decrease   in   the   end.   This   group   comprised   of   3   patients,   one  with   24  
months  overall  survival  and  for  two  of  the  patients  the  clinical  information  is  unknown.  
Decline  of  the  level  of  Serpin  B1  in  the  middle  of  the  treatment  and  rise  at  the  end,  was  
detected  in  the  third  group  of  patients.  This  pattern  in  changes  in  protein  expression  is  





Figure  3.5  Western  blot  analysis  of  the  correlation  between  changes  in  the  levels  
of  Serpin  B1  during  the  course  of  endocrine  treatment  and  survival  of  the  patients.  
WBCs  were  extracted  from  blood  of  breast  cancer  patients  prior  the  treatment-­baseline,  
in  the  middle  and  at  the  final  stage;;  cell  lysates  were  prepared  from  2x106  cells.  Samples  
were  separated  using  SDS-­PAGE,  blotted  and  probed  with  anti-­Serpin  B1  antibody.  The  
same  membrane  was  then  re-­probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  
corresponding  to  the  proteins  of  interest  were  visualised  using  Image  Analyser.  The  ratios  
of   the   intensity  of   the  Serpin  B1  bands  over  the   intensity  of   the  corresponding  β-­Actin  
bands  were  determined  as  a  control  healthy  donor  2  was  used  in  all  the  westerns  and  the  
results  plotted  on  a  graph  using  GraphPad  Prism  5  software.
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3.2.3.3  Western  blot  analysis  of  Serpin  B1  expression  in  WBCs  from  breast  cancer  
patients  with  advanced  disease  during  chemotherapy  treatment  in  correlation  with  
clinical  response.    
Next,  we  analysed  whether  Serpin  B1  can  serve  as  a  marker   for   the   response   to   the  
chemotherapy  treatment.  In  order  to  achieve  this,  the  level  of  Serpin  B1  was  evaluated  in  
WBCs  obtained  from  30  breast  cancer  patients  prior  the  first  (baseline),  third  (middle)  and  
sixth  (final)  treatments  and  grouped  according  to  the  clinical  response  to  the  treatment  -­  
CR  (complete  response)  -­  PR  (partial  response)  -­  PD  (progressive  disease)  -­  SD  (stable  
disease).      The   generated   data   showed   that   the   levels   of   Serpin   B1   during   the  





Figure  3.6  Western  blot  analysis  of  the  correlation  between  changes  in  the  levels  
of  Serpin  B1  during  the  course  of  chemotherapy  treatment  and  clinical  response.  
Complete   response  (CR),  partial   response  (PR),  stable  disease  (SD)  and  progressive  
disease  (PD).  WBCs  were  extracted   from  blood  of  breast  cancer  patients;;  cell   lysates  
were  prepared  from  2x106  cells.  Samples  were  separated  using  SDS-­PAGE,  blotted  and  
probed  with  anti-­Serpin  B1  antibody.  The  same  membrane  was  then  re-­probed  with  anti-­
β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  of  interest  were  
visualised  using  Image  Analyser.  The  ratios  of  the  intensity  of  the  Serpin  B1  bands  over  
the   intensity  of   the  corresponding  β-­Actin  bands  were  determined  as  a  control  healthy  
donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  using  GraphPad  
Prism  5  software.  
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3.2.3.4  Western  blot  analysis  of  Serpin  B1  expression  in  WBCs  from  breast  cancer  
patients   with   advanced   disease   during   the   course   of   endocrine   treatment   in  
correlation  with  clinical  response.    
Next,  we  analysed  whether  Serpin  B1  can  serve  as  a  marker   for   the   response   to   the  
endocrine   treatment.   In  order   to  achieve   this,   the   level  of  Serpin  B1  was  measured   in  
WBCs  obtained  from  10  breast  cancer  patients  prior  the  first  (baseline),  second  (middle)  
and  final  third  stage  of  the  treatments  and  grouped  according  to  the  clinical  response  to  
the   treatment   -­   CR   (complete   response)   -­   PR   (partial   response)   -­   PD   (progressive  
disease)  -­  SD  (stable  disease).    The  generated  data  showed  that  the  levels  of  Serpin  B1  





Figure  3.7  Western  blot  analysis  of  the  correlation  between  changes  in  the  levels  
of   Serpin   B1   during   the   course   of   endocrine   treatment   and   clinical   response.  
Complete   response  (CR),  partial   response  (PR),  stable  disease  (SD)  and  progressive  
disease  (PD).  WBCs  were  extracted   from  blood  of  breast  cancer  patients;;  cell   lysates  
were  prepared  from  2x106  cells.  Samples  were  separated  using  SDS-­PAGE,  blotted  and  
probed  with  anti-­Serpin  B1  antibody.  The  same  membrane  was  then  re-­probed  with  anti-­
β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  of  interest  were  
visualised  using  Image  Analyser.  The  ratios  of  the  intensity  of  the  Serpin  B1  bands  over  
the  intensity  of  the  corresponding  β-­Actin  bands  were  determined,  as  a  control  healthy  
donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  using  GraphPad  
Prism  5  software.  
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Table   3.2   Initial   levels   of   Serpin   B1   and   Lipocalin   2   in   WBCs   of  
advanced(metastatic)  breast  cancer  patients  prior  the  treatment  received.  
  





Treatment  type   Prognosis   Survival   in  
months  
ABS2   1.746      Endocrine   PR   48  months  
ABS3     2.11   1.72   Chemotherapy   CR   7  months  
ABS4   3.009   1.42   Chemotherapy   PD   3  months  
ABS5   1.174      Endocrine   SD   Alive  
ABS6   5.98   0.96   Chemotherapy   PD   48  months  
ABS8   2.98      Endocrine      4  months  
ABS9   2.48      Endocrine   PD     
ABS10   2.42   1.49   Chemotherapy   PD   12  months  
ABS11   2.38   1.64   Endo/Chemo   PR   13  months  
ABS12   2.92   4.28   Chemotherapy   PR   Alive  
ABS13         Chemotherapy      1  month  
ABS14   4.02   6.83   Endocrine   PR     
ABS15         Chemotherapy   NE   1  month  
ABS16   4.98      Chemotherapy   PR   10  months  
ABS17   4.34   1.05   Chemotherapy   PR   12  months  
ABS18   5.52      Chemotherapy   PR   12  months  
ABS19         Endocrine   PR   24  months  
ABS20   3.9      Chemotherapy   PD   18  months  
ABS21         Endocrine   PD   23  months  
ABS22   2.8   1.11   Chemotherapy   SD   24  months  
130  
  
ABS23   4.4   1.05   Chemotherapy   PR   6  months  
ABS24      1.39   Chemotherapy   PD   4  months  
ABS25   3.85   1.2   Chemotherapy   PR   12  months  
ABS26   3.07   1.19   Chemotherapy   SD   4  months  
ABS27         Endocrine   PD   22  months  
ABS28   2.76   1.28   Chemotherapy   RIP   2  months  
ABS29   4.9   1.7   Chemotherapy   PR   7  months  
ABS30   3.68   1.36   Endo/Chemo   SD   23  months  
ABS31   2.49   1.68   Chemotherapy   PD   19  months  
ABS32   2.82   1.59   Chemotherapy      15  months  
ABS33   7.7   4.38   Chemotherapy   PD   48  months  
ABS34   6.8   2.14   Endocrine   SD   14  months  
ABS35   1.11      Chemotherapy   PD   1  month  
ABS36   11.60   3.008   Chemotherapy      3  months  
ABS37   4.74   6.18   Chemotherapy   PD   6  months  
ABS38         Chemotherapy   PD   4  months  
ABS39         Chemotherapy   RIP   1  months  
ABS40   4.95   2.7   Chemotherapy   PD   9months  
ABS41   1.9   5.78   Chemotherapy   PR   24  months  
ABS42   4.98   4.52   Chemotherapy   PD   3  months  
ABS43   5.64   2.77   Chemotherapy   PD   7  months  
ABS44   3.09   2.81   Chemotherapy   CR   17  months  
ABS45   3.67   2.98   Chemotherapy   PR     
ABS46   3.088   2.63   Endocrine   SD   12  months  
ABS47   1.72   1.5   Endocrine   CR   24  months  
ABS48   2.38   2.3   Endocrine   CR     
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ABS49         Endocrine   PR   10  months  
ABS50   1.31   0.83q   Chemotherapy   SD   8  months  
ABS51   1.28   0.79   Chemotherapy   PR   24  months  
ABS52   1.048      Endocrine   PD   3  months  
ABS53   4.488   2.15   Endocrine   PD   4  months  
ABS54   2.67   1.29   Chemotherapy   SD     
ABS55   7.86   0.92   Endocrine   SD   Alive  
ABS56   1.97   2.11   Chemotherapy   SD   1  months  
ABS57   3.76   1.49   Chemotherapy   PD   20  months  
ABS58   3.89   1.54   Chemotherapy   PD   26  months  
ABS59   1.05   1.53   Endocrine   SD     
ABS60      1.68   Chemotherapy   PD     
ABS61   1.02   1.86   Chemotherapy   PD   26  months  
ABS62   4.73   1.45   Endocrine   PR   12  months  
ABS63   6.28   1.55   Endocrine   PR   12  months  
ABS64   1.96   0.87   Chemotherapy   PR   3  months  
ABS65   0.75      Chemotherapy   PR   3  months  
ABS66   1.86   0.88   Chemotherapy   PD     
ABS67   5.16   0.93   Endocrine   SD     
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3.2.3.5  Western  Blot  analysis  of  the  basal  levels  of  Serpin  B1  in  WBCs  of  patients  
with  advanced  breast  cancer  in  correlation  with  survival.  
The  aim  of  the  next  experiment  was  to  analyse  whether  the  basal  levels  of  Serpin  B1  in  
WBCs  of  the  advanced  breast  cancer  patients  before  treatment  have  any  correlation  with  
overall  survival.  For  this  purpose,  the  levels  of  Serpin  B1  were  assessed  by  western  blot  
analysis  using  hand  cast  gels.  The  obtained  results  showed  that  low  levels  of  the  protein  
in   the   beginning   of   the   treatment   correlate   with   longer   survival   of   the   patients   with  
chemotherapy   treatment   (Figure   3.8).   These   results   suggest   that   Serpin   B1   has   a  
potential  to  be  used  as  a  marker  of  survival  for  the  patients  commencing  chemotherapy.  
The  results  for  patients  with  endocrine  treatment  showed  no  correlation  between  basal  
levels  of  Serpin  B1  and  overall  survival  (Figure  3.9).  Therefore,  it  can  be  concluded  that  






Figure  3.8  Analysis  of   the  correlation  between   initial   levels  of  Serpin  B1  before  
treatment   and   response   to   chemotherapy   treatment   in   advanced   breast   cancer  
patients  by  western  blot.  WBCs  were  extracted  from  blood  of  breast  cancer  patients;;  
cell  lysates  were  prepared  from  2x106  cells.  Samples  were  separated  using  SDS-­PAGE,  
blotted   and   probed   with   anti-­Serpin   B1   antibody.   The   same  membrane   was   then   re-­
probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  
of   interest  were  visualised  using   Image  Analyser.  Densitometry  was  performed  on   the  
blots  using  Image  J  Software.  The  ratios  of  the  intensity  of  the  Serpin  B1  bands  over  the  
intensity  of  the  corresponding  β-­Actin  bands  were  determined  as  a  control  healthy  donor  
2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  using  GraphPad  Prism  







Figure  3.9  Analysis  of   the  correlation  between   initial   levels  of  Serpin  B1  before  
treatment  and  response  to  endocrine  treatment  in  advanced  breast  cancer  patients  
by  western  blot.  PD  progressive  disease;;  PR  partial  response;;  SD  stable  disease;;  CR  
complete   response.  WBCs   were   extracted   from   blood   of   breast   cancer   patients;;   cell  
lysates   were   prepared   from   2x106  cells.   Samples   were   separated   using   SDS-­PAGE,  
blotted   and   probed   with   anti-­Serpin   B1   antibody.   The   same  membrane   was   then   re-­
probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  
of   interest  were  visualised  using   Image  Analyser.  Densitometry  was  performed  on   the  
blots  using  Image  J  software.  The  ratios  of  the  intensity  of  the  Serpin  B1  bands  over  the  
intensity  of  the  corresponding  β-­Actin  bands  were  determined  as  a  control  healthy  donor  
2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  using  GraphPad  Prism  





3.2.3.6  Western  Blot  analysis  of  the  basal  levels  of  Serpin  B1  in  WBCs  of  advanced  
breast  cancer  patients  in  correlation  with  response  to  treatment.  
  
To  assess  whether  Serpin  B1  can  serve  as  a  marker  of  treatment  response,  the  basal  
levels  of  the  protein  of  interest  were  compared  with  corresponding  clinical  data.  According  
to   the   obtained   results   the   lower   levels   of   Serpin   B1   in   the   beginning   of   the   both,  
chemotherapy  and  endocrine  therapy,  correlate  with  complete  response  to  the  treatment  






Figure  3.10  Analysis  of   the  correlation  between  initial  levels  of  Serpin  B1  before  
treatment  and  response  to  chemotherapy  in  advanced  breast  cancer  patients  by  
western   blot.  PD   progressive   disease;;   PR   partial   response;;   SD   stable   disease;;   CR  
complete   response.  WBCs   were   extracted   from   blood   of   breast   cancer   patients;;   cell  
lysates   were   prepared   from   2x106  cells.   Samples   were   separated   using   SDS-­PAGE,  
blotted   and   probed   with   anti-­Serpin   B1   antibody.   The   same  membrane   was   then   re-­
probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  
of   interest  were  visualised  using   Image  Analyser.  Densitometry  was  performed  on   the  
blots  using  Image  J  Software.The  ratios  of  the  intensity  of  the  Serpin  B1  bands  over  the  
intensity  of  the  corresponding  β-­Actin  bands  were  determined  as  a  control  healthy  donor  
2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  using  GraphPad  Prism  








Figure  3.11  Analysis  of   the  correlation  between  initial  levels  of  Serpin  B1  before  
treatment  in  correlation  with  response  to  endocrine  treatment  in  advanced  breast  
cancer  patients  by  western  blot.     PD  progressive  disease;;  PR  partial   response;;  SD  
stable   disease;;   CR   complete   response.   WBCs   were   extracted   from   blood   of   breast  
cancer  patients;;  cell   lysates  were  prepared   from  2x106  cells.  Samples  were  separated  
using  SDS-­PAGE,  blotted  and  probed  with  anti-­Serpin  B1  antibody.  The  same  membrane  
was  then  re-­probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  corresponding  to  
the   proteins   of   interest   were   visualised   using   Image   Analyser.   Densitometry   was  
performed  on  the  blots  using  Image  J  software.  The  ratios  of  the  intensity  of  the  Serpin  
B1  bands  over   the   intensity  of   the  corresponding  β-­Actin  bands  were  determined  as  a  
control  healthy  donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  
using  GraphPad  Prism  5  software.  Statistical  difference  between  groups  was  analysed  




3.2.3.7  Kaplan-­Meier  survival  analysis    
Next,  we  carried  out  Kaplan-­Meier  analysis  to  study  the  correlation  between  high  and  low  
levels  of  Serpin  B1  expression  and  patient’s  overall  survival  (Figure  3.12).  The  baseline  
protein  levels  of  Serpin  B1  were  measured  by  Western  Blot  in  55  advanced  breast  cancer  
patients.   The   Serpin   B1   signal   was   normalised   to   the   b   Actin   signal   using   Image   J  
software.   Expression   values   between   the   gels   were   compared   by   normalising   to   the  
expression  value  of  the  common  healthy  donor  2  sample  used  in  all  experiments.  The  
cut-­off  point  was  determined  by  average  of  all  the  values,  as  2.  The  generated  data  shows  






Figure   3.11   Survival   curves   according   to   Serpin   B1   expression.   Kaplan-­Meier  
survival  curve   for  high  Serpin  B1  expression  versus   low  Serpin  B1  expression  did  not  
show  significant  difference.  WBCs  were  extracted  from  blood  of  breast  cancer  patients;;  
cell  lysates  were  prepared  from  2x106  cells.  Samples  were  separated  using  SDS-­PAGE,  
blotted   and   probed   with   anti-­Serpin   B1   antibody.   The   same  membrane   was   then   re-­
probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  
of  interest  were  visualised  using  Image  Analyser.  The  ratios  of  the  intensity  of  the  Serpin  
B1  bands  over   the   intensity  of   the  corresponding  β-­Actin  bands  were  determined  as  a  
control  healthy  donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  
using  GraphPad  Prism  5  software.
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3.2.4  Immunofluorescent  analysis  
3.2.4.1  Distribution  of  Serpin  B1  in  WBCs  of  breast  cancer  patients  
Next,  the  distribution  of  Serpin  B1  protein  in  WBCs  of  breast  cancer  patients  and  healthy  
donors  was  examined  by  Immunofluorescent  staining  technique  using  primary  anti-­Serpin  
B1  antibody  (Figure  3.13).  Examination  of  slides  revealed  different  distribution  of  Serpin  
B1.   In   leukocytes   from   the   node   negative   primary   breast   cancer   patients   Serpin   B1  
appeared  to  be  present  in  the  cytoplasm  and  nuclei  of  the  cells.  Leukocytes  from  node  
positive  breast  cancer  patients  were  characterised  by  higher  intensity  of  the  staining  and,  
in   addition   to   nuclei   and   cytoplasm,   the   extracellular   localisation   of   Serpin   B1   was  
detected.  In  leukocytes  of  patients  with  advanced  breast  cancer  Serpin  B1  protein  was  
detected  in  the  cytoplasm  of  the  cells  with  high  intensity.  In  the  samples  obtained  from  
healthy  individuals  the  intensity  of  the  staining  was  weak.  These  results  support  the  data  
obtained  from  western  blot  analysis.  
  
In  order  to  statistically  compare  the  staining  intensity  between  the  samples  ImageJ  was  
used.  Densitometric  analysis  of  the  Serpin  B1  expression,  showed  statistically  significant  
(p<0.05)  increase  in  the  Serpin  B1  levels  in  white  blood  cells  of  breast  cancer  patients  





Figure  3.13  Serpin  B1  protein  distribution  in  WBCs  of  BRCA  node  negative,  node  
positive,  advanced  cancer  patients  and  healthy  donors.  A  WBCs  from  breast  cancer  
patients  and  healthy  donors  were  stained  with  FITC-­labelled  anti-­rabbit  secondary  IgG  
antibody   (dilution   1:400)   against   Serpin   B1   primary   antibody   (dilution   1:200),   plus  
secondary  only  as  the  control.  The  blue  staining  shows  the  position  of  the  nucleus.  The  
green  staining  in  the  cytoplasm  and  the  green  dots  in  the  nucleus  corresponds  to  Serpin  
B1  protein.  All  images  were  taken  by  Confocal  Scanning  Microscope  (BioRad  Hercules)  
at  60X  magnification.  B  Bar  graph  represents  the  proportion  of  signal  distribution  among  















3.2.4.2  Identification  of  Serpin  B1  expressing  cells    
In  order  to  further  understand  exactly  which  immune  cells  overexpress  Serpin  B1  double  
immunofluorescence  procedure  was  carried  out  and  analysed  by  laser-­scanning  confocal  
microscopy.  For  this  purpose,  white  blood  cells  from  breast  cancer  patients  were  double  
stained   against   the   cluster   of   differentiation   (CD)   cell   surface   markers   to   distinguish  
between  subpopulation  of  white  blood  cells  and  the  protein  of  interest.  
First  leukocyte  fractions  were  stained  with  CD15  antibody  which  recognises  carbohydrate  
epitope   expressed   in   mature   neutrophils   and   eosinophils.   The   obtained   double  
immunofluorescence  analysis  revealed  that  the  majority  of  Serpin  B1  positive  cells  were  
neutrophils   (Figure  3.14).  Staining  with  only   the  secondary  antibody  did  not  show  any  
nonspecific  background.  
Next  in  order  to  determine  whether  populations  of  lymphocytes  express  Serpin  B1,  white  
blood  cells  were  stained  with  B  cells   related  antigen  CD21  and  T  cells  related  antigen  
CD43.  However,  the  staining  for  lymphocytes  showed  negative  results  (Figure  3.15).  In  
order   to   validate   antibody   used   in   the   present   study   western   blot   and  
immunofluorescence  analysis  were  performed  on  CD15  positive  K562  cell  line,  CD21  and  
CD43  positive  Raji  cell  line.  As  the  result,  positive  staining  was  observed  in  all  analysed  
cell   lines  (Figures  3.16,  3.17).  These  results  suggest   that   there  were  no  population  of  
lymphocytes  on  the  analysed  leukocyte  smears.  
The  described   findings  may  be  associated  with   the   fact   that   neutrophils   are   the  most  
abundant  circulating  blood   leukocytes   that  comprise  up   to  80%  of  all  white  blood  cells  
(Borregaard  2010).    Lymphocytes  are  immune  cells  responsible  for  cellular  and  humoral  
immunity.  In  the  blood  of  human  adults  they  make  up  20%  of  the  total  number  of  white  







Figure   3.14   Immunofluorescence   analysis   of   Serpin   B1   protein   distribution   in  
leukocytes  of  primary  and  advanced  breast  cancer  patients.  WBCs  extracted  from  
blood  of  primary  and  advanced  breast  cancer  patients  were  double  stained  with  FITC-­
labelled  anti-­rabbit  secondary  IgG  antibody  (1:400)  against  Serpin  B1  primary  antibody  
(dilution   1:200)   and  Tritc-­labelled   anti-­mouse   secondary   IgG   antibody   (1:400)   against  
CD15  neutrophil  primary  antibody  (1:200),  plus  secondary  only  as  the  control.  The  blue  
staining  shows  the  position  of  the  nucleus.  The  green  staining  corresponds  to  Serpin  B1  
protein   and   red   staining   represents   Neutrophils.   All   images   were   taken   by   Confocal  












Figure   3.15   Immunofluorescence   analysis   of   Serpin   B1   protein   distribution   in  
lymphocytes  of  primary  and  metastatic  breast  cancer  patients.  WBCs  extracted  from  
blood  of  primary  breast  cancer  patients  were  double  stained  with  FITC-­labelled  anti-­rabbit  
secondary  IgG  antibody  (1:400)  against  Serpin  B1  primary  antibody  (dilution  1:200)  and  
Tritc-­labelled  anti-­mouse  secondary  IgG  antibody  (1:400)  against  CD21  positive  B  cells  
and  CD43  positive  T-­cells  primary  antibody  (1:200),  plus  secondary  only  as  the  control.  
The  blue  staining  shows  the  position  of  the  nucleus.  The  green  staining  corresponds  to  













Figure   3.16   Representative   immunofluorescence   staining   pattern   of   anti-­
CD43   antibody-­positive   Raji   cell   line   and   anti-­CD43   antibody-­negative  
control  Jurkat  cell  line.  Cell  were  fixed  with  cold  methanol  and  stained  with  Tritc-­
labelled   anti-­mouse   secondary   IgG   antibody   (1:400)   against   CD43   primary  
antibody   (1:200).  The  blue  staining  shows   the  position  of   the  nucleus.  The   red  
staining   corresponds   to  membrane   cell   surface  marker  CD43.  All   images  were  












Figure   3.17   Representative   immunofluorescence   staining   pattern   of   anti-­CD21  
antibody-­positive  Raji  cell  line  and  anti-­CD21  antibody-­negative  control  K562  cell  
line.  Cell  were  fixed  with  methanol  and  stained  with  Tritc-­labelled  anti-­mouse  secondary  
IgG  antibody  (1:400)  against  CD21  primary  antibody  (1:200).  The  blue  staining  shows  the  
position  of  the  nucleus.  The  red  staining  corresponds  to  membrane  cell  surface  marker  









3.2.5  Evaluation  of  the  levels  of  Serpin  B1  in  neutrophils  of  primary  breast  cancer  
patients  using  flow  cytometric  analysis.  
Here  we  aimed  to  further  validate  the  increased  expression  of  the  Serpin  B1  using  flow  
cytometry   (FACS).   Flow   cytometry   is   the   method   that   allows   for   rapid   quantitative  
assessment  of  proteins  within  the  specific  cell  type  via  cell  surface  marker  phenotyping.    
For   this   experiment,   freshly   isolated  WBCs   (within   6   hours   from  blood  draining)   from  
randomly  selected  primary  breast  cancer  patient  and  healthy  donor  were  stained  with  two  
pre-­labelled   markers   expressed   by   mature   neutrophils:   CD15,   CD66b   (BioLegend).  
Serpin  B1  is  intracellular  protein  therefore  pre-­stained  cells  were  fixed,  permeabilised  and  
stained   with   unlabeled   polyclonal   rabbit   anti-­Serpin   B1   antibody   followed   by   the  
incubation  with  FITC-­labelled  anti-­rabbit  secondary  antibody.      
For   a   negative   control,   cells   were   stained   with   an   isotype   control   antibody.   Isotype  
controls  are  antibodies  of  the  same  isotype  as  the  target  primary  antibody.  They  are  of  
unknown  specificity  or  are   raised  against  antigens  known   to  be  absent   in   target  cells.  
Isotype  controls  are  used  to  estimate  non-­specific  staining  of  primary  antibodies.    
The  results  obtained  for  Mean  fluorescent  intensity  (MFI)  show  that  the  levels  of  Serpin  
B1  are  almost  two-­fold  higher  in  the  neutrophils  from  a  primary  breast  cancer  patient  than  








                          
Figure  3.18  Flow  cytometric  analysis  of  the  Serpin  B1  levels  in  neutrophils  of  breast  
cancer  patient  and  a  healthy  donor  (randomly  selected).  Freshly  isolated  WBCs  were  
stained  for  20  minutes  with  pre-­labelled  neutrophils  cell  surface  markers  (CD15/CD66b)  
at  room  temperature.  Cells  were  washed  with  the  staining  buffer  (PBS/Serum/BSA)  and  
fixed  with  cold  4%  formaldehyde  on  ice  for  20  minutes.  Cells  were  permeabilised  in  0.25%  
tween/PBS  for  20  minutes  on  ice,  washed  twice  with  the  staining  buffer  and  incubated  
with   antibody   against   Serpin   B1(1:200)   o/n.   The   cells   were   then   stained   with   FITC-­
labelled  anti-­rabbit  secondary  IgG  antibody  (1:400)  for  45  minutes  in  the  dark  to  detect  
Serpin  B1  and  analysed  using  flow  cytometer  (BD  Accuri  C6).  For  a  negative  control,  cells  
were  stained  with  an  isotype  control  antibody.  A  Gating  of  the  CD15+CD66b+SerpinB1+  
neutrophils.  B  Peaks  representing   fluorescent   intensity  of   the  Serpin  B1  expression   in  
BRCA,  HD  and  background   isotype  control  C  Quantification  of   the   levels  of  Serpin  B1  
expression  in  the  neutrophils  of  HD  and  BRCA  according  to  the  Mean  fluorescent  intensity  









































3.2.6  Analysis  of  the  expression  of  the  Serpin  B1  using  ELISA  
3.2.6.1  Analysis  of  the  expression  of  the  Serpin  B1  in  healthy  donors  and  cancer  
patients  using  ELISA    
In  the  final  step  of  the  validation  experiment,  the  levels  of  Serpin  B1  were  analysed  in  the  
white   blood   cells   and   plasma   of   two   cohorts   of   breast   cancer   patients   (primary   and  
advanced).   This   was   achieved   using   a   quantitative   sandwich   enzyme   immunoassay  
technique   (ELISA)   commercial   kit.   The   sandwich   ELISA   is   the   immunological   assay,  
designed  to  detect  and  quantify  the  presence  of  the  specific  antigen  or  antibody  in  the  
given   sample.  The   technique   represents   the   basic   tool   for   the   laboratory   diagnosis   in  
hospitals.  Given  that  Serpin  B1  is  a  promising  marker  of  breast  cancer  prognosis,  the  use  
of  the  ELISA  kit  in  medical  practice  to  quantitatively  evaluate  Serpin  B1  levels  in  the  blood  
of  cancer  patients  would  be  of  particular  interest.  
White  blood  cell  pellets  (10x106)  obtained  from  the  blood  of  breast  cancer  patients  and  
healthy  donors  using  a   fractionation  method  as  described   in  section  2.1.  The  resulting  
cell  pellet  was  lysed  by  the  addition  of  equal  volume  of  Buffer  1  and  Buffer  2  (Table  2.1)  
with  the  volume  ratio  of  1mL/4x106  and  incubated  on  ice  for  20  minutes.  The  cell  lysate  
was  centrifuged  at  13000  rpm  and  at  4°C  for  15  minutes.  The  pellet  was  discarded  and  
the  supernatant  (cell  lysate)  was  used  for  the  experiment.  
The  aim  was  to  analyse  the  expression  pattern  and  concentration  of  Serpin  B1  in  plasma  
and  WBC  of  healthy  donors  and  two  cohorts  of  breast  cancer  patients.  To  calculate  the  
concentration   of  Serpin  B1   in   plasma  and  white   blood   cells  of   breast   cancer   patients  
(primary  and  advanced)  a  standard  curve  method  was  used.  The  results  demonstrate  a  
significant  increase  of  the  Serpin  B1  levels  in  white  blood  cells  from  primary  and  advanced  
breast  cancer  patients  in  comparison  with  healthy  individuals  (Figure  3.19).  Furthermore,  
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the  white  blood  cell  levels  of  the  analysed  protein  correlate  with  their  respective  serum  
levels   (Figure   3.20).  Upon  measurement  of  Serpin  B1   levels,   it  was  observed   that   its  
concentration  in  WBCs  of  healthy  individuals  ranges  between  1.12ng/mL  and  10ng/mL.  
In  primary  breast  cancer  patients,  it  was  detected  to  be  greater,  between  3.44ng/mL  and  







Figure  3.19  Analysis  of   the  concentration  of  Serpin  B1  levels   in  WBCs  of  breast  
cancer  patients  using  ELISA.  WBCs  and  plasma  were  isolated  from  blood  of  cancer  
patients  and  healthy  donors.  Cell   lysates  were  prepared  from  1x107  cells.  To  calculate  
the  concentration  of  Serpin  B1  in  plasma  and  white  blood  cells  a  standard  curve  method  
was  used.     Optical  density   readings  were   taken  at  single  wavelength  of  450  nm.  HD-­  
healthy  donors,  BRCA-­  primary  breast  cancer  patients,  ABC-­  advanced  breast  cancer  
patients.   The   concentration   of   Serpin   B1   in   WBC   of   breast   cancer   patients   differ  










Figure   3.20   Concentration   of   serum   and   WBCs   levels   of   Serpin   B1   using  
quantitative  sandwich  ELISA  commercial  kit.  WBCs  and  plasma  were  isolated  from  
blood   of   cancer   patients   and   healthy   individuals.   Each   dot   represents   an   individual  
patient.  Cell   lysates  were  prepared   from  1x107  cells.  To  calculate   the  concentration  of  
Serpin  B1  in  plasma  and  white  blood  cells  a  standard  curve  method  was  used.    Optical  
density  readings  were  taken  at  single  wavelength  of  450  nm.  HD-­  healthy  donors,  BRCA-­  
primary  breast  cancer  patients,  Concentration  of  Serpin  B1  in  WBCs  correlates  with  its  
corresponding  serum  concentration.  *P<0.05;;  **P<0.01;;  ***P<0.001
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3.2.6.2  Analysis  of  the  Serpin  B1  levels  in  a  cohort  of  patients  with  advanced  breast  
cancer  in  response  to  treatment  using  ELISA.  
To  analyse  whether  the  changes  in  circulating  Serpin  B1  concentration  could  be  indicative  
of  the  treatment  response  in  advanced  breast  cancer  patients  undergoing  chemotherapy  
and  endocrine  treatment,  the  levels  of  the  analyte  were  measured  from  the  serum  of  10  
patients  (6  chemotherapy,  4  endocrine)  at  three  treatment  time  points;;  beginning,  middle  
and  final  stage.  The  data  revealed  different  patterns  and  were  grouped  according  to  the  
clinical  information  (Figure  3.21).  The  data  indicates  that  changes  in  circulating  levels  of  
Serpin  B1  do  not  correlate  with  treatment  response.  
To  see  if  trends  in  Serpin  B1  concentration  correlate  with  patient  survival  from  advanced  
cancer,   the  results  were  grouped  according   to   the   length  of  survival   (Figure  3.22.  The  








Figure  3.21  Analysis  of  the  correlation  between  circulating  levels  of  Serpin  B1  in  
serum  of  advanced  breast  cancer  patients  and  treatment  response  using  sandwich  
ELISA.  Serum  was  separated  from  blood  of  advanced  breast  cancer  patients  prior  the  
first  (baseline),  second  (middle)  and  final  third  stage  of  the  treatments.  To  calculate  the  
concentration  of  Serpin  B1  in  plasma  a  standard  curve  method  was  used.    Optical  density  
readings  were  taken  at  single  wavelength  of  450  nm.  PD  progressive  disease;;  PR  partial  
response;;  SD  stable  disease;;  CR  complete  response.  Chemo  chemotherapy  treatment.  







Figure  3.22  Analysis  of  the  correlation  between  circulating  levels  of  Serpin  B1  in  
serum   of   advanced   breast   cancer   patients   and   survival   time   using   sandwich  
ELISA.  Serum  was  separated  from  blood  of  advanced  breast  cancer  patients  prior  the  
first  (baseline),  second  (middle)  and  final  third  stage  of  the  treatments.  To  calculate  the  
concentration  of  Serpin  B1  in  plasma  a  standard  curve  method  was  used.    Optical  density  




3.3  Discussion    
Previous  studies  have  demonstrated   that   the  protein  expression  profile  of  WBCs   from  
cancer  patients  differ  from  those  in  healthy  donors  (Aarøe  et  al.  2010;;  Sotiriou  &  Pusztai  
2009).  In  our  laboratory,  several  differentially  expressed  proteins  were  identified  in  WBCs  
of  cancer  patients.  In  the  presented  study,  we  aimed  to  analyse  the  expression  pattern  of  
five  of  the  identified  targets.  The  aim  of  this  part  of  the  study  was  to  validate  heightened  
expression  of  Serpin  B1  on  protein  level.  
The  levels  of  expression  of  previously  identified  protein  Serpin  B1  were  analysed  in  WBCs  
of  different  groups  of  breast  cancer  patients:  primary  breast  cancer  patients  and  patients  
with   advanced   (metastatic)   breast   cancer;;  WBCs   from   healthy   donors   were   used   as  
control.  We  observed  that  the  levels  of  Serpin  B1  increases  as  the  disease  advances.  
The  obtained  data  revealed  that  Serpin  B1  levels  differ  significantly  between  two  cohorts  
of   breast   cancer   (primary   and   advanced)   and   healthy   donor   group.   Furthermore,   the  
higher   levels  of  Serpin  B1  observed   in  some  of  healthy  donors  correlated  with  familial  
history  of  breast  and  prostate  cancer.  This  data  suggests  that  Serpin  B1  has  features  of  
prognostic  marker  for  disease  progression.  Measurement  of  its  levels  in  WBCs  of  primary  
breast  cancer  may  be  useful  to  distinguish  between  patients  with  node  negative  and  node  
positive  disease.  Furthermore,  as  Serpin  B1   levels  differ  significantly  between  primary  
and  advanced  cohorts,  the  high  levels  of  the  protein  in  samples  from  primary  cohort  may  
help  to  identify  patients  that  have  risk  of  development  of  the  invasive  disease.    
Next,  we  examined  whether  Serpin  B1  can  serve  as  a  predictive  marker  for  the  treatment  
response.   In   order   to   achieve   this,   the   expression   levels   of   the   target   protein   were  
measured  by  western  blot   in  the  group  of  patients  with  advanced  (metastatic)  disease.  
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The   obtained   data   revealed   the   most   favourable   pattern   in   protein   expression   in  
correlation  with  survival.    
The   results   from  Western   blot   were   supported   by   immunofluorescent   staining,   where  
higher   degree   of   staining   was   observed   in   white   blood   cells   of   advanced   and   node  
positive  primary  breast  cancer  patients  in  comparison  with  node  negative  primary  breast  
cancer  and  healthy  donor’s  samples.  Moreover,  distinct  distribution  of  Serpin  B1  protein  
in  WBCs  of  patients  in  association  with  different  stages  of  the  disease  was  detected.  In  
leukocytes   of   node  negative   and  node  positive   breast   cancer   patients  Serpin  B1  was  
appeared  to  be  present  in  vesicles  at  the  cell  surface.  This  observation  was  the  interesting  
one  as  it  was  previously  reported  that  Serpin  B1  is  cytoplasmic  proteins  characterised  by  
the  absence  of  N-­terminal  signal  peptide  that  is  required  for  the  secretion  pathway  and  
therefore   reside   intracellularly   (Pemberton  et  al.  1997).  Since   the  main  known  role   for  
Serpin  B1  appears  to  protect  granulocytes  by  the  inhibition  of  their  own  granule  proteases  
a  possible  explanation  of  the  overexpression  of  Serpin  B1  in  leukocytes  of  breast  cancer  
patients  would  be  the  protection  of  these  cells  (Zhao  et  al.  2014  &  Benarafa  et  al.  2011).    
The  nuclei  localisation  of  SerpinB1  observed  in  the  present  study  is  also  reported  in  other  
studies.  For  example,  Farley  and  co-­workers  showed  that  in  resting  neutrophils  Serpin  
B1   localises   in   the   cytoplasm   and   translocates   into   the   nucleous   during   NETosis  
(neutrophil  extracellular  trap  generation).  These  structures  are  sought  to  be  released  by  
dying  neutrophils  in  order  to  trap  and  kill  pathogens  and  reported    be  negatively  regulated  
by  Serpin  B1  (Farley  et  al.  2012;;  Remijsen  et  al.  2011).  
Measurement  of  the  levels  of  Serpin  B1  in  WBCs  of  the  patients  with  advanced  disease  
undergoing   chemotherapy   and   endocrine   treatment   revealed   that   lower   levels   of   the  
protein  in  the  beginning  of  the  both  treatments  correlate  with  complete  response  to  the  
158  
  
treatment.  Furthermore,  lower  initial   levels  of  the  protein  were  shown  to  associate  with  
longer  survival  of  the  group  of  patients  received  chemotherapy  treatment.    This  trend  was  
not   observed   for   the   patients   received   endocrine   treatment.   Kaplan-­Meier   test   for  
combined  chemotherapy  and  endocrine  patients  did  not  show  the  significant  difference  
between  lower/higher  levels  of  Serpin  B1  and  overall  survival  of  the  patients.  Interestingly,  
the  lower  initial  Serpin  B1  levels  showed  association  with  complete  response  to  treatment  
in  both  chemotherapy  and  endocrine  treatment  groups  of  patients.    
Consistent   with   the   above   results,   the   flow   cytometric   analysis   of   the   Serpin   B1  
expression   in   randomly   selected   sample   from   primary   breast   cancer   patient   shows  
elevated  levels  of  the  protein  and  supports  the  overall  validation  data  generated  in  this  
study.  However,  these  results  are  based  on  one  sample  analysed,  therefore  the  panel  
needs  to  be  expanded.    
Finally,  analysis  of  the  circulating  levels  of  Serpin  B1  expression  using  ELISA  revealed  
heightened  patterns  of  the  protein  expression  in  WBCs  of  both  (primary  and  advanced)  
cohorts  of  breast  cancer  patients.  Furthermore,  the  serum  Serpin  B1  levels  showed  the  
same  trend  as  previously  observed  WBCs  one.  In  serum  of  primary  breast  cancer  patients  
significantly  higher  concentration  of  Serpin  B1  was  detected.  
Serpin  B1  primarily  acts  as  intracellular  protein  as  it  lacks  the  hydrophobic  signal  peptide,  
the  typical  feature  of  the  secretory  proteins  (Pemberton  et  al.  1997).    Here  consistent  with  
the  IF  results  its  extracellular  localisation  was  detected  using  ELISA.  The  high  levels  of  
Serpin  B1were  also  reported  in  serum  of  the  patients  with  type  2  diabetes  (Takebayashi  
et  al.  2016).    
Taken  together  these  results  demonstrate  the  potential  of  Serpin  B1  as  a  biomarker  for  




4.1  Lipocalin  2  
Lipocalin  2,  also  referred  to  as  neutrophil  gelatines  associated  lipocalin  (NGAL)  belongs  
to  the  family  of  small  proteins  characterised  by  their  ability  to  bind  and  transport  lipophilic  
molecules  such  as  retinols,  steroid  and   iron  (Xiao  et  al.  2017).    Recently,  several  new  
properties  attributed  to  lipocalins  have  been  reported,  such  as  prostaglandin  synthesis,  
protease  inhibition  and  modulation  of  cell  growth.  The  expression  of  NGAL  is  induced  by  
cytokines  and  found  to  be  upregulated  under  inflammatory  conditions  (Bauer  et  al.  2008).  
Heightened   expression   of   Lipocalin   2   has   been   reported   in   many   epithelial   cancers  
including  breast  carcinomas.  For  example,  Lipocalin  2  was  found  to  be  up-­regulated  in  
plasma  in  a  mouse  model  of  breast  cancer  (Pitteri  et  al.  2008).  In  human  studies,  Bauer  
et   al   (2008)   examined   localization   of   NGAL   in   tumours   of   208   primary   breast   cancer  
patients   using   immunostaining   and   correlated   the   results   with   clinical   outcome.   The  
researchers  detected  a  strong  correlation  between  cytoplasmic  localisation  of  NGAL  and  
HER2   overexpression,   lymph   node   metastasis   and   decreased   disease-­free   survival  
(Bauer  et  al.  2008).  More  information  about  Lipocalin  2  is  given  in  the  section  1.2.4.2.  
Objectives  of  the  present  chapter:  
Our  previous  proteomic  studies  reported  heightened  expression  of  Lipocalin  2  in  WBCs  
of   breast   cancer   patients.  We   hypothesised   that   Lipocalin   2   expression   in  WBCs  will  
correlate   with   clinical   outcomes   (e.g.   survival   and   therapy   response).   This   chapter  
comprises   of   two  major   aims.   The   first   one   is   to   validate   the   heightened   expression  
pattern  of  Lipocalin  2  in  WBCs  from  breast  cancer  patients  in  comparison  with  healthy  
individuals.  The  second  aim  is  to  study  the  changes  in  Lipocalin  2  levels  in  a  cohort  of  
advanced  breast  cancer  patients  undergoing  treatment  in  order  to  evaluate  the  prognostic  
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and  predictive  biomarker  value  of  Lipocalin  2.  To  achieve  this,  target  protein  levels  were  
assessed   in   plasma   and   WBCs   of   breast   cancer   patients   using   western   blot,  





4.2.1  Western  blot  analysis  of  Lipocalin  2  expression  in  WBCs  obtained  from  blood  
of  healthy  donors  and  breast  cancer  patients  
Proteomic   analysis   revealed   elevated   levels   of   Lipocalin   2   in   WBCs   of   individuals  
diagnosed  with  breast  cancer  (Many,  J.,  PhD  thesis,  2015).  In  order  to  further  verify  this  
data,  protein  levels  of  Lipocalin  2  were  measured  by  western  blot  in  13  healthy  donors,  
11  primary  and  47  patients  with  advanced  breast  cancer.    In  agreement  with  the  expected  
size,   a   band   of   25   kDa   was   observed   (Figure   4.1)   Densitometry   analysis   was   then  
performed  using   the   Image  J  software  and  the  Lipocalin  2  signal  was  normalised   to  b  
Actin.  Expression  levels  between  the  gels  was  normalised  to  the  expression  value  of  the  
common  healthy  donor  2  (HD2)  sample  used  in  all  experiments  (Figure  4.2).  The  results  
revealed  significant  overexpression  of  Lipocalin  2  protein  levels  in  WBCs  of  both  primary  







Figure   4.1   Representative  western   blots   of   Lipocalin   2   levels   in   breast   cancer  
patients  with  different  disease  conditions.  WBCs  were  isolated  from  blood  of  cancer  
patients.  Cell  lysates  were  prepared  from  2x106  cells.  The  samples  were  separated  using  
SDS-­PAGE,  blotted  and  probed  with  anti-­Lipocalin  2  antibody.  The  same  membrane  was  
then  re-­probed  with  anti-­  β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  
proteins  of  interest  were  visualised  using  Image  Analyser.  The  ratios  of  the  intensity  of  
the   Lipocalin   2   bands   over   the   intensity   of   the   corresponding   β-­actin   bands   were  
determined  as  a  control  healthy  donor  2  was  used  in  all  the  western  blots  and  the  results  


























Figure  4.2  Lipocalin  2  protein  levels  in  breast  cancer  patients  with  different  disease  
states.  Cell  lysates  were  prepared  from  2x106  cells.  The  samples  were  separated  using  
SDS-­PAGE,  blotted  and  probed  with  the  anti-­Lipocalin  2  antibody.  The  same  membrane  
was  then  re-­probed  with  anti-­  β-­Actin  antibody  (loading  control).  Band  corresponding  to  
the   proteins   of   interest   were   visualised   using   Image   Analyser.   Densitometry   was  
performed   (Image   J)   and   the   ratios  of   the   intensity   of   the   Lipocalin  2   bands  over   the  
intensity  of  the  corresponding  β-­actin  bands  were  determined  as  a  control  healthy  donor  
2  was  used   in  all   the  western  blots  HD-­  healthy  donors,  BrCa-­  primary  breast  cancer,  
ABC-­  breast  cancer  patients  with  advanced.    Statistical  difference  between  groups  was  
analysed   by   non-­parametric   Kruskal-­Wallis   test.   *P<0.05,   **   P<0.01.   The   difference  




4.2.2  Western  blot   analysis   of   Lipocalin   2   expression   in  WBCs  of  patients  with  
advanced  breast  cancer.
4.2.2.1  Western  blot  analysis  of  Lipocalin  2  expression  in  WBC  from  breast  cancer  
patients   with   advanced   disease   during   treatment   in   correlation   with   clinical  
response.    
Advanced/metastatic  breast  cancer  is  when  the  disease  has  spread  beyond  the  breast  to  
other   organs   in   the   body.  Biomarkers   that   predict   response   to   therapy  may  eliminate  
unnecessary   treatment  or  could  be  used  to  guide   therapeutic  strategies.  Currently   the  
assessment   of   response   to   therapy   is   based   upon   both   subjective   and   objective  
measures.  Objective  assessment  is  evaluated  on  the  basis  of  measurement  of  the  tumour  
size  before  and  after  treatment.  However,  the  response  monitoring  is  recommended  after  
2-­3  cycles  of  chemotherapy  or  several  months  of  endocrine  therapy.  As  the  aim  of  the  
treatment  for  advanced  breast  cancer  patients  is  to  provide  prolongation  of  good  quality  
of   life.  The  subjective   response  to   treatment   is  based  on  estimation  of   the  balance  of  
benefit   and   side-­effects   of   the   therapy   given.   The   currently   available   serum  markers  
CA15-­3  and  CEA  have  their   limitations.  For  example,  these  biomarkers  do  not  reliably  
show  an  early  response  to  treatment  (Kabel  2017).    
In  this  part  of  the  project  the  level  of  Lipocalin  2  was  assessed  in  a  cohort  of  patients  with  
advanced   breast   cancer   undergoing   chemotherapy   and   endocrine   treatment.   These  
analyses  are  important  to  determine  whether  Lipocalin  2  could  be  a  potential  prognostic  
biomarker  to  predict  treatment  response.    In  order  to  achieve  this,  western  blotting  was  
performed  to  evaluate  the  expression  levels  of  Lipocalin  2  were  measured  in  WBCs  taken  
from  patients  at  the  beginning,  middle  and  end  of  treatment.  The  ratios  of  the  intensity  of  
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the   Lipocalin   2   bands   over   the   intensity   of   the   corresponding   β-­Actin   bands   were  
determined  using  densitometry,  as  a  control  healthy  donor  2  was  used  in  all  the  westerns.    
These  trends  were  then  correlated  with  data  for  the  patients’  treatment  response,  which  
was  divided  into  four  categories:  complete  response  (CR),  partial  response  (PR),  stable  
disease  (SD)  and  progressive  disease  (PD).    
Lipocalin   2   levels,   in   response   to   chemotherapy,   declined   in   stable  disease,   although  
these   results   are   not   reliable   as   only   one   sample   was   analysed   within   this   category  
(Figure  4.3).  The  rest  of  the  response  categories  showed  mixed  trends  of  the  changes  in  
protein  expression.  The  results  obtained  for  patients  with  endocrine   treatment   indicate  
that  the  levels  of  Lipocalin  2  decline  in  the  response  to  treatment  in  all  four  categories  of  
the  patient,  with  the  exception  for  one  patient  with  stable  disease  which  shows  a  slight  






Figure  4.3  Western  blot  analysis  of  the  correlation  between  changes  in  the  levels  
of  Lipocalin2  during  the  course  of  chemotherapy  treatment  and  clinical  response.  
Complete   response  (CR),  partial   response  (PR),  stable  disease  (SD)  and  progressive  
disease  (PD).  WBC  were  extracted  from  blood  of  breast  cancer  patients;;  cell  lysates  were  
prepared   from   2x106   cells.   Samples   were   separated   using   SDS-­PAGE,   blotted   and  
probed  with  anti-­Lipocalin2  antibody.  The  same  membrane  was  then  re-­probed  with  anti-­
β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  of  interest  were  
visualised  using  Image  Analyser.  The  ratios  of  the  intensity  of  the  Lipocalin2  bands  over  
the   intensity  of   the  corresponding  β-­Actin  bands  were  determined  as  a  control  healthy  
donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  using  GraphPad  






Figure  4.4  Western  blot  analysis  of  the  correlation  between  changes  in  the  levels  
of   Lipocalin   2   during   the   course   of   endocrine   treatment   and   clinical   response.  
Complete   response  (CR),  partial   response  (PR),  stable  disease  (SD)  and  progressive  
disease  (PD).  WBC  were  extracted  from  blood  of  breast  cancer  patients;;  cell  lysates  were  
prepared   from   2x106   cells.   Samples   were   separated   using   SDS-­PAGE,   blotted   and  
probed  with  anti-­Lipocalin2  antibody.  The  same  membrane  was  then  re-­probed  with  anti-­
β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  of  interest  were  
visualised  using  Image  Analyser.  The  ratios  of  the  intensity  of  the  Lipocalin2  bands  over  
the  intensity  of  the  corresponding  β-­Actin  bands  were  determined  using  densitometry,  as  
a  control  healthy  donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  
using  GraphPad  Prism  5  software.  
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4.2.2.2  Western  Blot  analysis  of  the  basal  levels  of  Lipocalin  2  in  WBCs  of  advanced  
breast  cancer  patients  in  correlation  with  response  to  treatment.
Next,  assessed  the  basal  levels  of  the  protein  of  interest  was  assessed  at  the  beginning  
of   treatment   in  correlation  with  corresponding  clinical  data   for   the   treatment  response.  
The  aim  of  this  experiment  was  to  assess  if  Lipocalin  2  could  be  used  as  a  biomarker  to  
predict   response   to   treatment.  According   to   the   obtained   results   lower   initial   levels  of  
Lipocalin  2  associate  with  stable  disease  in  the  cohort  of  chemotherapy  patients  (Figure  
4.5).  Although,  Kruskal-­Wallis  test  of  the  data  showed  that  the  p  value  is  not  significant,  
the  median  of  the  patients  with  stable  disease  was  lower  than  of  the  patients  with  partial  
response,  complete  response  and  progressive  disease.    
The  results  for  patients  with  endocrine  treatment  showed  a  similar  trend,  with  lower  initial  
levels  of  Lipocalin  2  correlating  with  stable  disease  (Figure  4.6).  Statistical  test  showed  
that  the  p  value  was  not  significant,  but  the  median  for  stable  disease  cohort  was  lower  







Figure  4.5  Analysis  of   the  correlation  between  initial   levels  of  Lipocalin  2  before  
treatment  and  response  to  chemotherapy  in  advanced  breast  cancer  patients  by  
western   blot.  PD   progressive   disease;;   PR   partial   response;;   SD   stable   disease;;   CR  
complete  response.  Leukocytes  were  extracted  from  blood  of  breast  cancer  patients;;  cell  
lysates   were   prepared   from   2x106  cells.   Samples   were   separated   using   SDS-­PAGE,  
blotted   and   probed   with   anti-­Lipocalin2   antibody.   The   same  membrane   was   then   re-­
probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  
of   interest   were   visualised   using   Image   Analyser.   The   ratios   of   the   intensity   of   the  
Lipocalin2  bands  over  the  intensity  of  the  corresponding  β-­Actin  bands  were  determined  
as  a  control  healthy  donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  
graph   using   GraphPad   Prism   5   software.   Statistical   difference   between   groups   was  








Figure  4.6  Analysis  of   the  correlation  between  initial   levels  of  Lipocalin  2  before  
treatment  in  correlation  with  response  to  endocrine  treatment  in  advanced  breast  
cancer   patients   by   western   blot.   Leukocytes   were   extracted   from   blood   of   breast  
cancer  patients;;  cell   lysates  were  prepared   from  2x106  cells.  Samples  were  separated  
using  SDS-­PAGE,  blotted  and  probed  with  anti-­Lipocalin2  antibody.  The  same  membrane  
was  then  re-­probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  corresponding  to  
the  proteins  of  interest  were  visualised  using  Image  Analyser.  The  ratios  of  the  intensity  
of   the   Lipocalin2   bands   over   the   intensity   of   the   corresponding   β-­Actin   bands   were  
determined  as  a  control  healthy  donor  2  was  used   in  all   the  westerns  and   the   results  
plotted   on   a   graph   using   GraphPad   Prism   5   software.   Statistical   difference   between  
groups  was  analysed  by  non-­parametric  Kruskal-­Wallis  test.  
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4.2.2.3  Western  blot  analysis  of  the  changes  in  the  Lipocalin  2  expression  levels  in  
WBCs  from  breast  cancer  patients  with  metastatic  disease  during  chemotherapy  
treatment  in  correlation  with  survival.
Next,   we   analysed   whether   Lipocalin   2   can   serve   as   a   marker   for   the   response   to  
treatment   in   patients   with   advanced   disease.   In   order   to   achieve   this,   Lipocalin   2  
expression   was   assessed   in  WBC   of   breast   cancer   patients   with  metastatic   disease  
during  chemotherapy  treatment.  Patients  with  invasive  breast  cancer  had  undergone  six  
rounds  of  chemotherapy   treatment.  The   level  of  Lipocalin  2   in  WBC  was  evaluated   in  
WBC  obtained  from  18  breast  cancer  patients  prior  the  first  (baseline),  third  (middle)  and  
sixth   (final)   rounds   of   treatment   using   western   blot   technique.   Upon   evaluation,   four  
different  patterns  of  Lipocalin  2  levels  in  the  response  to  chemotherapy  treatment  were  
observed  and  results  were  divided  into  four  groups  of  response  (Figure  4.7).  
In  patient  group  1,  Lipocalin  2  levels  gradually  decreased  and  survival  times  ranged  from  
3  to  15  months.  In  group  2  Lipocalin  2  levels  increased  in  the  middle  of  the  treatment  and  
declined  at  the  end;;  survival  times  ranged  from  4  to  24  months.  Group  3  represents  the  
majority   of   the   patients   treated   with   chemotherapy.   In   this   group,   Lipocalin2   levels  
declined   in   the  middle  of   the  treatment  and   increased   in   the  end;;  survival   time  ranged  
from   4   to   48   months.   In   group   4   Lipocalin   2   levels   increased   during   the   course   of  
treatment.   The   group   comprised   of   2   patients   and   correlates   with   more   favourable  






Figure  4.7  Western  blot  analysis  of  the  correlation  between  changes  in  the  levels  
of  Lipocalin2  during  the  chemotherapy  treatment  and  survival  of  the  patients.  WBC  
were  extracted  from  blood  of  breast  cancer  patients  prior  the  treatment-­baseline,  in  the  
middle  and  at  the  final  stage;;  cell  lysates  were  prepared  from  2x106  cells.  Samples  were  
separated  using  SDS-­PAGE,  blotted  and  probed  with  anti-­Lipocalin2  antibody.  The  same  
membrane   was   then   re-­probed   with   anti-­β-­Actin   antibody   (loading   control).   Bands  
corresponding  to  the  proteins  of  interest  were  visualised  using  Image  Analyser.  The  ratios  
of   the   intensity  of   the  Lipocalin2  bands  over  the   intensity  of   the  corresponding  β-­Actin  
bands  were  determined  as  a  control  healthy  donor  2  was  used  in  all  the  westerns  and  the  
results  plotted  on  a  graph  using  GraphPad  Prism  5  software.
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4.2.2.4  Western  Blot  analysis  of  the  basal  levels  of  Lipocalin  2  in  WBCs  of  
advanced  breast  cancer  patients  in  correlation  with  survival.
The  aim  of  the  next  experiment  was  to  analyse  whether  the  initial  levels  of  Lipocalin  2  in  
WBCs   of   the   advanced   breast   cancer   patients   before   chemotherapy   and   endocrine  
treatment   have   any   correlation   with   overall   survival.   For   this   purpose,   the   levels   of  
Lipocalin  2  were  assessed  by  Western  Blot  analysis  using  hand  cast  gels.  The  obtained  
data  showed  that  the  levels  of  protein  in  the  beginning  of  the  treatment  do  not  correlate  
with  the  survival  of  the  patients  and  therefore  Lipocalin2  cannot  be  used  as  a  marker  of  








Figure  4.8  Analysis  of   the  correlation  between   initial   levels  of  Lipocalin2  before  
treatment  and  response  to  chemotherapy  in  advanced  breast  cancer  patients  by  
western   blot.   Leukocytes   were   extracted   from   blood   of   breast   cancer   patients;;   cell  
lysates   were   prepared   from   2x106  cells.   Samples   were   separated   using   SDS-­PAGE,  
blotted   and   probed   with   anti-­Lipocalin2   antibody.   The   same  membrane   was   then   re-­
probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  
of   interest   were   visualised   using   Image   Analyser.   The   ratios   of   the   intensity   of   the  
Lipocalin2  bands  over  the  intensity  of  the  corresponding  β-­Actin  bands  were  determined  
as  a  control  healthy  donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  
graph   using   GraphPad   Prism   5   software.   Statistical   difference   between   groups   was  







Figure  4.9  Analysis  of   the  correlation  between   initial   levels  of  Lipocalin2  before  
treatment  and  response  to  endocrine  treatment  in  advanced  breast  cancer  patients  
by  western  blot.  Leukocytes  were  extracted  from  blood  of  breast  cancer  patients;;  cell  
lysates   were   prepared   from   2x106  cells.   Samples   were   separated   using   SDS-­PAGE,  
blotted   and   probed   with   anti-­Lipocalin2   antibody.   The   same  membrane   was   then   re-­
probed  with  anti-­β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  
of   interest   were   visualised   using   Image   Analyser.   The   ratios   of   the   intensity   of   the  
Lipocalin2  bands  over  the  intensity  of  the  corresponding  β-­Actin  bands  were  determined  
as  a  control  healthy  donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  
graph   using   GraphPad   Prism   5   software.   Statistical   difference   between   groups   was  
analysed  by  non-­parametric  Kruskal-­Wallis  test.  
176  
  
4.2.2.5  Kaplan-­Meier  survival  analysis  
Next,  we  carried  out  Kaplan-­Meier  analysis  to  study  the  correlation  between  high  and  low  
levels  of  Lipocalin  2  expression  and  patient’s  overall  survival  (Figure  4.10).  The  baseline  
protein   levels   of   Lipocalin   2   were  measured   by  Western   Blot   in   47   advanced   breast  
cancer  patients.  The  Lipocalin  2  signal  was  normalised  to  the  b  Actin  signal  using  Image  
J  software.  Expression  values  between  the  gels  were  compared  by  normalising   to   the  
expression  value  of  the  common  healthy  donor  2  sample  used  in  all  experiments.  The  
cut-­off  point  was  determined  by  average  of  all  the  values,  as  2.  The  generated  data  shows  







Figure   4.10   Survival   curves   according   to   Lipocalin   2   expression.   Kaplan-­Meier  
survival   curve   for   high   Lipocalin   2   expression   versus   low   expression   did   not   show  
significant  difference.  The  cut-­off  point  was  determined  by  average  of  all  the  values,  as  2  
WBCs  were  extracted  from  blood  of  advanced  breast  cancer  patients;;  cell  lysates  were  
prepared   from   2x106   cells.   Samples   were   separated   using   SDS-­PAGE,   blotted   and  
probed  with  anti-­Lipocalin  2  antibody.  The  same  membrane  was  then  re-­probed  with  anti-­
β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  of  interest  were  
visualised  using  Image  Analyser.  The  ratios  of  the  intensity  of  the  Lipocalin  2  bands  over  
the   intensity  of   the  corresponding  β-­Actin  bands  were  determined  as  a  control  healthy  
donor  2  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  using  GraphPad  
Prism  5  software
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4.2.3.1  Distribution  of  Lipocalin  2  in  WBCs  of  breast  cancer  patients  
Next,  the  distribution  of  Lipocalin2  protein  in  WBC  of  breast  cancer  patients  and  healthy  
donors   was   examined   by   immunofluorescent   staining   using   primary   anti-­Lipocalin   2  
antibody  (Figure  4.10  A).  Examination  of  slides  revealed  different  distribution  of  Lipocalin  
2.  In  the  healthy  donor  samples  Serpin  B1  appeared  to  be  present  in  the  cytoplasm  of  the  
cells.  WBCs  samples  from  primary  breast  cancer  patients  were  characterised  by  higher  
intensity  of  the  nuclei  and  cytoplasmic  staining.  In  leukocytes  of  patients  with  advanced  
breast  cancer  Lipocalin  2  protein  was  detected   in   the  cytoplasm  of   the  cells  with  high  
intensity.   In   the  samples  obtained  from  healthy   individuals   the   intensity  of   the  staining  
appears  to  be  lower.  These  results  support  the  data  obtained  from  Western  Blot  analysis.  
The   proportion   of   the   distribution   of   the   Lipocalin   2   signal   among   the   samples   was  
measured  using  Image  J  software.  The  results  show,  that  that  the  distribution  of  the  signal  
corresponding  to  the  Lipocalin  2  protein  is  significantly  higher  in  the  WBCs  samples    from  





Figure  4.10  Immunofluorescent  analysis  of  Lipocalin  2  protein  distribution  in  WBC  
of   BRCA   node   negative,   node   positive,   advanced   cancer   patients   and   healthy  
donors.  A  WBC  from  breast  cancer  patients  and  healthy  donors  were  stained  with  FITC-­
labelled  anti-­rabbit   secondary   IgG  antibody   (dilution  1:400)  against  Lipocalin2  primary  
antibody  (dilution  1:200),  plus  secondary  only  as  the  control.  The  blue  staining  shows  the  
position  of  the  nucleus.  The  green  staining  in  the  cytoplasm  corresponds  to  Lipocalin2  
protein.   Scale   bar   0.1mm.   All   images   were   taken   by   Confocal   Scanning  Microscope  
(BioRad  Hercules)  at  60X  magnification.  B  Bar  graph  represents  the  proportion  of  signal  












4.2.3.2  Lipocalin  2  expression  in  immune  cells  
In  order  to  further  understand  exactly  which  immune  cells  overexpress  Lipocalin  2,  cells  
were  co-­stained  with  antibodies  for  Lipocalin  2  and  immune  cell  specific  markers.  For  this  
purpose,  WBCs  from  breast  cancer  patients  were  double  stained  against  the  cluster  of  
differentiation  (CD)  cell  surface  markers   to  distinguish  between  subpopulation  of  white  
blood  cells  and  the  protein  of  interest.  
First   leukocyte   fractions   were   stained   with   CD15   antibody,   which   recognises   a  
carbohydrate   epitope   expressed   in  mature   neutrophils   and   eosinophils.   The  obtained  
double   immunofluorescence  analysis  revealed   that   the  majority  of  Lipocalin  2  positive  
cells  were  neutrophils  (Figure  4.11).  The  results  show,  that  the  cells  negative  for  CD15  







Figure   4.11   Immunofluorescence   analysis   of   Lipocalin2   protein   distribution   in  
leukocytes  of  primary  and  advanced  breast  cancer  patients.  WBC  extracted   from  
blood  of  primary  and  advanced  breast  cancer  patients  were  double  stained  with  FITC-­
labelled  anti-­rabbit  secondary  IgG  antibody  (1:400)  against  Lipocalin2  primary  antibody  
(dilution   1:200)   and  Tritc-­labelled   anti-­mouse   secondary   IgG   antibody   (1:400)   against  
CD15  neutrophil  primary  antibody  (1:200),  plus  secondary  only  as  the  control.  The  blue  
staining   (DAPI)  shows   the  position  of   the  nucleus.  The  green  staining  corresponds   to  
Lipocalin2  protein  and  red  staining  represents  Neutrophils.  Scale  bar  0.01mm.  All  images  










4.2.4  Evaluation  of  the  levels  of  Lipocalin  2  in  neutrophils  of  primary  breast  cancer  
patients  using  flow  cytometric  analysis.
Previously   we   reported   elevated   levels   of   Lipocalin   2   in   neutrophils   of   breast   cancer  
patients   in  comparison  with  healthy   individuals.  Here  we  aimed   to   further  validate   the  
increased  expression  of  the  above  protein  using  flow  cytometry  (FACS).  Flow  cytometry  
is  the  method  that  allows  for  rapid  quantitative  assessment  of  proteins  within  the  specific  
cell  type  via  cell  surface  marker  phenotyping.    
Because  granulocytes  rapidly  degenerate  soon  after  collection,  WBCs  were  isolated  from  
the  blood  sample  within  6  hours   from  the  blood  draining  and   immediately  used  for   the  
experiment  (Chue  &  Neagu  2014).    For  this  experiment,  freshly  isolated  WBCs  randomly  
selected  from  a  primary  breast  cancer  patient  and  a  healthy  donor  were  stained  with  two  
pre-­labelled  markers  expressed  by  mature  neutrophils:  CD15,  CD66b.  The  combination  
of  these  two  markers  is  commonly  used  to  identify  the  mature  neutrophils.  Lipocalin  2  is  
intracellular  protein  therefore  pre-­stained  cells  were  fixed,  permeabilised  and  stained  with  
unlabelled   polyclonal   rabbit   anti-­Lipocalin   2   antibody   followed   by   the   incubation   with  
FITC-­labelled  anti-­rabbit  secondary  antibody  to  detect  Lipocalin  2.      
For   a   negative   control,   cells   were   stained   with   an   isotype   control   antibody.   Isotype  
controls  are  antibodies  of  the  same  isotype  as  the  target  primary  antibody.  They  are  of  
unknown  specificity  or  are   raised  against  antigens  known   to  be  absent   in   target  cells.  
Isotype  controls  are  used  to  estimate  non-­specific  staining  of  primary  antibodies.    
The  results  obtained  for  Mean  Fluorescent  Intensity  (MFI)  show  that  the  levels  of  Lipocalin  
2  in  WBCs  of  randomly  selected  primary  breast  cancer  patient  is  two-­fold  higher  than  in  







Figure  4.12:  Flow  cytometric  analysis  of   the  Lipocalin  2   levels   in  neutrophils  of  
breast  cancer  patient  and  a  healthy  donor  (randomly  selected).  Quantification  of  the  
levels  of  Lipocalin  2  expression  in  the  neutrophils  of  HD  and  BRCA  according  to  the  Mean  
Fluorescent   Intensity   (MFI)   of   the   samples   and   control.      Freshly   isolated  WBCs  were  
stained  for  20  minutes  with  pre-­labelled  neutrophils  cell  surface  markers  (CD15/CD66b)  
at  room  temperature.  Cells  were  washed  with  the  staining  buffer  (PBS/Serum/BSA)  and  
fixed  with  cold  4%  formaldehyde  on  ice  for  20  minutes.  Cells  were  permeabilised  in  0.25%  
tween/PBS  for  20  minutes  on  ice,  washed  twice  with  the  staining  buffer  and  incubated  
with   antibody  against   Lipocalin   2   (1:200)   o/n.   The   cells  were   then   stained  with  FITC-­
labelled  anti-­rabbit  secondary  IgG  antibody  (1:400)  for  45  minutes  in  the  dark  to  detect  
Lipocalin  2  and  analysed  using  flow  cytometer  (BD  Accuri  C6).  For  a  negative  control,  
cells  were  stained  with  an  isotype  control  antibody.  
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4.2.5  Analysis  of  the  expression  of  the  Lipocalin  2  using  ELISA
In  the  final  step  of  the  validation  experiment,  the  levels  of  Lipocalin  2  were  analysed  in  
the  WBCs  and  plasma  of  two  cohorts  of  breast  cancer  patients  (primary  and  advanced).  
This   was   achieved   using   a   quantitative   sandwich   enzyme   immunoassay   technique  
(ELISA)   commercial   kit.   The   technique   represents   the   basic   tool   for   the   laboratory  
diagnosis   in   hospitals.  Given   that   Lipocalin   2   is   a   promising  marker   of   breast   cancer  
prognosis,  the  use  of  the  ELISA  kit  in  medical  practice  to  quantitatively  evaluate  Lipocalin  
2  levels  in  the  blood  of  cancer  patients  would  be  of  particular  interest.  
WBC  pellets  (1x107)  were  obtained  from  the  blood  of  breast  cancer  patients  and  healthy  
donors  using  a  fractionation  method  as  described  in  section  2.3.  The  resulting  cell  pellet  
was  lysed  by  the  addition  of  equal  volume  of  Buffer  1  and  Buffer  2  (Table  2.3.)  with  the  
volume   ratio   of   1mL/4x106  and   incubated   on   ice   for   20  minutes.   The   cell   lysate  was  
centrifuged  at  13000  rpm  and  at  4°C  for  15  minutes.  The  pellet  was  discarded  and  the  
supernatant  (cell  lysate)  was  used  for  the  experiment.  
The  aim  was  to  analyse  the  expression  pattern  and  concentration  of  Lipocalin  2  in  plasma  
and  WBC  of  healthy  donors  and  two  cohorts  of  breast  cancer  patients.  To  calculate  the  
concentration  of  Lipocalin  2   in  plasma  and  white  blood  cells  of  breast  cancer  patients  
(primary   and   advanced)   a   standard   curve   method   was   used.   The   obtained   results  
demonstrate   that   the   concentration   of   Lipocalin   2   in  WBCs   of   primary   breast   cancer  
patients  is  significantly  higher  than  in  those  of  healthy  donors  (p<0.05)  (Figure  4.19).  In  
WBCs  of   advanced  breast   cancer   patients,   the   concentration   of   Lipocalin   2  was  also  
shown  to  be  higher,  but  these  results  were  not  statistically  significant.    
The  measurement   of   the   levels   of   Lipocalin   2   concentration   in  WBCs   and  plasma  of  
cancer  patients  revealed   that  while   its   levels  correlate   in  samples   from  primary  breast  
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cancer  patients,  in  samples  from  healthy  donors,  the  WBCs  concentration  of  Lipocalin  2  
is  lower  than  in  the  corresponding  serum  samples  (Figure  4.20).    
To  assess   the   changes   in   the   serum  concentration   of   Lipocalin   2   in   advanced  breast  
cancer   patients   in   the   response   to   treatment,   its   levels   were   measured   in   samples  
obtained  in  the  beginning,  middle  and  the  final  stage  of  the  treatment.  In  the  results,  no  
significant  change  in  the  serum  concentration  of  Lipocalin  2  in  response  to  treatment  was  









Figure  4.19  Analysis  of  the  concentration  of  Lipocalin  2  levels  in  WBCs  of  breast  
cancer  patients  using  sandwich  ELISA.  WBCs  were   isolated   from   blood   of   cancer  
patients  and  healthy  individuals  (Each  dot  represents  an  individual  patient).  Cell  lysates  
were  prepared   from  1x107  cells.  To  calculate   the  concentration  of  Lipocalin  2   in  white  
blood  cells  a  standard  curve  method  was  used.    Optical  density  readings  were  taken  at  
single  wavelength  of  450  nm.  HD-­  healthy  donors,  BRCA-­  primary  breast  cancer  patients,  
ABC-­   advanced   breast   cancer   patients.   The   concentration   of   Lipocalin   2   in  WBCs   of  
primary  breast  cancer  patients  differ  significantly   from  that  of  healthy  donors  (p<0.05).  


























Figure  4.20  Concentration  of  Lipocalin  2  in  WBCs  and  plasma  of  healthy  donors  
and  primary  breast  cancer  patients  using  quantitative  sandwich  ELISA  commercial  kit.  
WBCs  and  plasma  were  isolated  from  blood  of  cancer  patients  and  healthy  individuals  
(Each  dot  represents  an  individual  patient).  Cell  lysates  were  prepared  from  1x107  cells.  
To  calculate  the  concentration  of  Lipocalin  2  in  plasma  and  white  blood  cells  a  standard  
curve  method  was  used.    Optical  density  readings  were  taken  at  single  wavelength  of  450  
nm.  HD-­  healthy  donors,  BRCA-­  primary  breast  cancer  patients.  The  concentration  of  
Lipocalin   2   in  WBCs   of   breast   cancer   patients   differ   significantly   from   that   of   healthy  
donors  (p<0.05).  Data  analysed  by  Kruskal-­Wallis   test.  Concentration  of  Lipocalin  2   in  








































Figure  4.21  Analysis  of  the  correlation  between  circulating  levels  of  Lipocalin  2  in  serum  
of  advanced  breast  cancer  patients  and  treatment  response  using  ELISA.  quantitative  
sandwich  ELISA  commercial  kit.  Serum  was  separated  from  blood  of  advanced  breast  
cancer   patients   prior   the   first   (baseline),   second   (middle)   and   final   third   stage   of   the  
treatments.  To  calculate  the  concentration  of  Lipocalin  2  in  plasma  and  white  blood  cells  
a   standard   curve   method   was   used.      Optical   density   readings   were   taken   at   single  



























Proteomic   analysis   revealed   that   Lipocalin   2   (NGAL)   is   up-­regulated   in   leukocytes   of  
individuals  diagnosed  with  breast  cancer.  Analysis  of  corresponding  mRNA  expression  
demonstrated  stable  coordinate  changes  with  protein  levels  (Mani,  J  PhD  thesis.  2015).  
In  order  to  further  verify  the  reported  findings,  the  levels  of  Lipocalin  2  protein  expression  
in  leukocytes  were  measured  by  Western  blot  and  the  distribution  of  the  protein  within  the  
cells  was  analysed  by  Immunofluorescent  staining  (IF).  The  data  obtained  from  Western  
blot  analysis  confirms  the  upregulation  of  Lipocalin  2  protein   levels   in  WBCs  of  breast  
cancer  patients  in  comparison  with  healthy  donors’  data.  Furthermore,  advanced  breast  
cancer  WBCs  samples  have  more  Lipocalin  2  than  primary  breast  cancer  samples.  These  
findings  correlate  with  studies  on  cell  lines  where  highly  metastatic  cell  lines  are  shown  
to  express  higher  amount  of  the  protein  than  benign  (Stoesz  et  al.  1998).  Suggesting  that  
Lipocalin  2  could  provide  benefit  for  cancer  cell  growth  (Shi  et  al.  2008).  The  IF  staining  
of  WBCs  using  anti-­Lipocalin  2  antibodies  revealed  strong  elevated  cytoplasmic  presence  
of  NGAL  in  the  inspected  WBCs  from  breast  cancer  patients  and  this  data  is  consistent  
with  report  obtained  from  the  Western  blot  analysis.  Lipocalin  2  was  first  discovered  as  a  
component  of  neutrophil  granules  (Le  Cabec  et  al.  1997).    
The  data  from  flow  cytometry  experiment  showed  that  the  levels  of  the  analysed  protein  
is   increased   in   WBCs   of   randomly   selected   primary   breast   cancer   patient,   when  
compared  with  healthy  volunteer.    
Furthermore,   analysis   of   the   data   obtained   by   ELISA,   revealed   that   concentration   of  
Lipocalin  2  in  WBCs  of  breast  cancer  patients  is  higher  than  in  those  of  healthy  donors,  
supporting  the  prognostic  value  of  the  candidate  biomarker.  The  serum  concentration  of  
the  above  protein  showed  no  changes  in  the  response  to  the  treatment  in  the  analysed  
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samples  from  advanced  breast  cancer  cohort.  Therefore,  the  use  of  Lipocalin  2  as  the  
predictive  marker  of  treatment  response  is  not  possible.    
Here,  the  elevated  levels  of  Lipocalin  2  in  WBCs  of  breast  cancer  patients  were  confirmed  
by   three   independent   techniques.  These  findings  are   in   line  with   the  existing   literature  
reports  indicating  that  the  expression  of  Lipocalin  2  is  significantly  increased  in  several  
solid  tumours  including  breast  and  endometrium  (Bauer  et  al.  2008).  Whether  immune  
cells  have   the  same   trend   is  unknown.  Lipocalin  2   is  a  secreted  protein  (Zhang  et  al.  
2014).  A  recent  study  indicate  that  Lipocalin  2  could  be  secreted  by  hematopoietic  cells  
into  tumour  microenvironment  to  promote  breast  tumour  growth  (Ören  et  al.  2016).    
The  overexpression  of  NGAL  in  leukocytes  of  breast  cancer  patients  could  be  explained  
by  its’  well  documented  ability  to  bind  and  transport  iron  to  the  cytoplasm  which  results  in  
the  increased  intracellular  iron  concentration  (Flo  et  al.  2004).  The  beneficial  role  of  iron  
uptake   for   the   cancer   cells   is  widely   recognised.  Cancer   cells   require  more   iron   than  
normal  cells  to  sustain  their  rapid  growth.  For  instance,  in  breast  cancer  cells  increased  
concentration  of  Lipocalin  2  in  a  complex  with  iron  was  found  to  serve  as  a    source  of  iron  
(Torti  &  Torti  2013).    
Furthermore,  most   commonly   used   biomarkers   in   cancer   diagnosis   are   glycoproteins  
such   as   CAE   and   CA125.   Lipocalin   2   being   a   small   glycoprotein   has   drawn   much  
attention  during  the  recent  years  as  potential  biomarker  due  to  its  differential  expression  
in  several  epithelial  malignancies.  For   instance,   in  gastric  and  ovarian  cancers,  serum  
levels  of  Lipocalin  2  could  distinguish  between  cancer  patients  and  healthy   individuals  
with  high  accuracy  (Argani  et  al.  2001;;  Wang  et  al.  2010).  
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Chapter  5  Validation  results  for  Integrin  a4
5.1  Integrin  a4  
Integrin  a4   is   the  cell  adhesion   receptor   required   for   the  migration  of   immune  cells.   It  
belongs   to   a   large   family   of   heterodimer   molecules   composed   of   24   members  
(Johnson  et   al.  2009).  More   information   about   Integrin  a4   is   given   in   the   section  
1.2.3.3.    
Objectives  of  the  present  chapter:  
Our  previous  studies  of  proteome  profiles  demonstrated   that   Integrin  a4  protein   levels  
are  decreased  in  WBCs  of  breast  cancer  patients  in  comparison  with  healthy  donors  
(Many,  J.,  PhD  thesis,  2015).  We  hypothesised  that  Integrin  a4  expression  in  WBCs  
will   correlate   with   clinical   outcomes   (e.g.   survival   and   therapy   response).   This  
chapter   comprises   of   two  major  aims.  The   first   one   is   to   validate   the   heightened  
expression  pattern  of  Integrin  a4  in  WBCs  from  breast  cancer  patients  in  comparison  
with  healthy  individuals.  The  second  aim  is  to  study  the  changes  in  Integrin  a4  levels  
in   a   cohort   of   advanced   breast   cancer   patients   undergoing   treatment   in   order   to  
evaluate  the  prognostic  and  predictive  biomarker  value  of  Integrin  a4  .  To  achieve  
this,   target   protein   levels   were   assessed   in   plasma   and  WBCs   of   breast   cancer  





5.2.1  Western   blot   analysis   of   Integrin  a4  expression   in   the  WBCs   from  breast  
cancer  patients  with  different  stages  of  breast  cancer  
Integrin  a4   levels   were   compared   in   two   cohorts   of   breast   cancer   patients’   samples  
(primary  and  advanced)  and  healthy  donors  using  Western  blot  analysis.  The  membranes  
were  probed  with  the  anti-­Integrin  a4  antibody  and  anti-­b  Actin  antibody  used  as  a  loading  
control.  The  results  are  presented  in  Figure  5.1.  Densitometry  was  performed  on  the  blots  
using  Image  J  software.  The  values  for  integrin  a4  were  normalised  to  b  Actin  and  the  
values  between  different  gel  images  were  normalised  using  the  expression  values  of  the  
common  sample  (Healthy  Donor  4,  HD4)  run  on  all  gels.  The  results  are  presented   in  
Figure  5.2.  For  the  statistical  analysis  Kruskal-­Wallis  test  was  performed  using  GraphPad  
Prism  software.  The  obtained  results  showed  significantly  (p<0.05)  lower  levels  of  Integrin  
a4  expression  in  WBCs  of  primary  and  advanced  breast  cancer  cohorts  in  comparison  






Figure  5.1  Representative  western  blot  assays  demonstrating  Integrin  a4  levels  in  
WBCs   from   healthy   donors   and   breast   cancer   patients   with   different   disease  
conditions.  WBCs  were  isolated  from  blood  of  cancer  patients  or  healthy  donors.  Cell  
lysates  were  prepared  from  2x106  cells.  The  samples  were  separated  using  SDS-­PAGE,  
blotted   and  probed  with   anti-­Integrin  a4  antibody.  The   same  membrane  was   then   re-­
probed  with  anti-­  β-­Actin  antibody  (loading  control).  Bands  corresponding  to  the  proteins  
of  interest  were  visualised  using  Image  Analyzer.  The  results  of  the  quantitative  analysis  























Figure  5.2  Quantitative  analysis  of  the  Western  blot  data  for  Integrin  a4  levels  in  
healthy  donors  and    breast  cancer  patients  with  different  states  of  the  disease.  The  
ratios  of  the  intensity  of  the  Integrin  a4  bands  over  the  intensity  of  the  corresponding  β-­
actin  bands  were  determined;;  as  a  control  healthy  donor  4  was  used  in  all  the  westerns  
and  the  results  plotted  on  a  graph  using  GraphPad  Prism  6  software.  Statistical  difference  
between  groups  was  analysed  by  non-­parametric  Kruskal-­Wallis  test.  HD-­healthy  donors,  
BRCA-­   primary   breast   cancer   patients,  ABC-­advanced  breast   cancer  patients.   ns  not  
significant,  P>0.05;;  *  P<0.05;;  ***  P<0.0001
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5.2.2  Western  blot  analysis  of  Integrin  a4  expression  in  WBCs  of  advanced  breast  
cancer  patients  during  treatment
To  further  investigate  the  apparent  absence  of  Integrin  a4  signal  in  WBCs  samples  from  
advanced   breast   cancer   patients,   it   was   decided   to   run   samples   taken   during   the  
treatment.  The  samples  from  four  patients  were  resolved  on  the  gel  (ID  numbers  3,  16,  
18  and  20)  and  the  results  are  shown  in  Figure  5.3.  The  cell  lysates  from  the  WBCs  from  
the  ABC  cohort  were  prepared  from  the  blood  samples  taken  at  the  beginning  (1),  middle  
(3)   and   final   (6)   stage   of   the   chemotherapy   treatment.   Interestingly,   Integrin   a4  









Figure  5.3  Western  blots  analysis  of  Integrin  a4  levels  in  WBCs  of  advanced  breast  
cancer  patients  during  the  chemotherapy  treatment.  WBCs  were  isolated  from  blood  
of  advanced  breast  cancer  patients  during  the  treatment.  3,  16,  18,  20  represent  patients’  
number.  Numbers  in  the  brackets  represent  treatment  number  of  the  treatment  cycle.  Cell  
lysates  were  prepared  from  2x106  cells.  The  samples  were  separated  using  SDS-­PAGE,  
blotted   and  probed  with   anti-­Integrin  a4  antibody.  The   same  membrane  was   then   re-­
probed  with  anti-­  β-­Actin  antibody  (loading  control).  Band  corresponding  to  the  proteins  









5.2.3  Immunofluorescence  analysis  
Immunofluorescence  analysis  of  Integrin  a4  in  WBCs  of  breast  cancer  patients  and  HD  
using  Confocal  Scanning  Microscope  (Nikon)  at  60X  magnification.  Integrin  a4  is  reported  
to   be   expressed   in   lymphocytes   and   involved   in   lymphocyte   migration   and   T   cell  
activation.  Therefore,  in  this  experiment  CD3  and  CD4  markers  of  T  cells  differentiation  
were  used  to  study   the  distribution  of   Integrin  a4   in  WBCs.  According   to   the  obtained  
results,   the   expression   of   Integrin   a4   is   not   exclusive   to   lymphocytes.   The   positive  
staining  for  the  protein  of  interest  was  detected  in  all  WBCs  of  breast  cancer  patients  and  
healthy  donors.  However,  in  WBCs  of  healthy  donors,  the  staining  appears  to  be  stronger  






Figure  5.4  Immunofluorescence  analysis  of  Integrin  a4  in  WBCs  of  primary  breast  
cancer   patients   (BRCA)   and   healthy   donors   (HD)   using   Confocal   Scanning  
Microscope   (Nikon)   at   60X  magnification.  A  WBC   from  breast   cancer   patients   and  
healthy   donors   were   stained   with   FITC-­labelled   anti-­rabbit   secondary   IgG   antibody  
(dilution  1:400)  against  Integrin  a4  primary  antibody  (dilution  1:200),  plus  secondary  only  
as  the  control  and  Tritc-­labelled  anti-­mouse  secondary  IgG  antibody  (1:400)  against  CD4  
T-­cell  primary  antibody  (1:200),  plus  secondary  only  as   the  control.  The  blue  staining  
(DAPI)  shows  the  position  of  the  nucleus.  The  green  staining  corresponds  to  Integrin  a4  
protein  and  the  red  to  T-­cells.  All  images  were  taken  by  Confocal  Scanning  Microscope  
(BioRad  Hercules)  at  60X  magnification.  Scale  bar  10  µm.  B  Bar  graph  represents  the  
Integrin   a4   expression   (fluorescent   intensity)   in   the   immunofluorescent   images,   as  






























5.2.4   Evaluation   of   the   levels  of   Integrin  a4   in   T   cells   of   primary   breast   cancer  
patients  using  flow  cytometric  analysis  
Here  we  aimed  to  further  validate  the  decreased  expression  of  the  Integrin  a4  using  flow  
cytometry.  For  this  experiment,  freshly  isolated  WBCs  (within  6  hours  from  venipuncture)  
from  a  randomly  selected  primary  breast  cancer  patient  and  healthy  donor  were  stained  
with   two   pre-­labelled   markers   expressed   by   T   cells   CD3/CD4.   Integrin   a4   is   an  
intracellular  protein  and  therefore  pre-­stained  cells  were  fixed,  permeabilised  and  stained  
with   unlabeled   polyclonal   rabbit   anti-­Integrin  a4   antibody   followed   by   incubation   with  
FITC-­labelled  anti-­rabbit  secondary  antibody.    For  a  negative  control,  cells  were  stained  
with  an  isotype  control  antibody.    
The  results  obtained  for  Mean  Fluorescent  Intensity  (MFI)  show  that  the  levels  of  Integrin  
a4   is   lower   in   randomly   selected   WBCs   sample   obtained   from   primary   BRCA   in  
comparison  with  healthy  donor  (Figure  5.5).  However,   these   results  are  based  on   the  









Figure  5.5  Flow  cytometric  analysis  of  the  Integrin  a4  levels  in  neutrophils  of  breast  
cancer  patient  and  a  healthy  donor  (randomly  selected).  Freshly  isolated  WBCs  were  
stained   for   20   minutes   with   pre-­labelled   T   cell   surface   markers   (CD3/CD4)   at   room  
temperature.  Cells  were  washed  with  the  staining  buffer  (PBS/Serum/BSA)  and  fixed  with  
cold   4%   formaldehyde   on   ice   for   20   minutes.   Cells   were   permeabilised   in   0.25%  
tween/PBS  for  20  minutes  on  ice,  washed  twice  with  the  staining  buffer  and  incubated  
with   antibody  against   Integrin  a4   (1:200)  o/n.   The   cells  were   then   stained  with  FITC-­
labelled  anti-­rabbit  secondary  IgG  antibody  (1:400)  for  45  minutes  in  the  dark  to  detect  
Integrin  a4  and  analysed  using  flow  cytometer  (BD  Accuri  C6).  For  a  negative  control,  
cells  were  stained  with  an  isotype  control  antibody.  Quantification  of  the  levels  of  Integrin  
a4   expression   in   the   neutrophils   of   HD   and   primary   BRCA   according   to   the   Mean  



























5.2.5  Analysis  of  the  expression  of  the  Integrin  a4  using  ELISA  
5.2.5.1  Analysis  of  the  expression  of  the  Integrin  a4  in  healthy  donors  and  breast  
cancer  patients  using  ELISA    
In  the  final  step  of  the  validation  experiment,  the  levels  of  Integrin  a4  were  analysed  in  
the  white  blood  cells  and  plasma  of  two  cohorts  of  breast  cancer  patients  (primary  and  
advanced)   using   an   alternative   method,   namely,   the   quantitative   sandwich   enzyme  
immunoassay  technique  (ELISA).  Given  that  Integrin  a4  is  a  promising  marker  of  breast  
cancer  prognosis,  the  use  of  the  ELISA  kit  in  medical  practice  to  quantitatively  evaluate  
Integrin  a4  levels  in  the  blood  of  cancer  patients  would  be  of  particular  interest.  
White  blood  cell  pellets  (1x107)  were  obtained  from  the  blood  of  breast  cancer  patients  
and  healthy  donors.  The  resulting  cell  pellet  was  lysed  by  the  addition  of  equal  volume  of  
Buffer  1  and  Buffer  2  (Table  2.3.1)  with  the  volume  ratio  of  1mL/4x106  and  incubated  on  
ice   for   20  minutes.   The   cell   lysate   was   centrifuged   at   13000   rpm   and   at   4°C   for   15  
minutes.   The  pellet  was  discarded  and   the   supernatant   (cell   lysate)  was  used   for   the  
experiment.  
The  aim  was  to  analyse  the  expression  pattern  and  concentration  of  Integrin  a4  in  plasma  
and  WBC  of  healthy  donors  and  two  cohorts  of  breast  cancer  patients.  To  calculate  the  
concentration  of   Integrin  a4   in  plasma  and  white  blood  cells  of  breast  cancer  patients  
(primary   and   advanced)   a   standard   curve   method   was   used.      The   obtained   results  
revealed  that  high  variation  of  the  protein  concentration  in  the  plasma  samples  (Figure  
5.6).  Although  the  concentration  of  Integrin  a4  was  found  to  be  higher  in  WBCs  samples  
from  primary   and  advanced  breast   cancer   patient   in   comparison  with   healthy   donors,  
many  samples  were  found  to  be  negative  for  Integrin  a4.    Further,  Integrin  a4  levels  in  
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WBCs  of  healthy  donor  samples  varied  from  0  to  2.1ng/mL,  in  primary  breast  samples  
from  0  to  9  ng/mL  and  in  advanced  breast  cancer  samples  from  0  to  7ng/mL.  Overall,  
these  results  are  not  statistically  significant  (p>0.05).    
Next,   the  measurement   of   the   Integrin  a4   concentration   was   performed   in  WBCs   of  
cancer  patients  and   the  corresponding  plasma  samples.  The  results   revealed   that   the  
Integrin  a4  in  WBCs  correlates  with  plasma  concentration.  In  the  case  of  primary  breast  
cancer  samples,  results  showed  that  Integrin  a4  levels  are  higher  in  WBCs  than  in  plasma  
(Figure  5.7).  The   inconsistency  with  Western  blots  and  ELISA   results  observed   in   the  
presented   study   can  be  explained  by   the  use  of   different   antibodies   in   these  assays.  






Figure  5.6  Concentration  of  Integrin  a4  in  WBCs  in  different  participants’  cohorts  
using  quantitative  sandwich  ELISA  commercial  kit.  WBCs  and  plasma  were  isolated  
from  blood  of  cancer  patients  and  healthy  individuals  (Each  dot  represents  an  individual  
patient).  Cell   lysates  were  prepared  from  1x107  cells.  To  calculate  the  concentration  of  
Integrin  a4  in  plasma  and  white  blood  cells  a  standard  curve  method  was  used.    Optical  
density  readings  were  taken  at  single  wavelength  of  450  nm.  HD-­  healthy  donors,  BRCA-­  





Figure   5.7   Concentration   of   Integrin   a4   in   WBCs   and   plasma   in   different  
participants’  cohorts  using  quantitative  sandwich  ELISA  commercial  kit.  Each  dot  
represents  an  individual  patient.  WBCs  and  plasma  were  isolated  from  blood  of  cancer  
patients  and  healthy  individuals.  To  calculate  the  concentration  of  Integrin  a4  in  plasma  
and  white  blood  cells  a  standard  curve  method  was  used.    Optical  density  readings  were  
taken  at  single  wavelength  of  450  nm.    HD-­  healthy  donors,  BRCA-­  primary  breast  cancer  
patients,  results  are  not  statisticaly  significant.
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5.2.5.2   Analysis   of   the   Integrin   a4   levels   in   cohort   of   advanced   breast   cancer  
patients  in  response  to  treatment  using  ELISA.  
To   analyse   whether   the   changes   in   circulating   Integrin   a4   concentration   could   be  
indicative   of   the   treatment   response   in   advanced   breast   cancer   patients   undergoing  
chemotherapy   and   endocrine   treatment,   the   levels   of   the   analyte   were   measured   in  
serum   of   10   patients   (6   chemotherapy,   4   endocrine)   at   three   treatment   time   points;;  
beginning,  middle  and  final  stage  of  treatment.  
  The   data   revealed   different   patterns   and   the   results   were   grouped   according   to   the  
clinical  information.    According  to  the  obtained  data,  the  levels  of  Integrin  a4  decrease  in  
the  middle  of  the  chemotherapy  treatment  and  increase  in  the  end  (Figure  5.8).  The  data  
for  the  patients  with  endocrine  treatment  showed  different  trends.  For  the  patients  with  
stable  disease,  plasma  levels  of  Integrin  a4  increased  in  the  middle  of  the  treatment  and  
then  declined  at  the  end  for  one  patient,  and  gradually  declined  during  the  treatment  for  
another.    
To   see   if   trends   in   Integrin  a4   concentration   correlate   with   advanced   cancer   patient  
survival,  the  results  were  grouped  according  to  the  length  of  survival  (Figure  5.9).  The  
data  showed  that  in  the  category  of  patients  with  chemotherapy,  the  levels  of  Integrin  a  
4  declines  in  the  middle  of  the  treatment  and  rises  in  the  end  in  all  analysed  samples,  the  
patient   with   6  months   survival   time   showed   the   same   trend   as   the   alive   patient.   The  
results  for  the  patients  with  endocrine  treatment  indicate  that  in  patients  that  are  still  alive,  
that  the  levels  of  the  protein  of  interest  increased  in  the  middle  and  decreased  at  the  end  







Figure  5.8  Analysis  of  the  correlation  between  plasma  levels  of  Integrin  a4  in  serum  
of  advanced  breast  cancer  patients  and  treatment  response  using  sandwich  ELISA.  
To  calculate   the  concentration  of   Integrin  a4   in  plasma  a  standard  curve  method  was  
used.      Optical   density   readings   were   taken   at   single   wavelength   of   450   nm.   PD  
progressive  disease;;  PR  partial   response;;  SD   stable  disease;;  CR   complete  response.  
Chemo  chemotherapy  treatment.  Endo  endocrine  treatment.  Serum  was  separated  from  
blood  of  advanced  breast  cancer  patients  prior  the  first  (baseline),  second  (middle)  and  












































































































































Figure  5.9  Analysis  of  the  correlation  between  circulating  levels  of  Integrin  a4  in  
serum   of   advanced   breast   cancer   patients   and   survival   time   using   sandwich  
ELISA.  To  calculate  the  concentration  of  Integrin  a4  in  plasma  a  standard  curve  method  
was  used.    Optical  density  readings  were  taken  at  single  wavelength  of  450  nm.  Chemo  








































































































































5.3      Discussion  
In   the   experiments   conducted   in   this   chapter   the   early   biomarker,   prognostic   and  
predictive  values  of  previously  identified  candidate  breast  cancer  biomarker  Integrin  a4  
was  evaluated.    A  value  of  this  protein  as    possible  early  biomarker  of  breast  cancer  was  
confirmed   by   a   Western   blot   assay,   whereby   the   decreased   levels   Integrin   a4   were  
detected   in  WBCs  of   two   cohorts  of   breast  cancer  patients,   primary   and  advanced   in  
comparison   with   healthy   donors.   The   results   of   this   experiment   were   significant   (   p  
<0.0107  for  the  primary  breast  cancer  cohort).  The  low  expression  of  the  Integrin  a4  was  
confirmed   by   IF   study   and   FACS   analysis   using   WBCs   from   a   randomly   selected  
participant  with  primary  breast  cancer.    
In  the  WBCs  samples  of  the  advanced  breast  cancer  cohort,  the  signal  was  very  difficult  
to  distinguish  from  the  background.  We  reasoned  that  if  treatment  is  successful,  Integrin  
a4  could  re-­appear  in  the  WBCs.  To  test  this  possibility,  the  WBCs  isolated  from  blood  
taken  in  the  beginning,  middle  and  end  of  the  treatment  were  tested.  In  the  results,  the  
signal  for  the  protein  of  interest  was  detected  in  the  late  stage  of  the  treatment  in  some  
of   the   patients.   These   findings   however   disagree   with   the   observations   that  
chemotherapy  has  direct  effect  on   immune  cells,   resulting   in  depletion  of   lymphocytes  
population  decreased  expression  levels  of  Integrin  a4  (Bracci  et  al.  2014).  These  results  
need  to  be  explored  further.    
The   data   obtained   from   ELISA   experiment   showed   different   results.   The   Integrin  a4  
protein  concentration  was   found  to  be  higher   in  breast  cancer  samples   in  comparison  
with   healthy   donors.  However,   it   should   be  noted   that   in  many  analysed   samples   the  
concentration  was  not  measurable.    
209  
  
Interestingly,  the  analysis  of  the  protein  expression  in  plasma  obtained  from  patients  with    
advanced   breast   cancer   undergoing   chemotherapy   and   endocrine   treatment   showed  
higher  concentration  of  Integrin  a4.    Thus,  in    response  to  chemotherapy  treatment  the  
levels  of  Integrin  a4  in  plasma  raised  and  in  response  to  endocrine  treatment  declined.    
The  results  of  ELISA  might  have  been  compromised  by  the  presence  of  additional  forms  
of  Integrin  a4,  cross-­reactivity  with  other  proteins  or  some  technical  problems  with  the  kit  
or  protocol.  The  ELISA  experiments  will  need  to  be  repeated  in  the  future  and  a  different  
kit  for  Integrin  a4  measurements  should  be  used.  
Due  to  such  conflicting  results,  it  is  difficult  to  conclude  whether  Integrin  a4  has  a  potential  
a  value  as  a  biomarker  of  successful  treatment  and  cancer  progression.    
Integrin  a4  mediates  lymphocyte  migration  to  the  sites  of  infection  (Wang  et  al.  2009).    
The  decreased  expression  of  Integrin  a4  revealed  by  the  present  study  correlates  with  
the  findings  that  during  HIV  infection  detectable  loss  of  circulating  CD4+T  cells  expressing  
Integrin  a4  is  observed.  Furthermore,  throughout  the  infection,  these  cells  are  reported  
to   be   eventually   eliminated.   However,   in   animal   controlling   the   infection   the   levels   of  
CD+4  T  cells  positive  for  Integrin  a4  were  eventually  restored  (Wang  et  al.  2009).  The  
decrease  of   this  particular  subset  of  T  cells  has  been  suggested   to  have  a  role   in   the  
development  of   immunosuppression,  as   the  recruitment  of   immune  cells   to   the  site  of  
inflammation  and  potentially  cancer  is  limited  (Wang  et  al.  2009)      
In  the  present  study,  the  decreased  Integrin  a4  levels  were  observed  in  WBCs  of  breast  
cancer  patients  using  western  blot,   flow  cytometry  and  IF.  Accordingly,  as   integrin  are  
required   for   the   adhesion   of   immune   cell   to   the   endothelium   and   migration   for   the  
subsequent   elimination   of   pathogens   or   malignant   cells,   the   decreased   levels   of   this  
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protein   could   be  one  of   the   strategy  of   cancer   cells   to   escape   the   immune   response.  
Escape   from      immune   control   is   recognised   as   a   one   of   the   “Hallmarks   of   Cancer”  
(Hanahan  &  Weinberg  2011).    
Another  explanation  of  the  observed  decreased  levels  of  Integrin  a4  protein  in  WBCs  of  
breast  cancer  patients  is  that  chemotherapy  has  direct  effect  on  immune  cells,  resulting  
in   depletion   of   lymphocytes   population   (Bracci   et   al.   2014)Therefore,   resulting   in   the  
decreased  expression  levels  of  Integrin  a4.    
The  question  whether  the  immune  system  has  positive,  negative  or  none  effect  on  tumour  
development  is  still  open  (Mittal  et  al.  2014)    The  findings  presented  in  this  chapter  may  
help  understand  the  extent  of  the  immune’s  system  interaction  with  cancer.
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Chapter  6  Validation  results  for  Lipoxygenase  5  (LOX5)
6.1  Lipoxygenase  5  
Lipoxygenase   5,   or   5LOX,   is   an   inflammatory   response   protein   related   to   leukotriene  
synthesis.  This  enzyme  catalyses  first  two  steps  in  leukotriene  formation  from  arachidonic  
acid  (Steinhilber  et  al.  2010).  Overexpression  of   lipoxygenases  and  their  products  has  
been  implicated  in  acute  and  chronic  inflammatory  diseases  and  in  cancer  as  these  two  
processes   are   closely   linked.      Various   types   of   malignant   cells   are   reported   to   have  
elevated   levels  of  5LOX   (Erler  et  al.  2009;;  Le  et  al.  2009;;  Sundaram  &  Ghosh  2006).  
Furthermore,   the   5LOX   gene-­silencing   is   shown   to   reduce   viability   of   cancer   cells,  
suggesting   that  arachidonic  acid  metabolites  play   important   role   in  cancer  progression  
(Sundaram  &  Ghosh  2006).   It   has   been   linked   to   the   promoting   prostate   cancer   and  
breast   cancer   cells   survival   (Sarveswaran   et   al.   2011;;   Borin   et   al.   2017).   The  
overexpression  of   5LOX  protein   has  been  previously   reported   in   the  WBCs  of   breast  
cancer  patients,  especially  in  high  grade  category.  More  information  about  5LOX  is  given  
in  section  1.2.3.5.  
Objectives  of  the  present  chapter:  
Our   previous   proteomic   studies   reported  heightened  expression  of   5LOX   in  WBCs  of  
breast  cancer  patients.  We  hypothesised  that  5LOX  expression   in  WBCs  will  correlate  
with  clinical  outcomes  (e.g.  survival  and  therapy  response).  This  chapter  comprises  of  
two  major  aims.  The  first  one  is  to  validate  the  heightened  expression  pattern  of  5LOX  in  
WBCs  from  breast  cancer  patients  in  comparison  with  healthy  individuals.  The  second  
aim  is  to  study  the  changes  in  5LOX  levels  in  a  cohort  of  advanced  breast  cancer  patients  
undergoing  treatment  in  order  to  evaluate  the  prognostic  and  predictive  biomarker  value  
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of  5LOX.  To  achieve  this,  target  protein  levels  were  assessed  in  plasma  and  WBCs  of  




6.2.1  Western  blot  analysis  of  5LOX  expression  in  WBCs  of  breast  cancer  
patients  and  healthy  donors  
The   levels   of   5LOX  were  measured  by  Western  blot  assay   in  WBCs   from  13  healthy  
donors,  and  20  and  13  patients  with  primary  and  advanced  breast  cancer,  respectively.  
A  representative  Western  blot  image  is  shown  in  Figure  6.1.  For  quantitative  analysis  of  
these  data,  the  values  obtained  from  the  bands  of  78  kDa  corresponding  to  5LOX  were  
normalised   to   the   values   from   b-­Actin   signals   using   Image   J   software.   The   values  
between  the  gels  were  compared  by  normalising  to  the  expression  value  of  the  common  
healthy   donor   4   (HD4)   sample   used   in   all   experiments.   The   results   revealed  
overexpression   of   5LOX   protein   levels   in   WBCs   of   primary   breast   cancer   cohort   in  
comparison  with  healthy  donors.  In  the  advanced  breast  cancer  cohort,  5LOX  levels  was  
shown  to  be  lower  than  in  healthy  donors.  However,  the  Kruskal-­Wallis  test  showed  that  





Figure  6.1  Representative  western  blots  of  5LOX  levels  in  breast  cancer  patients  
with  different  disease  conditions.  WBC  were  isolated  from  blood  of  cancer  patients.  
Cell   lysates  were  prepared  from  2x106  cells.  The  samples  were  separated  using  SDS-­
PAGE,  blotted  and  probed  with  anti-­5LOX  antibody.  The  same  membrane  was  then  re-­
probed  with  anti-­  β-­Actin  antibody  (loading  control).  Band  corresponding  to  the  proteins  
of  interest  were  visualised  using  Image  Analyzer.  The  ratios  of  the  intensity  of  the  5LOX  
bands  over  the  intensity  of  the  corresponding  β-­actin  bands  were  determined  as  a  control  
healthy  donor  4  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  using  
GraphPad  Prism  6  software.  Statistical  difference  between  groups  was  analysed  by  non-­




















Figure  6.  2:  Western  blot  analysis  of  5LOX   levels   in  breast  cancer  patients  with  
different  disease  conditions.  WBC  were   isolated   from  blood  of  cancer  patients.  Cell  
lysates  were  prepared  from  2x106  cells.  The  samples  were  separated  using  SDS-­PAGE,  
blotted  and  probed  with  anti-­5LOX  antibody.  The  same  membrane  was  then  re-­probed  
with  anti-­  β-­Actin  antibody  (loading  control).  Band  corresponding  to  the  proteins  of  interest  
were  visualised  using  Image  Analyzer.  The  ratios  of  the  intensity  of  the  5LOX  bands  over  
the   intensity  of   the  corresponding  β-­actin  bands  were  determined  as  a  control  healthy  
donor  4  was  used  in  all  the  westerns  and  the  results  plotted  on  a  graph  using  GraphPad  
Prism  6  software.  Statistical  difference  between  groups  was  analysed  by  non-­parametric  
Kruskal-­Wallis  test.  Results  are  not  statistically  significant.    HD-­  healthy  donors,  BRCA-­  






























6.2.2  Immunofluorescent  analysis  of  5LOX  distribution  in  immune  cells  
Next,   the   distribution   of  5LOX  protein   in  WBCs  of   breast   cancer  patients   and  healthy  
donors  was  examined  by  Immunofluorescent  staining  technique  using  primary  anti-­5LOX  
antibody  (Figure  6.3).  This  analysis  revealed  higher  intensity  of  the  5LOX  in  the  WBCs  of  
healthy  donor,  than  in  breast  cancer  patient.  It  should  be  noted  that  WBCs  from  HD5  that  
was  used  in  the  present  experiment  also  showed  stronger  signal  in  Western  blot  analysis.  
The  WBCs  from  the  breast  cancer  patient  2228,  on  the  other  hand,  showed  lower  signal.  
The   pattern   of   protein   expression   correlated   with   previously   observed   Western   blot  
results.  Later  on,  the  healthy  donor  5  was  diagnosed  with  cancer,  which  may  explain  the  
elevation  of  LOX5.    
In  order  to  determine  which  immune  cells  overexpress  LOX5  the  WBCs    were  also  stained  
with   the  CD15   antibody  which   recognises   carbohydrate   epitope   expressed   in  mature  
neutrophils  and  eosinophils.  The  obtained  double  immunofluorescence  analysis  revealed  
that  the  majority  of  5LOX  positive  cells  were  neutrophils  (Figure  6.3).  Staining  with  only  






6.3   Immunofluorescence   analysis   of   5LOX   protein   distribution   in   leukocytes   of  
primary  and  advanced  breast  cancer  patients.  WBC  extracted  from  blood  of  healthy  
donor  5  and  primary  cancer  patient  2228  were  double  stained  with  FITC-­labelled  anti-­
rabbit  secondary  IgG  antibody  (1:400)  against  5LOX  primary  antibody  (dilution  1:200)  and  
Tritc-­labelled   anti-­mouse   secondary   IgG   antibody   (1:400)   against   CD15   neutrophil  
primary  antibody  (1:200),  plus  secondary  only  as  the  control.  The  blue  staining  shows  the  
position  of  the  nucleus.  The  green  staining  corresponds  to  5LOX  protein  and  red  staining  
represents  Neutrophils.  Scale  bar  0.01mm.  All  images  were  taken  by  Confocal  Scanning  









6.2.3   Evaluation   of   the   levels   of   5   LOX   in   neutrophils   of   primary   breast   cancer  
patients  using  flow  cytometric  analysis.  
Data  presented  in  this  Chapter  suggested  that  levels  of  5LOX  are  elevated  in  WBCs  of  
breast  cancer  patients  in  comparison  to  healthy  donors  (Figures  6.1  and  6.2),  and  it   is  
expressed  in  neutrophils  (Figure  6.3).    In  our  next  experiments  we  aimed  to  confirm  the  
expression  pattern  of  5LOX  using  flow  cytometry  (FACS).  Flow  cytometry  is  the  method  
that  allows  for  rapid  quantitative  assessment  of  proteins  within  the  specific  cell  type  via  
cell  surface  marker  phenotyping.    
Because  granulocytes  rapidly  degenerate  soon  after  collection,  WBCs  were  isolated  from  
the   blood   sample   within   6   hours   from   blood   collection   and   immediately   used   for   the  
experiment.  Furthermore,  due  to  their  large  size,  these  cells  are  the  most  unstable  type  
of  WBCs,  therefore  accurate  pipetting  required  in  order  to  avoid  cell  burst.    
For   this   experiment,   freshly   isolated  WBCs   from   a   randomly   selected   primary   breast  
cancer  patient  (2225)  and  healthy  donor  5  were  stained  with   two  pre-­labelled  markers  
expressed   by   mature   neutrophils:   CD15,   CD66b.   5LOX   is   an   intracellular   protein  
therefore   pre-­stained   cells   were   fixed,   permeabilised   and   stained   with   unlabeled  
polyclonal  rabbit  anti-­5LOX  antibody  followed  by  the  incubation  with  FITC-­labelled  anti-­
rabbit  secondary  antibody.      
For  a  negative  control,  cells  were  stained  with  an  isotype  control  antibody,  which  are  of  
the   same   isotype   as   the   target   primary   antibody.   The   Isotype   controls   are   used   to  
estimate  non-­specific  staining  of  primary  antibodies;;    they  are  of  unknown  specificity  or  
are  raised  against  antigens  known  to  be  absent  in  target  cells.    
Surprisingly,  the  levels  of  5LOX  in  a  neutrophils  from  a  breast  cancer  patient  were  lower  
than  in  a  healthy  donor  (Figure  6.4).  For  this  experiment,  the  WBC  sample  from  the  same  
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healthy  donor  5   (HD5)  was  used.  The  higher  5LOX   levels  observed   in   this  sample   in  
comparison   with   BRCA   sample   can   be   explained   by   the   fact,   that   this   donor   was  






Figure  6.4:  Flow  cytometric  analysis  of  the  5LOX  levels  in  neutrophils  of  breast  cancer  
patient  and  a  healthy  donor  (randomly  selected).  Freshly  isolated  WBCs  were  stained  for  
20  minutes  with   pre-­labelled   neutrophils   cell   surface  markers   (CD15/CD66b)   at   room  
temperature.  Cells  were  washed  with  the  staining  buffer  (PBS/Serum/BSA)  and  fixed  with  
cold   4%   formaldehyde   on   ice   for   20   minutes.   Cells   were   permeabilised   in   0.25%  
tween/PBS  for  20  minutes  on  ice,  washed  twice  with  the  staining  buffer  and  incubated  
with  antibody  against  5LOX  (1:200)  o/n.  The  cells  were  then  stained  with  FITC-­labelled  
anti-­rabbit  secondary  IgG  antibody  (1:400)  for  45  minutes  in  the  dark  to  detect  5LOX  and  
analysed  using  flow  cytometer  (BD  Accuri  C6).  For  a  negative  control,  cells  were  stained  
with   an   isotype   control   antibody.   A   Gating   of   the   CD15+CD66b+5LOX.   B   Peaks  
representing  fluorescent  intensity  of  the  5LOX  expression  in  BRCA,  HD  and  background  
isotype  control  C  Quantification  of  the  levels  of  5LOX  expression  in  the  neutrophils  of  HD  

















The  aim  of   the   present   study  was   to   validate   the   expression  patterns   of   5LOX  using  
Western  blot  assay,  IF  and  FACS  techniques.  
According  to  the  data  obtained  by  Western  blot  analysis  the  levels  of  5LOX  protein  are  
elevated  in  the  WBCs  of  primary  and  decreased  in  advanced  breast  cancer  patients  in  
comparison   with   healthy   donors,   supporting   previously   reported   proteomic   findings.  
FACS  and  IF  analysis  however,  showed  that  it’s  levels  are  higher  in  healthy  donor  than  
in  primary  breast  cancer  patient.  It  is  important  to  mention,  that  for  FACS  and  IF  only  one,  
randomly  selected  sample  from  the  cancer  patients  was  used.  Healthy  donor  5  sample  
that  was  used   in   these  experiments   showed   the  highest   signal   on  Western   blot.   This  
volunteer  was  later  diagnosed  with  lung  cancer,  confirming  that  heightened  expression  
of  5LOX  is  specific  for  cancer  related  changes  in  protein  expression.    
Collectively,  the  data  generated  in  the  present  study  is  in  agreement  with  findings  that  
elevated   levels  of  5LOX  may  be  a  biomarker  of  various  cancers   in  particular  prostate  
cancer  (Sarveswaran  et  al.  2011).  
Malignant   cells   grow   more   rapidly   than   normal   cells   and   require   more   nutrients   and  
oxygen.  A  connection  between   fat  and  various   types  of  cancer   is   recognised,  as   fatty  
acids   produce   energy   and   metabolites   important   for   cell   growth   and   proliferation  
Arachidonic  acid  is  metabolised  via  5LOX  to  generate  series  of  eicosanoids,  which  are  
essential  for  cancer  cells  to  survive  (Sarveswaran  et  al.  2010;;  Sarveswaran  et  al.  2011).  
Due   to   the   low  number  of  samples  analysed,   the  correlation  of  5LOX  expression  with  
clinical  data  for  advanced  breast  cancer  patients  was  not  performed.
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Chapter  7  Validation  results  for  Copine  3  
7.1  Copine  3  
Copine  3  is  calcium-­dependent  membrane  binding  protein.  The  function  of  Copine  protein  
family  have  been  shown  to  be  related  to  cell  growth  and  cancer  development  (Yang  et  al.  
2006;;  Ramsey  et  al.  2008).  The  exact  mechanism  is  unknown,  but  existing  reports  show  
that  Copine  3  expression  correlates  with  ErbB2  amplification  in  breast  cancer  (C  Heinrich  
et  al.  2010).    Due  to  its  previously  reported  elevated  expression  in  WBCs  of  breast  cancer  
patients  and  the  role  in  breast  cancer  progression,  it  was  chosen  for  further  validation.  
More  information  about  Copine  3  is  provided  in  section  1.2.4.4.  
Objectives  of  the  present  chapter:  
Proteomic  studies  revealed  that  the  protein  levels  of  Copine  3  is  upregulated  in  WBCs  of  
breast  cancer  patients  (Many,  J.,  PhD  thesis,  2015).  This  chapter  comprises  of  two  major  
aims.  The  first  is  to  validate  the  heightened  expression  pattern  of  Copine  3  in  WBCs  from  
breast  cancer  patients  in  comparison  with  healthy  individuals.  The  second  aim  is  to  study  
the  changes  in  Copine  3  levels  in  a  cohort  of  advanced  breast  cancer  patients  undergoing  
treatment  in  order  to  evaluate  the  prognostic  and  predictive  biomarker  value  of  Copine  3.  
To  achieve  this,  Copine  3  levels  were  assessed  in  WBCs  of  breast  cancer  patients  using  
western  blot  and    Immunofluorescence  techniques.  
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7.2  Results    
7.2.1  Western  blot  analysis  of  Copine  3  expression  in  the  WBCs  from  breast  cancer  
patients  with  different  stages  of  breast  cancer  
In  previous  study  microarray  data  and  2D  gel  electrophoresis  showed  +1.2-­fold  change  
in  the  expression  of  Copine  3  in  WBCs  of  primary  and  advanced  breast  cancer  samples  
in   comparison   to   healthy   control   group   (Many,   J.,   PhD   thesis,   2015).   Based   on   this  
finding,  in  the  present  study  the  biomarker  property  of  Copine  3  was  initially  assessed  
using   a   western   blot   technique.   In   these   experiments,   the   levels   of   Copine   3   were  
evaluated   in   different   categories   of   breast   cancer   patients   (primary   and  advanced)   in  
comparison  with  healthy  donors.  
The  membranes  with  different  samples  were  probed  with  anti-­Copine  3  antibody,  and  
then  with  the  anti-­  β-­Actin  antibody  to  detect  β-­Actin  served  as  a  loading  control.  The  gels  
were   digitalised  and   the   intensity   values  were   obtained   using   Image   J   software.   The  
values  for  Copine  3  were  normalised  to  the  values  for  b  Actin  for  each  sample.  The  values  
between   different   gel   images   were   normalised   with   each   other   using   the   expression  
values  of  common  sample  (HD2)  run  on  all  gels.  These  results  are  presented  in  Figure  
7.1.   For   statistical   analysis  Kruskal-­Wallis   test  was  performed  using  GraphPad  Prism  
software   (data   are   shown   in   Figure   7.2).   The   observed   data   revealed   conflicting   and  
inconsistent   results   for   the   protein   expression   in   different   participants’   groups.   In  
particular,  levels  of  Copine  3  differ  within  the  same  cohorts  of  breast  cancer  patients  and  
healthy  donors.  Levels  of  Copine  3  expression  in  samples  from  patients  with  advanced  
breast  cancer    also  varied.      
According   to   the   literature,   the  Copine  3  expression   in  breast  cancer   tissue  correlates  
with  HER2  expression  (C.  Heinrich  et  al.  2010)    We  asked  whether  a  similar  trend  can  be  
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observed  in  WBCs  of  breast  cancer  patients  and  levels  of  Copine  3  were  linked  to  the  
tumour  HER2  status.  However,  no  correlation  was  observed  following  this  analysis  (data  
is   not   presented).The   expression   pattern   did   not   show   correlation   with   the   patients’  
clinical  data  provided  by  the  hospital.  Therefore,  it  can  be  concluded  that  Copine  3  cannot  




Figure  7.1  Representative  western  blots  of  Copine  3  expression  in  WBCs  of  breast  
cancer  patients  with  different  disease  conditions  and  healthy  donors.  WBCs  were  
isolated  from  blood  of  cancer  patients  or  healthy  donors.  Cell  lysates  were  prepared  from  
2x106  cells.  The  samples  were  separated  using  SDS-­PAGE,  blotted  and  probed  with  anti-­
Copine  3  antibody.  The  same  membrane  was  then  re-­probed  with  anti-­  β-­Actin  antibody  
























Figure  7.2  Copine  3  protein  levels  in  breast  cancer  patients  with  different  disease  
conditions.  Cell   lysates  were  prepared  from  2x106  cells.  The  samples  were  separated  
using  SDS-­PAGE,  blotted  and  probed  with  anti-­Copine  3  antibody.  The  same  membrane  
was  then  re-­probed  with  anti-­  β-­Actin  antibody  (loading  control).  Band  corresponding  to  
the   proteins   of   interest   were   visualised   using   Image   Analyser.   Densitometry   was  
performed   (Image   J)   and   the   ratios   of   the   intensity   of   the      Copine   3   bands   over   the  
intensity  of  the  corresponding  β-­actin  bands  were  determined  as  a  control  healthy  donor  
2  was  used  in  all  the  western  blots.  
HD-­   healthy   donors,  BRCA-­   primary   breast  cancer,  ABC-­   breast   cancer   patients  with  




7.2.2  Immunofluorescence  analysis  of  Copine  3  expression  in  the  WBCs  of  
healthy  donors,  primary  and  advanced  breast  cancer  patients  
In   order   to   visualise   the   distribution   of   Copine   3   in   the  WBCs   of   healthy   donors   and  
primary   and   advanced   breast   cancer   patients   the   immunofluorescent   staining   was  
performed.  As  shown  in  Figure  7.3,  Copine  3  is  present  in  the  WBCs  of  healthy  donor  at  
relatively   low   levels   compared   to   the   primary  BRCA  sample   and   it   is   restricted   to   the  
nucleus.  In  the  primary  BRCA  sample  Copine  3  is  localized  both  in  the  cytoplasm  and  
nucleus.  In  the  WBCs  sample  from  a  patient  with  advanced  breast  cancer  Copine  3  levels  
are  higher  than  in  the  healthy  donor  and  a  patient  with  primary  BRCA.  The  protein  can  
be  detected  in  the  cytoplasm  and  in  the  nucleus.  No  signal  was  detected  in  the  control  
experiments  when  cells  were  incubated  with  the  secondary  antibody  only.    
Therefore,  based  on  the  obtained  images,  it  may  be  concluded  that  the  localisation  and  
level   of   expression   of   Copine   3   is   different   in   the   WBCs   of   breast   cancer   patients  
compared   to   the  WBCs  of   healthy   individuals.   It   should  however  be  noted   that   these  
experiments  have  been  limited  to  single  WBCs  samples  and  need  to  involve  specimens  
from  more  participants.    
In  order  to  determine  which  type  of  blood  cells  express  Copine  3,  WBCs  were  co-­stained  
with   the   anti-­   Copine   3   antibody   and   the   antibodies   against   the   immune-­cell   specific  
markers,   i.e.  cluster  of  differentiation  (CD)  cell  surface  antigens  to  distinguish  between  
subpopulation  of  WBCs.  
When  WBCs  were  stained  with  CD15  antibody,  which  recognises  a  carbohydrate  epitope  
expressed   in   mature   neutrophils   and   eosinophils,   the   double   immunofluorescence  
analysis   revealed   that   the  majority  of  Copine  3  positive  cells  were  neutrophils   (Figure  
7.4).  These  results  also  demonstrated  that  cells  negative  for  CD15  were  also  negative  for  
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Figure   7.3   Representative   Immunofluorescent   analysis   of   Copine   3   protein  
distribution   in   WBC   of   BRCA   node   negative,   node   positive,   advanced   cancer  
patients  and  healthy  donors.  WBC   from  breast   cancer   patients   and  healthy  donors  
were   stained   with   FITC-­labelled   anti-­rabbit   secondary   IgG   antibody   (dilution   1:400)  
against  Copine  3  primary  antibody  (dilution  1:200),  plus  secondary  only  as  the  control.  
The  blue  staining  shows  the  position  of  the  nucleus.  The  green  staining  in  the  cytoplasm  
corresponds  to  Copine  3  protein.  Scale  bar  0.01mm.  All  images  were  taken  by  Confocal  













Figure  7.4  Immunofluorescence  analysis  of  Copine  3  protein  distribution  in  WBCs  
advanced   breast   cancer   patients.  WBC   extracted   from   blood   of   advanced   breast  
cancer   patients   were   double   stained   with   FITC-­labelled   anti-­rabbit   secondary   IgG  
antibody   (1:400)   against  Copine  3   primary   antibody   (dilution   1:200)   and  Tritc-­labelled  
anti-­mouse  secondary   IgG  antibody   (1:400)  against  CD15  neutrophil  primary  antibody  
(1:200),  plus  secondary  only  as  the  control.  The  blue  staining  shows  the  position  of  the  
nucleus.  The  green  staining  corresponds  to  Copine  3  protein  and  red  staining  represents  
Neutrophils.  Scale  bar  10µm.  All  images  were  taken  by  Confocal  Scanning  Microscope  








The  precise   role   of   the  Copine   family   in   the   cells   is   currently   unclear,  although   some  
studies   reported   that   it   influences   the   activities   of   membrane   proteins   and   lipids  
(Perestenko  et  al.  2010).  The  existing  reports  indicate  that  Copine  3  interacts  with  ErbB2  
to  promote  tumour  metastasis  and  it  also  shown  to  be  upregulated  in  breast  and  prostate  
tumours  (C  Heinrich  et  al.  2010).  Recent  studies  demonstrate   that  Copine  3   is  able   to  
bind  several  nuclear  proteins  including  Interleukin  enhancer  binding  protein  2  and  DNA  
topoisomerase  1  (Perestenko  et  al.  2010).  As  reported  in  the  literature,  normally  copines  
show  nuclear  localisation,  however  in  response  to  specific  stimuli  these  proteins  can  re-­
localise  to  the  plasma  membrane  (Perestenko  et  al.  2010)  This  is  consistent  with  the  IF  
results  observed  in  the  present  study,  where  in  WBCs  of  healthy  donor  the  location  of  the  
Copine  3  appeared  to  be  restricted  to  the  cell  nucleus,  whereas  in  WBCs  of  primary  and  
advanced  breast  cancer  patients  it  showed  cytoplasmic  location  as  well  as  nuclear.      
According  to  the  IF  results  generated  in  the  present  study  the  majority  of  cells  expressing  
Copine  are  neutrophils.  Neutrophils  contain  toxic  proteins  that  are  securely  stored  in  three  
granule   types   (azurophilic,   specific   and   gelatinase   granules)   and   secretory   vesicles.  
During  phagocytosis,  the  function  of  these  organelles  is  highly  dependent  on  the  ions  of  
calcium  (Nunes  &  Demaurex  2010).      The  one  of  the  proposed  role  for  copines  is  providing  
calcium  regulation  of  intracellular  signaling  pathways  (Creutz  &  Edwardson  2009).  Copine  
3   is   reported   to   translocate   to   the   cell  membrane   in   the   response   to   the   increase   in  
intracellular  calcium,  where  it  interacts  with  various  binding  partners  including  ErbB2  (C.  
Heinrich  et  al.  2010).  
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The  presence  of  Copine  3  in  neutrophils  was  previously  demonstrated.  this  study  isolated  
Copine  3  from  the  cytosol  of  human  neutrophils,  where  it  exists  as  monomer  and  undergo  
conformation  changes  upon  calcium  binding  (Cowland  et  al.  2003).  
The  results  obtained  in  the  present  investigation  show  higher  levels  of  Copine  3  in  WBCs  
samples  from  advanced  breast  cancer  patients,  but  not  consistently.  In  the  majority  of  the  
samples   from   cohorts   of   breast   cancer   patients   as  well   as   healthy   donors   it   was   not  
detected  at  all.  The  high  variation  in  the  levels  of  protein  in  different  participant  within  the  
same  group  could  be  associated  with  difference  in  age,  gender  or  ethnicity.  Furthermore,  
lifestyle   factors   (e.g.   diet,   smoking,   alcohol   intake,   obesity),   underlying   pathological  
conditions  or  certain  medicine  can  have  an  effect  on  protein  concentration  (Rifai  et  al.  
2006).    Due  to  the  inconsistency  of  the  generated  data  for  this  target,  its  application  as  
biomarker  for  breast  cancer  diagnosis  and  prognosis  is  questionable.    
Differential  expression  of  Copine  3  in  peripheral  blood  was  reported  previously.  In  these  
studies,   low   expression   of   Copine   3   in   peripheral   blood   was   suggested   to   be      an  
independent  risk  factor  of  occurrence  of  acute  myocardial  infarction  among  patients  with  
stable  coronary  artery  disease  (Tan  et  al.  2018).    
Copines  are  evolutionary  conserved  proteins  present  in  protozoa,  nematodes,  plants  and  
Mammalia  (Creutz  et  al.  1998).  Their  ubiquitous  expression  in  different  organisms  and  
high   sequence   conservation   suggest   the   important   role   of   these   proteins   in   cellular  
processes  (Li  et  al.  2010).  The  nuclear  localisation  of    the  majority  of  the  copines  points  
out  their  role  in  nuclear  processes  (Perestenko  et  al.  2010).  The  importance  of  studying  
this  family  of  proteins  is  also  supported  by  the  recent  report    demonstrating  interaction  of  
Copine   3   with   ErbB2   to   promote   breast   tumour   migration   (C   Heinrich   et   al.   2010).  
Furthermore,   general   role   of   Copine   3   in   carcinogenesis   is   proposed   as   differential  
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expression  of  the  protein  is  reported  in  normal  tissue  against  breast,  prostate  and  ovarian  
cancer  (C  Heinrich  et  al.  2010).
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Chapter  8  Assessment  of  the  presence  of  anti-­BORIS  autoantibody  in  the  plasma  
of  breast  cancer  patients  and  its  potential  as  an  early  cancer  biomarker  
8.1  Background  
The   quest   for   novel   cancer   biomarkers   is   a   continuing   process,   which   involves   huge  
efforts  at  different  stages  of   the  pipeline  (discovery,  validation  and   implementation).   In  
addition,   new   molecular   components   and   sources   are   considered   in   the   search   for  
biomarkers.  The  final  Chapters  8  and  9  of  this  study  represent  pilot  experiments  to  explore  
potential  new  biomarkers  in  plasma  and  urine  samples  from  breast  and  prostate  cancer  
patients,  respectively.    
BORIS,  a  paralogue  of  the  transcription  factor  CTCF,  is  a  member  of  the  cancer-­testis  
antigen  (CTA)  family  (D’Arcy  et  al.  2008)  CTCF  is  11-­ZF  DNA  binding  protein  that  has  
been  named  “master  waiver  of  the  genome”  due  to  its  diverse  role  in  the  regulation  of  the  
chromatin  structure  (Kim  et  al.  2015).    CTCF  has  been  considered  as  tumour  suppressor  
whereas  BORIS  demonstrates  features  of  an  oncogene  (Marshall  et  al.  2014).  BORIS  is  
normally  present  at  high  levels  in  the  testis;;  however,  it  is  aberrantly  expressed  in  various  
tumors  and  cancer  cell   lines.    Example   includes  breast,  prostate,  ovarian,  endometrial  
and  other  cancers  (Kholmanskikh  et  al.  2008;;  Cuffel  et  al.  2011;;  Makovski  et  al.  2012).  
The   presence   of   BORIS   in   tumours   suggested   that   it   can   be   potential   biomarker   of  
cancerous  condition,  which  has  been  which  has  been  supported  by  experimental  findings  
(Cheema  et  al.  2014;;  K.  Chen  et  al.  2013).  However,  there  has  been  some  controversy  
in  the  literature  regarding  BORIS  function  and  expression  in  breast  cancer  and  normal  
tissue  (Tiffen  et  al.  2013;;  Rosa-­Garrido  et  al.  2012;;  Hines  et  al.  2010).  Interestingly,  the  
circulating  cell-­free  BORIS  mRNA     was   recently   reported   in   the  blood  of  patients  with  
breast  cancer  (Joosse  et  al.  2014).  
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In  a  previous  study  conducted  in  our  laboratory,  BORIS  was  detected  in  leukocytes  of  
breast  cancer  patients,    but  it  was  absent  in  healthy  donors  (D’Arcy  et  al.  2008;;  Martin-­
Kleiner  2012).    
Objectives  of  the  present  chapter:  
The  observation  that  BORIS  is  aberrantly  expressed  in  various  tumours  but  not  in  normal  
tissues  led  to  a  proposition  that  the  appearance  of  BORIS  may  lead  to  generation  of  anti-­
BORIS  autoantibodies  which  can  be  detected  in  blood  plasma.  The  phenomenon  of  the  
autoantibody  generation  has  been  described  previously  for  a  number  of  proteins  such  as  
p53,  HER2  and  epithelial  mucin  1  (MUC1)  (Goodell  et  al.  2006;;  Disis  et  al.  1997;;  von  
Mensdorff-­Pouilly  et  al.  1996).  Furthermore,  since  their  appearance  is  associated  with  the  
development  of  cancer  they  may  be  considered  as  potential    cancer  biomarkers  (Zaenker  
et  al.  2016).  In  this  study,  the  presence  of  anti-­BORIS  autoantibody  in  plasma  of  breast  
cancer   patients   was   evaluated   with   the   aim   to   investigate   whether   anti-­   BORIS  




Generation   of   specific   autoantibodies   in   response   of   the   appearance   of   tumour-­
associated  antigens  is  one  of  the  mechanisms  of  anti-­tumour  immune  response,  although  
its  molecular  basis  is  not  well  understood  (Zaenker  et  al.  2016).      We  reasoned  that  anti-­
BORIS  autoantibodies  may  be  generated  as  part  of  such   response  mechanism  at   the  
early  stages  of  cancer  development  and  hence  may  be  potential  biomarkers  for  cancer  
detection.         In   order   to   explore   this,   we   applied   direct   enzyme-­linked   immunosorbent  
assay   (ELISA)   with   several   optimization   steps   applied   to  measure   the   levels   of   anti-­
BORIS  antibodies  in  plasma  of  breast  cancer  patients  and  healthy  donors.  The  layout  of  
ELISA  assay  is  presented  in  Figure  8.1.  It  relies  on  BORIS  protein  expressed  in  cultured  
cells  transfected  with  the  BORIS-­expressing  plasmid  (the  results  of  transfection  of  293T  
cell   line   with   pCMV6   BORIS   plasmid   are   presented   in   Figure   8.2).   Anti-­BORIS  
autoantibodies  (AAb)  were  detected  in  all  analysed  plasma  samples  from  breast  cancer  
patients  and  healthy  donors.  The  highest  level  of  anti-­BORIS  AAb  was  detected  in  plasma  
from  primary  breast  cancer  cohort.  Between  healthy  donors’  samples  and  samples  from  
the  patients’  cohort  with  metastatic  (advanced)  breast  cancer  no  significant  differences  
were  observed  (Figure  8.3).  
Next,   the   presence   of   anti-­CTCF   autoantibodies   was   assessed   in   the   same   plasma  
samples   as   BORIS   and   CTCF   share   a   similar   zinc   finger   domain   and   therefore   can  
potentially   cross-­react.   First,   the   293T   cells   were   transfected   with   CTCF   expressing  
vector,   pCI-­CTCF   vector   using   JetPRIME   transfection   reagent;;   the   results   of   the  
transfection  are  presented   in  Figure  8.4.     The  ELISA  analysis  of  cell   lysates  with  and  
without   exogenous  CTCF   revealed   the   presence   of   the   anti-­CTCF   antibodies   at   high  
levels  in  plasma  from  primary  breast  cancer  cohort,  but  not  in  healthy  donors  and  patients  






Figure  8.1  Represents  ELISA  assay  employed  in  the  preset  study.  Antigen  was  bound  
to  the  wells  of  ELISA  plates  in  50  μl/well  of  coating  buffer.  Antigen  coated  plates  were  
sealed  with  plastic  wrap  and  incubated  overnight  at  room  temperature.  The  next  day,  the  
coating  buffer  was   removed  by   inverting   the  plates  and   the  wells  were  blocked  for  30  
minutes   with   200   μl/well   of   1X   blocking   solution,   prepared   by   diluting   10X   blocking  
solution  in  distilled  water.  The  blocking  solution  was  removed  by  inverting  the  plates.  Pure  
plasma  samples  were  added  and  incubated  for  1  hour  with  gentle  agitation.  Plates  were  
washed  3  times  with  1X  washing  buffer  (prepared  by  diluting  10X  wash  buffer  in  distilled  
water)  by  filling  all  wells  and  then  inverting  the  plates.  Secondary  antibody,  was  diluted  
an  antibody  diluent  (1:15000  mouse  monoclonal  secondary  antibody  to  human  IgG  HRP  
ab99765).  Diluted  secondary  antibody  was  added  to  each  well  for  30  minutes  at  room  
temperature  with  gentle  agitation.  Plates  were  washed  3  times  with  1X  wash  buffer.  100  
μl/well  of  substrate  solution  were  added  and  plates  were  incubated  for  30  minutes  at  room  







Figure  8.2  Western  blot  analysis  of   the   transfection  of  293T  cells  with  pCMV6  BORIS  
plasmid.  293T*  transfected  with  pCMV6  BORIS,  293T  cells  lysate  non-­transfected.    For  
transfection  jetPRIME  transfection  reagent  from  PolyPlus  transfection  was  used.  For  the  
western  blot  hand-­cast  8%  polyacrimydil  gel  from  BioRad  was  used.  Total  cell   lysates  
were  prepared  and  resolved  in  SDS-­PAGE.  Samples  were  heated  prior  the  loading  to  a  
90°C  for  5  min,  loaded  in  a  volume  of  20  µL  per  sample  and  separated  by  electrophoresis.  
In   the   next   step,   proteins  were   transferred   from   the  gel   to   Immobilon-­P  nitrocellulose  
membrane  (Millipore)  with  transfer  buffer  by  semi-­transfer  method  (10V,  200mA,  30  min)  
and  membrane  was   incubated   overnight   in   blocking   solution   (5%  Tween,   50mM  Tris  
Base).  Next,  membrane  was  probed  with  1:1000  monoclonal  anti-­  BORIS  and  1:5000  
















Figure   8.3   Presence   of   anti-­BORIS   autoantibody   in   plasma   of   breast   cancer  
patients.  
Represents  ELISA  results  and  shows  the  presence  of  anti-­BORIS  autoantibody  in  plasma  
of  breast  cancer  patients  and  healthy  donors.  As  control,  secondary  antibody  only  and  
lysate   from   transfected   293T   cells   were   used.   Absorbance   was   taken   at   405   nm  
(measured   as   Optical   Density,   or  OD).*P<0.05,   HD   –   healthy   donor,   BRCA-­   primary  
breast  cancer  patients,  ABC-­  advanced  breast  cancer  cohort  (a  cohort  of  breast  cancer  






Figure   8.4   Western   blot   analysis   of   293T   cells   transfected   with   the   CTCF   –  
expressing  plasmid,  pCI-­CTCF.  For   transfection   jetPRIME   transfection   reagent   from  
PolyPlus   transfection  was  used.  For   the  Western  blot  hand-­cast  8%  polyacrimydil  gel  
from  BioRad  was  used.  Total  cell   lysates  were  prepared  and  resolved   in  SDS-­PAGE.  
Samples  were  heated  prior  the  loading  to  a  90°C  for  5  min,  loaded  in  a  volume  of  20  µL  
per  sample  and  separated  by  electrophoresis.  In  the  next  step,  proteins  were  transferred  
from  the  gel  to  Immobilon-­P  nitrocellulose  membrane  (Millipore)  with  transfer  buffer  by  
semi-­transfer  method  (10V,  200mA,  30  min)  and  membrane  was  incubated  overnight  in  
blocking  solution  (5%  Tween,  50mM  Tris  Base).  Next,  membrane  was  probed  with  1:1000  
monoclonal  anti-­His  Tag  and  1:5000  anti-­actin  primary  antibodies  for  two  hours.  Signal  
detection  was  performed  using  Luminata  Forte  (Millipore).  293T*  cell   lysate   from  cells  
transfected  with  pCI-­CTCF  plasmid,  293T  cells  lysate  non-­transfected.
            293T*            293T 
CTCF 







Figure  8.5  Presence  of  anti-­CTCF  autoantibody  in  plasma  of  breast  cancer  patients.  
Represents  ELISA  results  and  shows  the  presence  of  anti-­CTCF  autoantibody  in  plasma  
from  breast  cancer  patients  and  healthy  donors.  As  control,  secondary  antibody  only  and  
lysate  from  non-­transfected  293T  cells  were  used.HD  –  healthy  donor,  BRCA-­  primary  
breast  cancer  patients,  ABC-­  advanced  breast  cancer  cohort  (a  cohort  of  breast  cancer  




It   is   recognised   that   autoantibodies   (AAb)   to   tumour   antigens  are   found   in   plasma  of  
breast  cancer-­bearing  patients  (Tabernero  et  al.  2009;;  Anderson  et  al.  2010;;  Zhong  et  al.  
2008;;  Wang  et  al.  2015).  Although  the  process  of  their  formation  is  not  understood  it  is  
believed   to   be   a   part   of   natural   immune   response   of   the   immune   system   to   the  
appearance   of   the   new   antigen   or   antigen   mutation,   overexpression   or   degradation  
related  to  cancer.  It  is  of  particular  of  interest  in  breast  cancer,  as  females  are  known  to  
generate  greater  immune  response  than  males.    
BORIS  has  a  potential  for  being  biomarker  for  early  diagnosis  of  breast  cancer  and  since  
its   appearance   is   linked   to   cancer   it   could   induce   an   immune   response   leading   to  
production  of  the  anti-­BORIS  autoantibodies.  The  quantitative  technique  such  as  ELISA  
could  be  useful  in  medical  practice  for  detection  of  such  antibodies  in  plasma  samples.    
In  the  present  experiment,  the  sandwich  ELISA  assay  has  been  employed  to  assess  the  
presence   of   anti-­BORIS   autoantibody   in   plasma   samples   from   two   cohorts   of   breast  
cancer  patients   (primary  and  advanced)  and  healthy  donors.   It  was  observed   that   the  
levels  of  autoantibody  are  higher  in  samples  obtained  from  primary  breast  cancer  patients  
in   comparison  with   healthy   donors’.   Interestingly,   level   of   anti-­BORIS   autoantibody   in  
plasma   samples   from   patients   with   advanced   cancer   appeared   to   be   lower   than   in  
samples  from  primary  breast  patients.  
These  results  correlate  with  data  from  similar  studies.  For  example,  in  lung  cancer  the  
levels  of  AAb  against  Annexin1  in  samples  collected  1  year  before  the  diagnosis  were  
considerably  higher  than  in  already  diagnosed  individuals.  Moreover  their  levels  reported  
to  increase  with  proximity  to  disease  diagnosis  (Brichory  et  al.  2001).  
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To  explain  the  low  levels  of  AAb  in  samples  from  patients  with  advanced  stages  of  breast  
cancer,  we  hypothesize  that  anti-­BORIS  antibodies  are  generated  only  as  an  initial  bodily  
response   to   cancer   and   its   levels   decrease   with   tumour   progression.   These   results  
support   previous   findings   conducted   in   our   laboratory,   measuring   the   expression   of  
BORIS  in  leukocytes  of  cancer  patients  using  western  blotting  technique  (D’Arcy  et  al.  
2008).  
Similar  results  reported  in  reports  studied  antitumor  immune  responses  against  glioma  by  
measuring  serum  anti-­FLNC  and  demonstrating  the  decrease  of  the  above  AAb  in  high-­
grade   gliomas   or   in   a   late   stage   of   tumour   progression.   To   explain   these   results,  
researches  also  measured  numbers  of  the  peripheral  blood  lymphocyte  in  both  advanced  
and  early  stages  of  cancer  and  detected  overall  decrease  in  lymphocyte  count  in  patients  
with   higher   grade   of   glioma.   They   proposed   that   lymphocytopenia  may   contribute   to  
decrease  in  AAb  formation  (Adachi-­Hayama  et  al.  2014).  
  ELISA   technique   relies   on   specific   interaction   between   epitope   specific   sequence   of  
amino  acids  found  on  antigen  and  corresponding  to  the  antibody  binding  site.  As  BORIS  
and  CTCF  share  a  similar  zinc  finger  domain  and  therefore  can  potentially  cross-­react,  
we  analysed   the  presence  of  anti-­CTCF  autoantibodies   in   the  same  plasma  samples.  
Data  generated   in  our  experiment   indicate  cross   reactivity   thus   in  a   future   to   improve  




Chapter  9  Analysis  of  BORIS  as  urine  based  prostate  cancer  biomarker  
9.1   BORIS   (Brother   Of   the   Regulator   of   imprinted   Sites)-­a   potential   cancer  
biomarker  
BORIS,  a  paralogue  of  the  transcription  factor  CTCF,  is  a  cancer-­testis  antigen.  Under  
normal  condition  is  expressed  during  embryonic  male  germ  development  and  in  testis.  
BORIS   transcript   has   been   shown   be   aberrantly   expressed   in   the  majority   of   human  
tumours  including  prostate  cancer  (Kholmanskikh  et  al.  2008;;  Cuffel  et  al.  2011;;  Makovski  
et  al.  2012;;  Cheema  et  al.  2014).  Adding   to   the  complexity  of   this  gene,   recent  study  
identified  23  mRNA  splice  variants  potentially  encoding  17  variants  of  the  BORIS  isoform  
proteins    (Pugacheva  et  al.  2010).  In  the  study,  conducted  in  our  laboratory  the  BORIS  
expression  at  the  protein  and  mRNA  levels  was  reported  in  prostate  tumours  (Cheema  
et   al.   2014).   Urine   is   considered   as   a   viable   source   of  prostate-­derived   RNAs  
for  biomarker  discovery   since   it  may   contain  materials   (cells   or   exosomes)   shed   from  
tumours.  As  a  part  of  the  study  conducted  at  the  University  of  East  Anglia  (Pellegrini  et  
al.  2017),  the  urine  samples  from  prostate  cancer  patients  were  provided  and  tested  in  
our  laboratory  to  measure  the  levels  of  BORIS  mRNA  in  these  specimens.    
9.2  Experimental  Aim  
This  Chapter  represents  pilot  experiments  to  explore  the  potential  of  BORIS  mRNA  as  a  
urine   biomarker   for   early   diagnosis   and   prognosis   of   prostate   cancer.   In   these  
experiments,  the  levels  of  BORIS  mRNA  were  evaluated  using  RT-­qPCR  in  total  mRNA  
obtained  from  urine  sediments  and  urinary  exosomes  of  prostate  cancer  patients.  The  
results  were  then  correlated  with  the  clinical  information.
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9.3  Results    
9.3.1  Characterisation  of  RNA  samples  
In  the  present  study,  total  RNA  was  isolated  from  white  blood  cells  of  the  healthy  donors  
and   MCF7   breast   cancer   cell   line   to   be   used   as   negative   and   positive   controls,  
respectively.  Extraction  of  RNA  from  blood  can  be  very  challenging  due  to  several  factors.  
First,   in  order  to  preserve  RNA  from  degradation,  the  stabilising  reagent  RNAlater  was  
added  to  the  sample  prior  the  freezing.  However,  we  found  that  RNAlater  interfered  with  
the  RNA  precipitation  step,  due  to  its  high  density.  To  address  this  issue,  pure  ice-­cold  
water  was  added  to  the  samples  to  reduce  their  density.  The  second  reason  is  the  low  
concentration  of  extracted  RNA  (10  million  cells  were  used  to  obtain  only  around  ~100ng  
of  RNA).  To  solve  this,  the  conventional  phenol-­chloroform  RNA  extraction  protocol  was  
modified  with  the  addition  of  the  extra  chloroform  steps  and  ethanol  washing  step.    
Total  RNAs   isolated   in   the  presented  study  were   then  subjected   to   the  quality  control  
using  Agilent  2100  Bioanalyser.  Prior  to  the  assessment,  all  the  samples  were  heated  to  
75°C   for   2min   in   order   to   remove   secondary   structure.   Data   obtained   using   the  
Bioanalyser  show  the  examples  of  good  and  low  quality  RNAs  are  presented  in  Figure  
9.1.   Clear   18S   and   28S   peaks   with   low   noise   in   between   and   the   absence   of   DNA  
contamination   can   be   observed   indicating   high   quality   RNA   in   most   samples   (A).  
However,  in  some  of  the  samples  the  various  degree  of  degradation  can  be  observed  (B).    
The   concentration   of   extracted   RNA   was   determined   using   Nanodrop   ND   1000  
Spectrophotometer.   RNA   has   the   light   absorbance   at   260nm   and   the   ratio   of   the  
absorbance  at  260nm  and  280nm  is  used  to  assess  its  purity.  The  results  indicate  that  






Figure  9.1  Assessment  of  total  RNA  integrity  by  Agilent  2100  Bioanalyser.  Total  RNAs  
were  extracted  from  leukocytes  of  healthy  donors  and  MCF7  breast  cancer  cell   line  as  
described   in  Material   and  Methods   and   analysed   using   Agilent   2100   Bioanalyser.  A,  
electropherograms   represent   good   quality   RNA   used   in   the   present   study   and  
characterised   by   clear   18S   and   28S   peaks   and   two   well   separated   bands.   B,  
demonstrates  results  of  degraded  RNA  characterised  by  the  absence  of  clear  peaks  and  





  9.3.2  Quantitative   real   time  PCR  analysis  of  BORIS  mRNA  expression   levels   in  
urine  sediment  and  urinary  exosomes  obtained  from  prostate  cancer  patients  with  
different  disease  stages.  
It   has   been  previously   reported   that  BORIS-­cancer   testis   antigen   (CTA)   is   present   in  
prostate   tumours   (Cheema   et   al.   2014).   To   further   validate   the   potential   practical  
applications   of   BORIS   as   a   biomarker   for   early   diagnosis   and   prognosis   of   prostate  
cancer  here  we  employed  RT-­qPCR.  In  these  experiments,  the  levels  of  BORIS  mRNA  
were  evaluated  in  the  total  mRNA  obtained  from  urine  sediment  and  urinary  exosomes  
of  prostate  cancer  patients.    
The   presence   of   BORIS   was   assessed   in   cDNA   samples   from   urine   sediment   of  
individuals  diagnosed  with  prostate  cancer.  The  total  of  67  samples  was  received  from  
the  University  of  East  Anglia.  As  positive  control  the  total  RNA  extracted  from  MCF7  cell  
line,  MCF7  transfected  with  BORIS-­CMV  plasmid  was  used.  It  was  not  possible  to  obtain  
urine   sediment   samples   from   healthy   donors   in   these   experiments.   Therefore,   as  
negative   control   RNA   extracted   from   the   leukocytes   of   healthy   donors,   previously  
reported  to  be  BORIS-­negative  was  used.  The  obtained  RT-­qPCR  results  showed    
First  the  levels  of  BORIS  mRNA  in  samples  from  urinary  sediment  were  analysed  using  
SYBR  qPCR  (Figure  9.2).  Next,  the  levels  of  BORIS  mRNA  were  evaluated  in  total  urinary  
exosomal  mRNA.  To  detect  all   the  23  known  mRNA  variants  of  BORIS  its  expression  
was  analyzed  by  quantitative  RT-­PCR  with  two  sets  of  primers  encompassing  1–2  and  
3–4  exon  boundaries,  respectively  (Zampieri  et  al.  2014).    
The  obtained  results  were  grouped  according  to  the  disease  stage  and  the  levels  of  PSA  
and  plotted  using  Prism  GraphPad  5  software  (Figures  9.3.and  9.4.).  Consistent  with  the  
results  obtained  from  RT-­qPCR  using  SYBR  the  highest   levels  of  BORIS  mRNA  were  
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detected  in  sample  from  patient  with  advanced  prostate  cancer.  However,  the  rest  of  the  




                                                   
  
Figure  9.2  Quantitative  real  time  PCR  analysis  of  BORIS  mRNA  expression  levels  
in  urine  sediment  from  prostate  cancer  patients  in  different  disease  stages.  Real-­
time  qPCR  expression   levels  of  BORIS  mRNA  were  calculated  using   the  comparative  
CT  method  and  normalised  to  GapDH  expression.  HG-­PIN-­  atypia,  P-­  prostatitis,  CBN-­  
PSA  normal   to  age  and  clinical  benign;;  CB<1-­  PSA<1  clinically  benign,  Sneg-­     raised  
PSA  negative  biopsy;;  L-­  Low  risk  PSA<10,  IL  –  intermediate  risk  PSA>10;;  I  Intermediate  
risk  PSA<20,  HL-­High  risk,  PSA>20;;Hh  High  risk,  PSA<100,  Hhh-­High  risk,  PSA>100,  
A-­advanced  disease.  MCF+B-­MCF7  transfected  with  BORIS-­CMV  plasmid,  used  as  a  
positive  control,  HD-­RNA  from  blood  of  healthy  donor,  used  as  a  negative  control


















































                                                           
Figure  9.3  Quantitative  real  time  PCR  analysis  of  BORIS  mRNA  expression  
levels   in  urinary   exosomes   of   prostate   cancer   patients.  BORIS  expression  
was  analyzed  by  quantitative  RT-­PCR  with  set  of  primers  encompassing  1–2  exon.  
Gap-­DH  was  used  as  the  reference  gene  in  all  the  experiments.  HG-­PIN-­  atypia,  
P-­  prostatitis,  CBN-­  PSA  normal  to  age  and  clinical  benign;;  CB<1-­  PSA<1  clinically  
benign,  Sneg-­    raised  PSA  negative  biopsy;;  L-­  Low  risk  PSA<10,  IL  –  intermediate  
risk  PSA>10;;   I   Intermediate   risk  PSA<20,  HL-­High  risk,  PSA>20;;  Hh  High  risk,  




                                                     
Figure  9.4  Figure:  Quantitative  real  time  PCR  analysis  of  BORIS  mRNA  expression  
levels   in   urinary   exosomes   of   prostate   cancer   patients.   BORIS  expression   was  
analyzed  by  quantitative  RT-­PCR  with  set  of  primers  encompassing  3-­4  exon.  Gap-­DH  
was  used  as   the  reference  gene   in  all   the  experiments.  HG-­PIN-­  atypia;;  P-­  prostatitis;;  
CBN-­  PSA  normal   to   age  and   clinical   benign;;  CB<1-­  PSA<1   clinically   benign,  Sneg-­    
raised   PSA   negative   biopsy;;   L-­   Low   risk   PSA<10,   IL   –   intermediate   risk   PSA>10;;   I  





The  aim  of  this  chapter  was  to  evaluate  levels  of  BORIS  mRNA  in  urine  sediments  and  
urinary   exosomes   of   prostate   cancer   patients   and   investigate   its   possible   utility   as   a  
prostate   cancer   biomarker.   The   qPCR   data   demonstrates   that      BORIS   mRNA   was  
detected  in  all  analysed  samples  at  different  levels.  The  BORIS  mRNA  was  present  at  
the   highest   level   in   a   sample   with   the   advanced   disease.   Interestingly,   both   urinary  
exosomes  and  urine  sediment  from  patient  with  advanced  cancer  show  elevated  levels  
of  BORIS  mRNA.  Although  these  results  were  based  on  only  one  sample  from  a  patient  
with   advanced   prostate   cancer,   they   are   in   agreement   with   previous   observations  
(Cheema  et  al.  2014)  showing  positive  correlation  between  BORIS  protein  expression  in  
prostate   tumours   and   clinical   data   (tumour   stage   and   Gleason   score)   and   suggest  
potential  application  of  BORIS  as  a  prognostic  marker  of  the  aggressive  prostate  cancer.  
Given   that   there  are  23  known  mRNA  variants  of  BORIS  its  expression  was  analyzed  
with   two  sets  of  primers  encompassing  1–2  and  3–4  exon  boundaries.  The  rest  of  the  
data  shows  no  correlation  between  clinical  information  and  BORIS  levels.  
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Chapter  10:  General  Discussion  
Breast  cancer  is  a  complex  and  heterogeneous  disease,  which  makes  the  diagnosis  and  
management  of  this  condition  a  challenging  task.  Currently,  mammography  remains  the  
main   diagnostic   tools   for   screening   and   detection   of   breast   cancer.   However,  
mammography  has  false  negative  rates  of  approximately  15  %  which  puts  patients’  lives  
in   danger   (Chan  et   al.   2015).   False   positive   results   are   also   common,   causing   over-­
diagnosis   and   unnecessary   biopsy.   In   addition,   mammography   does   not   provide  
information  regarding  the  potential  malignancy  of  the  tumour.  Therefore,  there  is  a  need  
for   biomarkers   for   screening,   diagnosis   and   prognosis   of   breast   cancer.   Biomarkers  
currently  used  in  clinical  practice  include  cellular  markers  (HER2,  ER  and  PR)  that  help  
to  select  for  the  patients  who  will  benefit  from  the  endocrine  treatment  and  to  predict  the  
response   to   the  HER2   targeting   therapy.  The  humoral   biomarkers   (circulating   tumour  
cells,   CA   15-­3   and   CA   27-­29)   are   used   to   monitor   breast   cancer   progression   and  
treatment  efficacy.  However,  these  biomarkers  are  not  accurate  in  prediction  of  treatment  
response  and  are  only  recommended  to  be  used  in  combination  with  cellular  markers.  
Furthermore,  they  have  not  yet  been  approved  for  diagnostic  and  screening  purposes.  
Hence,   there   is   a   continuous   quest   to   identify   novel   accurate   non-­invasive  molecular  
biomarkers  for  detection,  prognosis  and  treatment  monitoring  of  breast  cancer.    
The   interaction   between   the   tumour   and   the   host’s   immune   system   is   complex.   This  
complex   interaction   has   been   studied   extensively,   largely   focusing   on   the   tumour  
microenvironment,  which  is  characterised  by  abundant  infiltration  of  immune  cells.  This  
study  focuses  on  the  changes  in  peripheral  blood  in  the  response  to  cancer.  In  particular  
the  changes  in  protein  profile  of  immune  cells,  which  could  be  utilised  as  the  source  for  
novel  breast  cancer  biomarkers.    
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The  proteomics  approach  employed  as  one  of  the  methods  for  identification  of  biomarkers  
for  this  study  is  very  popular  in  finding  novel  cancer  biomarkers  and  have  advantage  over  
gene  expression  studies  as  protein  biomarkers  are  more  preferable  in  clinical  settings.  
The  availability  of  well-­developed  antibody  assays  allows  for  their  easier  detection.  
In   the   previous   study   conducted   in   Professor   Klenova’s   laboratory,   proteomic   based  
strategies,   namely   2D   gel   electrophoresis   and   the  Orbitrap  mass   spectrometry,   were  
applied  to  identify  the  differences  in  protein  profiles  of  WBCs  of  breast  cancer  patients  
and   healthy   donors.   These   two   techniques   were   used   independently   to   identify  
overlapping  proteins  and  136  statistically  significant  differentially  expressed  proteins  were  
discovered.  Subsequent  gene  anthology  analysis  showed  that  34  of  those  were  involved  
in  the  immune  response  processes.  Furthermore,  it  revealed  that  inflammation  response  
was   generally   greater   in  WBCs   of   breast   cancer   patients,   supporting   the   theory   that  
inflammation   favours   tumour  progression  (Grivennikov  et  al.  2010;;  Elinav  et  al.  2013).  
The  generated  data  was  compared  with  publically  available  gene  expression  data  from  
Gene   Expression   Omnibus   (GEO)   to   identify   a   list   of   potential   biomarkers.   Fifteen  
candidate   biomarkers   were   shortlisted   involving   criteria   such   as:   normal   presence   in  
WBCs,   correlation   with   clinical   data,   expression   in   healthy   donors,   association   with  
cancer  and  function  in  immune  response.  To  validate  the  biomarkers,  RT-­qPCR  was  used  
and   the   list   was   further   reduced   to   five   potential   protein   biomarkers   which   were  
subsequently  chosen  for  extended  validation.    The  following  biomarkers  were  selected:  
Serpin   B1,   Lipocalin   2,   Integrin  a4,   Copine  3   and   5LOX.   It   should   be   noted   that   the  
greatest  obstacle  in  the  validation  of  biomarkers  is  the  lack  of  a  standard  protocol,  while  
for  drug  discovery  the  validation  protocols  are  well  established.    In  this  study,  to  validate  
the  potential  protein  biomarkers  a  variety  of  the  protein  assays  were  employed  such  as  
Western  blot,  IF,  FACS  and  ELISA.  The  ELISA  ba
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expression   of   the   above   proteins   in   WBCs   as   well   as   in   plasma   obtained   from   the  
participants’  blood.  These  techniques  proved  to  be  effective  for  the  given  task,  as  they  
successfully  supported  previously  reported  differential  expression  patterns  of  Serpin  B1  
and  Lipocalin  2.  For  Copine  3,  Integrin  a4  and  5LOX,  however,  the  data  proved  to  be  less  
consistent.    
Of  note,  the  assessment  of  mRNA  levels  of  the  candidate  proteins  is  also  often  conducted  
and  such  experiments  were  performed  in  the  previous  study  (Mani,  PhD  thesis,  2015).  
The  summary  of  these  analyses  presented  in  Table  10.1  shows  that  mRNA  levels  do  not  
correlate  with  protein  levels  in  all  cases.    However,  absence  of  correlation  between  levels  
of  proteins  and  corresponding  mRNAs   is  not  surprising  and  has  been   reported   in   the  
literature  (Tian  et  al.  2004;;  Vogel  et  al.  2010;;  Lundberg  et  al.  2010).   In   this  study,   the  
functional  significance  of  the  candidates  and  the  initial  analysis  at  protein  levels,  but  not  
RT-­qPCR  data,  were  important  for  the  selection  of  the  candidates  for  further  validation
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Table  10.1  The  summary  of  RT-­qPCR  results  for  five  WBC  biomarkers  (Serpin  B1,  
Lipocalin  2,  Copine  3,  Integrin  a4  and  5-­Lipoxygenase).  Genes  common  from  different  
datasets  comparing  healthy  donors,  primary  breast  cancer  patients  and  metastatic  breast  
cancer  patients  were  obtained.  Fold  change  refers  to  fold  change  in  primary  breast  cancer  
cohort.  Red  coloured  cells   indicate  overexpression;;  green   indicates  under-­expression.  
*T-­test  p  value<0.05.  The  presence  in  metastatic  breast  cancer  cohort  is  denoted  by  ‘X’  
and  the  fold  change  is  not  included  since  the  initial  analysis  did  not  include  comparison  
with  healthy  donors.  Adapted  from  J.  Mani  (J.Mani,  PhD  thesis,  University  of  Essex,  2015)  
and  Table  1.2  (  this  thesis).  
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Serpin  B1  as  a  prospective  biomarker  
Using   proteomic   and   genomic   approaches   Serpin   B1   was   identified   as   potential  
biomarker   for  breast  cancer.  Comparison  of   the  expression  profile  of   the  WBCs  of   the  
healthy  donors  and  breast  cancer  patients  using  2D-­PAGE  revealed  +1.3  and  +1.46-­fold  
change  in  the  expression  of  the  Serpin  B1  protein  in  breast  cancer  patients  respectively.  
Validation   of   these   results   using   RT-­qPCR   showed   downregulation   of   Serpin   B1   on  
mRNA  levels  (Table  10.1)  (Mani,  PhD  thesis,  University  of  Essex,  2015).  Data  generated  
in  the  present  study  suggests  that  Serpin  B1  has  features  of  diagnostic  and  prognostic  
biomarker.  Quantification  of  the  above  protein  by  the  Western  blot  showed  its  elevation  
in  WBCs  of  breast  cancer  patients.  Serpin  B1  levels  were  shown  to  be  higher  in  patients  
with  advanced  disease.  Furthermore,  its  expression  levels  were  higher  in  patients  with  
node  positive  status  than  in  node  negative  participants.  These  results  were  statistically  
significant  (p<0.05).  Higher  levels  of  Serpin  B1  in  primary  breast  cancer  patients  than  in  
healthy  donors  indicate  that  this  feature  of  Serpin  B1  is  associated  with  the  presence  of  
breast  cancer  and  hence  it  can  serve  as  an  early  biomarker  of  cancer.  It  will  be  important  
to  test  this  property  of  Serpin  B1  in  the  cohort  of  donors  which  include  the  pre-­diagnostic  
samples;;  this  will  allow  an  unbiased  validation  approach.    
Assessment  of  the  predictive  value  of  Serpin  B1  in  WBCs  from  patients  with  advanced  
breast   cancer   showed   that   low   levels   of   the  protein   in   the   beginning  of   the   treatment  
correlate  with  longer  survival  of  the  patients  with  chemotherapy  treatment.  These  results  
suggest   that  Serpin  B1  has  a  potential   to   be  used  as   a  marker   of   survival.  However,  
Kaplan-­Meier  analysis  of  the  combined  data  for  the  patients  received  chemotherapy  and  
endocrine  data  did  not  show  significant  difference  between  lower  or  higher  levels  of  the  
protein  and  the  survival  of  the  patients.    
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Analysis  of   the  changes   in   the   levels  of  Serpin  B1  during   the   treatment  did  not  show  
correlation  with  clinical  response.  Therefore,  it  can  be  concluded  that  Serpin  B1  cannot  
be  used  as  a  predictive  marker  for  the  treatment  efficacy.    
The  results  from  western  blot  analysis  were  confirmed  by  IF,  were  higher  staining  intensity  
was   detected   in  WBCs   of   node   positive   primary   breast   cancer   and   advanced   breast  
cancer  cohorts.  Interestingly,  different  distribution  of  the  Serpin  B1  was  detected  in  WBCs  
of  patients  with  different  stages  of  the  disease.  In  leukocytes  of  node  negative  and  node  
positive  breast  cancer  patients  Serpin  B1  was  appeared  to  be  present  in  vesicles  at  the  
cell   surface.   In   samples   from   patients   with   advanced   disease   strong   cytoplasmic  
localisation  of  the  protein  was  observed.    
The  data  from  FACS  analysis,  measuring  the  expression  levels  of  Serpin  B1  in  randomly  
selected   primary   breast   cancer   sample   show   almost   twofold   higher   expression   in  
comparison  with  a  healthy  donor.    Furthermore,  as  determined  by  ELISA,  Serpin  B1  was  
elevated   in   plasma  and  WBCs   from  patients  with   both,   primary   and  advanced  breast  
cancer,  in  comparison  with  healthy  donors.    
The  existing  literature  reports  may  help  to  explain  the  heightened  expression  of  Serpin  
B1  in  response  to  cancer.  Serpin  B1  belongs  to  the  class  of  serine  protease  inhibitors.  
Proteases   in   healthy   cells   are   important   in   carrying   out   biological   processes.   Their  
proteolytic  activity  is  carefully  regulated  and  balanced  by  the  work  of  protease  inhibitors,  
which  if  disturbed  often  leads  to  disease  like  cancer  (Rakash  2012).  The  abhorrent  activity  
of  serine  proteases  contributes  to  pathology  of  immune  diseases  and  cancer  metastasis  
(Grassi  et  al.  2009;;  Heutinck  et  al.  2010;;  Blanco  et  al.  2005).  Therefore,  serine  proteases  
are  attractive  targets  in  the  field  of  biomarker  research.  One  of  the  successful  example  of  
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the  existing  cancer  biomarker  that  belong  to  the  subgroup  of  serine  proteases  is  PSA,  
used  for  the  screening  for  prostate  cancer.    
Serine  proteases  that  are  expressed  in  endosomal  vesicle  of  granulocytes  are  involved  
in  different  immune  processes,  such  as  inflammation,  pathogen  clearance  and  apoptosis.  
The   release   of   neutrophil   proteases   during   infection   causes   damage   to   the   inflamed  
tissue.  Given  that  proteases  required  for  cell  death,  the  role  of  serpins  is  to  protect  cells  
by   inhibiting  serine  proteases.   In  particular,  neutrophils  express  Serpin  B1  that  protect  
leukocytes  from  self-­induced  damage  (Ashton-­Rickardt  2010).  Therefore,  the  data  from  
the  presented  research,  showing  overexpression  of  Serpin  B1  in  WBCs  of  breast  cancer  
patients,  suggest  that  upregulation  of  this  protease  inhibitor  may  be  a  strategy  to  protect  
neutrophils  from  self-­inflicting  damage.  These  results  are  supported  by  studies  on  Serpin  
B1-­deficient  mice,  which  exhibit  decreased  viability  of  neutrophils  (Charaf  Benarafa  et  al.  
2011;;  Burgener  et  al.  2016).    
Collectively  the  data  generated  in  the  present  study  show  that  levels  of  Serpin  B1  rises  
as  disease  progress,  suggesting  that  it  could  be  a  marker  of  lymph  node  metastasis  for  
primary   breast   cancer   and   a   general   advanced   breast   cancer   marker   of   disease  
prognosis.  The   results  confirm   that  Serpin  B1  could  be   taken   to   the  clinical  validation  
phase  of  biomarker  development  pipeline.  To  determine  the  specificity  of  the  Serpin  B1  
its  expression  has  to  be  evaluated  in  other  types  of  cancer.  Functional  studies  may  help  
to  explain  the  molecular  basis  of  the  generated  data.  
Lipocalin  2  as  prospective  biomarker  
Using   proteomic   and   genomic   approaches   Lipocalin   2   was   identified   as   potential  
biomarker   for  breast  cancer.  Comparison  of   the  expression  profile  of   the  WBCs  of   the  
healthy  donors  and  breast  cancer  patients  using  2D-­PAGE  revealed  +2.16-­fold  change  
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in  the  expression  of  the  Lipocalin  2  protein  in  breast  cancer  patients.  Validation  of  these  
results  using  RT-­qPCR  showed  downregulation  of  Lipocalin  2  on  mRNA   levels   (Table  
10.1)  (Mani,  PhD  thesis,  University  of  Essex,  2015).  The  aim  of  the  present  study  was  to  
validate  the  previously  reported  findings.  Prognostic  value  of  Lipocalin  2  was  evaluated  
using  Western  blot  technique.    The  generated  data  showed  significant  overexpression  of  
the   target  protein   in  both  cohorts  of  breast  cancer  patients   (primary  and  advanced)   in  
comparison   with   healthy   donors   suggesting   that   Lipocalin   2   has      properties   of      a  
diagnostic  and  prognostic  breast  cancer  marker.      
To  assess  the  value  of  the  Lipocalin  2  as  the  predictive  biomarker  of  treatment  efficacy  
in   the   cohort   of   advanced  breast   cancer   patients,   the   initial   levels   of   Lipocalin   2  was  
correlated  with  clinical   response   to   treatment.  The  obtained   results   indicate   that   lower  
initial  levels  of  Lipocalin  2  associate  with  better  prognosis  for  the  patients,  as  it  correlated  
with   the   stable   disease.   Although   the   p   value   was   not   significant,   the  median   of   the  
category  of  patients  with  stable  disease  was  lower  when  compared  with  less  favourable  
clinical  response  categories.  The  evaluation  of  the  changes  in  the  Lipocalin  2  expression  
during  the  treatment  indicate  that  the  levels  of  protein  decrease  in  response  to  endocrine  
treatment.  
The  comparison  between  initial  levels  of  Lipocalin  2  and  overall  survival  of  the  patients  
showed  no  correlation  for  both,  chemotherapy  and  endocrine  treatment.  
The  results  from  IF  experiment,  confirmed  the  data  from  Western  blot  analysis.  The  higher  
degree  of  staining  for  Lipocalin  2  was  observed  in  patients  with  primary  and  advanced  
breast   cancer   in   comparison   with   healthy   donors.   The   quantification   of   the   relative  
intensity  revealed  that  these  results  are  significant  for  both  cohorts  (p<0.05).  
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FACS   analysis   of   the   expression   of   Lipocalin   2   in   neutrophils   showed   +2-­fold   higher  
expression  ratio  in  randomly  selected  primary  breast  cancer  sample  when  compared  with  
healthy  donor.    
The  data  generated  using  ELISA  technique  supports  the  diagnostic  and  prognostic  value  
of  Lipocalin  2  protein.  It  showed  significantly  elevated  levels  of  the  protein  of  interest  in  
primary  breast  cancer  samples.  Although,  its  levels  in  advanced  breast  cancer  samples  
was  shown  to  be  elevated,  but  not  significantly.    
The   reports  available   in   the   literature  suggest   that  Lipocalin  2  has  an  oncogenic  role.    
However,   this   role   is   contrasting   and   location   dependant.   This   innate   immune  protein  
found  to  be  upregulated  in  various  inflammatory  disorders.  As  a  component  of  neutrophil  
granules,  its  required  for  the  neutrophil  function  and  plays  essential  role  in  innate  immune  
response   against   bacterial   infection   (Liu   et   al.   2013;;   Toyonaga   et   al.   2016).   Indeed,  
Lipocalin   2   deficient  mice  are   shown   to   exhibit   higher   susceptibility   to   pathogens  and  
higher  mortality   rate   than   the  wild   type   (Flo  et   al.   2004).   Furthermore,   in   the   state   of  
colonic  inflammation,  Lipocalin  2  deficiency  contributes  to  intestinal  carcinogenesis.  This  
may  be  explained   that   in   the   absence  of  Lipocalin   2,   the   iron   availability   is   increased  
facilitating      the   growth   advantage   for   the   certain   pathogenic   bacteria   that   promote  
inflammation  and  tumorigenesis  (Moschen  et  al.  2016).    
In  colorectal  cancer,  the  loss  of  Lipocalin  2  associates  with  increased  tumour  multiplicity,  
suggesting  that  it  has  a  tumour  suppressive  role  (Reilly  et  al.  2012).  In  contrast,  in  mice  
model  of  mammary  tumorigenesis,  inhibition  of  Lipocalin  2  supresses  tumour  formation  





Integrin  a4  as  prospective  biomarker  
In  the  proteomic  study  previously  conducted  in  our  laboratory,  Integrin  a4  expression  was  
shown  to  be  decreased   in  WBCs  of  breast  cancer  patients.  Validation  of   these  results  
using  RT-­qPCR  confirmed  the  downregulation  of  Integrin  a4  on  mRNA  levels  (Table  10.1)  
(Mani,  PhD  thesis,  University  of  Essex,  2015).  
The   aim  of   the   present   study  was   to   validate   previous   findings   using   various   protein  
assays.  The  data  generated  using  Western  blot  technique  confirmed  previously  reported  
changes.  The  protein  levels  of  Integrin  a4  were  found  to  be  significantly  lower  in  WBCs  
of   primary   and   advanced   breast   cancer   cohorts   in   comparison   with   healthy   donors.  
Furthermore,  in  WBCs  samples  from  advanced  breast  cancer  the  signal  for  Integrin  a4  
was  not  detected  at  all.  It  might  be  due  to  the  very  low  levels  of  the  above  protein  present  
in  WBCs  at  the  advanced  stage  of  the  disease.  To  further  investigate  these  finding,  the  
samples  taken  at  different  treatment  time  points  were  run  on  a  gel  to  see  whether  signal  
will  appear  after  the  treatment  received.  As  the  result,  the  signal  was  detected  at  the  later  
stages  of  the  treatment.  Integrin  a4  is  expressed  in    T-­  lymphocytes  playing  the  key  role  
in  the  immune  response  against  tumour.  The  increased  levels  of  T  cells  in  breast  cancer  
tissue   is   considered   as   a   prognostic   factor   for   disease   outcome   and   it   is   positively  
associated  with  overall  patient  survival  (Bates  et  al.  2006;;  Mahmoud  et  al.  2011).   It   is  
known   that   during   the   DNA-­   damaging   chemotherapy   the   absolute   number   of  
lymphocytes   is  decreased  (Onyema  et  al.  2015).  Therefore,  from  the  biological  sense,  
the  not  detectable  signal  of  Integrin  a4  in  western  blot  of  advanced  breast  cancer  patients  
could  be  explained  by  the  low  number  of  T  cells  in  the  WBCs  sample.  
The  results  from  IF  experiment  indicate  lower  fluorescent  intensity  for  the  Integrin  a4  in  
the  samples   from  primary  breast  cancer  patients,  supporting   the   finding   from  Western  
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blot  analysis.  Similar  trend  was  observed  using  FACS  analysis.  The  expression  of  Integrin  
a4    in  T  cells  of  cancer  patient  was  shown  to  be  1.22-­fold  change  lower  when  compared  
to  healthy  donor.  
Although   the   data   generated   so   far   showed   that   the   protein   levels   of   Integrin  a4   is  
decreased  in  WBCs  of  breast  cancer  patients,  the  data  obtained  by  ELISA  experiment  
contradict  the  above  results  indicating  the  increased  levels  of  Integrin  a4  in  the  samples  
from  breast  cancer  patients.  The  observed  discrepancy  in  the  results  could  be  explained  
by   the   different   antibody  used   in   the   commercial   assays  and,   naturally,   this  aspect   is  
beyond  our  control.  Furthermore,  the  results  of  ELISA  could  be  affected  by  the  technical  
problem   with   the   kit   or   protocol,   or   both.   In   the   future,   these   experiments   should   be  
repeated  with  the  use  of  another  kit.    
The  inconsistency  between  the  Western  blot  and  ELISA  data  is  not  a  new  challenge.  The  
combined  usage  of  these  two  techniques  provides  more  confidence  in  the  positive  results  
than   either   of   them   independently,   especially   if   different   antibody   are   used   for   each  
assays.  The  advantage  of  Western  blot  is  that  it  less  likely  to  give  false  positive  results,  
in  contrast,  false-­positive  results  are  often  observed  in  ELISA  due  to  the  cross  reactivity  
or  high  background.    
In  summary  the  validation  results  for  Integrin  a4    showed  conflicting  results  therefore  it  is  
difficult   to   evaluate   biomarker   property   of   this   protein.   It   still   remains   an   interesting  
candidate  biomarker  as  its  levels  were  shown  to  be  decreased  in  the  WBCs  of  cancer  
patients.  The  majority  of  the  investigated  biomarkers  show  elevated  levels  which  makes  
it  easier  to  investigate  their  levels  in    biological  specimens.  Specifically,  decreased    levels  
of  Integrin  a4  in  primary  breast  cancer  patients  than  in  healthy  donors  indicate  that  this  
feature  of  Integrin  a4    may  be  associated  with  the  presence  of  breast  cancer  and  hence  
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it  can  serve  as  an  early  biomarker  of  cancer.  It  will  be  important  to  test  this  property  of  
Integrin  a4   in   the  cohort  of  donors  which   include   the  pre-­diagnostic  samples;;   this  will  
allow  an  unbiased  validation  approach.    
5LOX  as  prospective  biomarker  
Using  proteomic  and  genomic  approaches  5LOX  was  previously  identified  as  potential  
biomarker   for  breast  cancer.  Validation  of   these  results  using  RT-­qPCR  confirmed  the  
upregulation   of   5LOX   on  mRNA   levels   (Table   10.1)   (Mani,   PhD   thesis,   University   of  
Essex,   2015).   In   this   study   the   heightened   levels   5LOX   in  WBCs   from  breast   cancer  
patients   were   confirmed   by   the   Western   blot   analysis.   However,   the   FACS   and   IF  
analyses  showed  the  opposite  results.  The  observed  discrepancy  in  the  data  could  be  
explained  by  the  fact,  that  for  FACS  and  IF  experiments,  the  WBCs  from  a  healthy  donor  
with  the  highest  5LOX  expression  was  used.  It  should  be  noted  that  later  this  person  was  
later  diagnosed  with  cancer.  The  use  of  the  samples  from  other  healthy  participants  in  
further  experiments  would  be  preferable  for  the  validation  of  5LOX  as  biomarker  of  breast  
cancer.    
The   importance  of  5LOX   in   tumorigenesis   has   been  well  documented.      For   example,    
heightened  expression  of  5LOX  by  malignant  cells  has  been   reported   to  promote  cell  
survival  and  proliferation  and  elevated  levels  of  5LOX  have  been  shown  in  human  cancer  
cell  lines  (colorectal,  pancreatic,  breast  and  prostate)  (Gupta  et  al.  2001;;  Matsuyama  et  
al.  2007;;  Wasilewicz  et  al.  2010;;  Jiang  et  al.  2006;;  Hennig  et  al.  2005)  The  knockdown  of  
5LOX  gene   induce  cell  death  and  5LOX   inhibitors  have  been  demonstrated   to   induce  
apoptotic  death  in  various  cancer  cells  (Avis  et  al.  2001;;  Sarveswaran  et  al.  2011;;  G.-­X.  
et  al.  2015).    Elevated  levels  of  5LOX  in  the  plasma  of  patients  at  the  late  stages  of  breast  
cancer  have  been   recently   reported   (Kumar  et  al.  2016).  These  observations  and   the  
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findings  of  the  present  study  suggest  the  properties  of  5LOX  as  a  potential    prognostic  
biomarker  for  breast  cancer.  
Copine  3  as  prospective  biomarker  
Using  proteomic  and  genomic  approaches  Copine  3  was  previously  identified  as  potential  
biomarker  for  breast  cancer.  The  levels  of  this  protein  was  found  to  be  up-­regulated  in  
WBCs   of   breast   cancer   patients.   Validation   of   these   results   using   RT-­qPCR   showed  
downregulation  of  Copine  3  on  mRNA  levels  (Table  10.1)  (Mani,  PhD  thesis,  University  
of  Essex,  2015).  To  further  verify  previously  reported  findings,  in  this  study  Western  blot  
and   IF   techniques  were   employed   to   study  differential   expression  of  Copine  3   in   two  
breast   cancer   cohorts   (primary   and  advanced)   and  healthy   donors.   The  Western  blot  
results  revealed  overexpression  of  Copine  3  in  the  advanced  cohort.  However,  in  almost  
50%  of   the  samples     Copine  3  was  not  detected.   In   the  primary  breast  cancer  cohort,  
Copine  3  levels  did  not  change  when  compared  to  healthy  donors.  Furthermore,  the  levels  
of  this  protein  differ  within  the  same  cohorts.  Due  to  this  fact,  the  levels  of  Copine  3  was  
not  measured  in  correlation  with  clinical  outcome  (e.g.  survival  and  therapy  response).  
The  data  from  IF,  shows  different  localisation  of  Copine  3  in  WBCs  sample  of  both  breast  
cancer   cohorts   (primary   and   advanced)   and   control,   healthy   donor   sample.   In  WBCs  
sample  of  healthy  donor  the  protein  appeared  to  be  present  mainly  in  nucleus  of  the  cell.  
Whereas   in   the   primary   and   advanced  WBCs   breast   cancer   samples   its   cytoplasmic  
localisation  can  be  observed.  In  the  sample  from  the  advance  cancer  patient,  the  intensity  
of  the  staining  for  Copine  3  seems  to  be  higher  than  in  healthy  donor  and  primary  patient.  
Based  on  these  observations  we  conclude  that  due  to  the  lack  of  consistency  in  the  data  
obtained  for  Copine  3  levels  in  WBCs,  this  protein  is  unlikely  to  be  a  suitable  biomarker  
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for  breast  cancer.  However,  Copine  3  still   remains  an   interesting  molecule   to  study   in  
relation  to  mechanisms  of  breast  tumorigenesis.  
Copine  3  is  a  member  of  Ca++  dependent  lipid-­binding  protein  family,  which  in  response  
to  increase  in  intracellular  Ca++    translocate  to  plasma  membrane  where  they  interact  with  
the  range  of  cell  signalling  proteins  (Perestenko  et  al.  2010).  One  of  the  interacting  partner  
of  Copine  3  in  breast  cancer  tumour  is  ErbB2  protein.  It  was  suggested  that  Copine  3  is  
involved  in    ErbB2-­  dependent  cancer  cell  motility  because    breast  cancer  cells  decrease  
in  ErbB2  dependent  wound  healing   following  Copine  3  knock  down  (C.  Heinrich  et  al.  
2010).  
Cancer   cells   proliferation   and   apoptosis   depend   of   intracellular   Ca++   concentration.  
Furthermore,   an   elevation   of   intracellular   Ca++   concentration   is   also   an   important  
requirement  for  the  function  of  immune  cells  for  the  elimination  of  their  target  pathogens  
and   cancer   cells   (Schwarz   et   al.   2013).   These   observation   and   the   finding   from   the  
present  study  suggest  that  increased  WBCs  levels  of  Copine  3  in  immune  cells  of  cancer  
patients  might  be  attributed   to   the  accumulation  of  Ca++   in   these  cells  with   the  aim   to  
eliminate  cancer  cells.  
Comparison   of   the   biomarker   properties   of   Serpin   B1,   Lipocalin   2,   Copine   3,  
Integrin  a4  and  5-­Lipoxygenase:  Conclusions  
The  aim  of  this  investigation  was  to  identify,  validate  and  assess  the  biomarker  potential  
of  five  proteins  differentially  expressed  in  WBCs  of  patients  with  primary  and  advanced  
breast  cancer.  The  results  of  the  assessment  of  these  proteins  are  summarised  in  Table  
10.2.  We  conclude  that  despite  the  promise  these  proteins  initially  showed,  not  all  of  them  
passed  more  rigorous  validation  tests  for  different  clinical  utilities  in  breast  cancer.  Due  
to  time  constraints  it  was  also  not  possible  to  characterise  all  five  proteins  to  the  same  
267  
  
extent.  Since  levels  of  Serpin  B1,  Lipocalin  2  and  Integrin  a4  change  in  the  BRCA  cohort  
in  comparison  with  HD,   they  may  serve  as  potential  biomarkers   for  early  diagnosis  of  
breast  cancer  (   individually  or  in  a  panel).  The  increase  in  the  levels  of  Serpin  B1  and  
Lipocalin  2  in  the  ABC  cohort  in  comparison  with  the  BRCA  cohort  suggests  that  these  
proteins  can  be  used  as  biomarkers  of  disease  progression.  Furthermore,  lower  levels  of  
Serpin  B1  in  the  beginning  of  both  chemotherapy  and  endocrine  treatment  correlate  with  
complete  response  to  treatment  received.  The  lower  initial  levels  of  Lipocalin  2  can  predict  
favourable  response  to  chemotherapy  and  endocrine  treatment  received.  These  results  
suggest  their  utility  as  predictive  biomarkers.  
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Table  10.2  The  summary  of  the  characteristics  of  five  WBC  biomarkers  (Serpin  B1,  
Lipocalin  2,  Copine  3,  Integrin  a4  and  5-­Lipoxygenase).  Levels  of  the  proteins    
in  BRCA  and  ABC  cohorts  are  presented  in  comparison  with  the  HD  cohort.  Red  coloured  
cells  indicate  over-­expression;;  green  indicates  under-­expression.  Increased  intensity  of  
the  colours  reflects  the  increased  levels  of  the  protein.    
Adapted  from  J.  Mani  (  Mani,  PhD  thesis,  University  of  Essex,  2015).    
Keys:  BRCA  –  patients  with  primary  breast  cancer;;  ABC  –  patients  with  advanced  breast  
cancer;;  HD  –  healthy  donors;;  N.D.  –  not  determined  
                      




















Serpin  B1   Neutrophils   Yes   Yes   Yes   No  
Copine  3  
(CPNE3)  
N.D   No   Yes   N.D   N.D  
Integrin  a4  
(ITGA4)  
T-­cells   Yes   Yes   No   N.D  
Lipocalin  2  
(LCN2)  




N.D.   No   No   N.D   N.D  
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Utility  of  anti-­BORIS  autoantibody  in  the  plasma  of  breast  cancer  patients
Early  detection  of  breast  cancer  offers  the  patients  greater  chance  of  cure.  In  the  present  
study,   the   presence   of   anti-­BORIS   autoantibody   was   assessed   in   plasma   of   primary  
breast  cancer  cohort  to  assess  whether  it  can  be  used  clinically  as  diagnostic  marker  of  
the   disease.   In   this   experiment,   the   quantitative   analysis   of   BORIS   expression   using  
ELISA  was  applied.  As  the  antigen,  the  lysate  from  293T  cells  transfected  with  pCMV6  
BORIS  and  overexpressing  BORIS  protein  was  used.  The  reason  to  use  overexpressed  
protein   instead  of   the   recombinant  was   that   it   creates   a  model   to   study   the   antibody-­
antigen  interaction  in  more  biologically  natural  way.    The  plasma  samples  from  primary  
breast  cancer  patients  showed  higher  absorbance  when  compared   to  healthy  donors,  
which   was   similar   to   the   control   (secondary   antibody   only).   The   obtained   results  
demonstrate   that  using  ELISA  assay   the  anti-­BORIS  autoantibody  can  be  detected   in  
plasma  of  primary  breast  cancer  patients  and  not  in  healthy  donors.  Knowing,  that  BORIS  
and  CTCF  share  a  similar  zinc  finger  domain  and  therefore  can  potentially  cross-­react,  to  
prove   that   the  detected  signal   is  specific   to  BORIS  we  analysed  the  presence  of  anti-­
CTCF  autoantibodies   in   the  same  plasma  samples.  Data  generated   in  our  experiment  
indicate  cross-­reactivity  therefore  in  the  future  the  generation  of  mutant  BORIS  construct  
lacking  ZF  domain  will  be  required  to  improve  reliability  of  these  experiments.    
Potential   application   of   BORIS   as   a   biomarker   of   prostate   cancer   in   urinary  
sediments  and  exosomes.  
BORIS  is  a  member  of  the  cancer-­testis  antigen  (CTA)  family  that  is  encoded  by  genes  
that  are  normally  expressed  only  in  germ  line,  but  are  also  expressed  in  various  tumours.  
CTA  represent  similarity  between  the  processes  of  spermatogenesis  and  tumorigenesis  
(Wang  et  al.  2016).  Aberrant  BORIS  expression   is   reported   in  several  cancers  and   is  
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required  for  the  proliferation  of  the  malignant  cells  (Dougherty  et  al.  2008;;  Mkrtichyan  et  
al.  2011;;  Gaykalova  et  al.  2012;;  Tiffen  et  al.  2013).  Furthermore,  BORIS  expression  is  
detected  in  the  leukocytes  of  the  breast  cancer  patients,  suggesting  a  potential  clinical  
significance  of  BORIS  as  a  marker  of  tumorigenesis  (D’Arcy  et  al.  2006).    
According  to  reported  findings,  BORIS    has  23  mRNA  isoforms  variants  classified  by  6  
subfamilies  and  encoding  17  different  peptides  (Pugacheva  et  al.  2010).  The  expression  
of   the   isoform  variants  of  BORIS  appears   to  differ  between   the  cancers  (Asano  et  al.  
2016;;  Yoon  et  al.  2016).    
Expression  of  BORIS   has   also   been   reported   in   prostate   tumours   indicating   potential  
diagnostic  application  of  the  protein  as  a  biomarker  of  prostate  cancer.  Furthermore,  the  
ability  of  BORIS  to  activate  the  AR  gene  is  described  as  the  mechanism    for  the  growth  
and  development  of  prostate  tumours  (Cheema  et  al.  2014).    
Based  on    potential  clinical  significance  of  BORIS  in  prostate  tumour  tissue,  in  the  present  
study  the  presence  of  BORIS  mRNA  in  urinary  sediment  and  exosomes  of  67  prostate  
cancer  patients  was  evaluated.  The  obtained  data  indicate  high  BORIS  expression  levels  
in  the  urine  sediment  from  a  patients  with  advanced  prostate  cancer.  These  results  are  
consistent   with   the   previously   reported   findings   demonstrating   positive   correlation  
between  BORIS  protein  expression   in  prostate   tumour  and   the  aggressiveness  of   the  
disease  (Cheema  et  al.  2014).  Elevated  BORIS  mRNA  levels,  which  were  30  folds  higher  
than  in  the  negative  control,  were  also  detected  in  the  group  of  patients  with  intermediate  
risk  (PSA>10).    
The  qPCR  data  for  the  exosomal  BORIS  mRNA  using    set  of  primers  encompassing  1–2  
exon  boundaries  revealed  that  BORIS  present  at  its  highest  in  the  sample  from  a  patient  
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with  the  advanced  prostate  cancer.  Two  other  groups  that  display  high  BORIS  levels  were  
intermediate  (PSA>10)  and  high  risk  (PSA<100)  groups.    
The  results  from  qPCR  analysing  BORIS  mRNA  in  urinary  exosomes  using  set  of  primers  
encompassing   3–4   exon   boundaries   showed   high   levels   of   BORIS   in   the   groups   of  
patients  with  intermediate  (PSA<20),  high  (PSA>20)  and  advanced  disease.    
In  conclusion  the  data  presented  here  indicate  that  BORIS  present  at  its  highest  in  urine  
sediment   and   urinary   exosomes   of   patients  with   advanced   PCa   and   therefore   has   a  
potential  as  a  PCa  urine  biomarker  of  the  aggressiveness  of  the  disease.  
Several   promising   RNA-­based   urine   PCa   biomarkers   are   described   in   the   literature.  
However  only  PCA3  is  FDA  approved  and  commercially  available  diagnostic  test  to  be  
used  in  clinical  settings.  However,  it  is  not  routinely  used  in  the  hospitals  as  the  accuracy  
of  the  test  is  not  significant  enough  to  warrant  a  biopsy  (Mengual  et  al.  2016).  
To   improve   the  diagnostic  accuracy  of   the  disease,  many  studies  now   focus  panel  of  
biomarkers  and  prove  that  combined  multiple  markers  outperform  the  use  of  the  single  
marker   (Laxman   et   al.   2008;;   Mengual   et   al.   2014;;   Rigau   et   al.   2010).   Given   the  
heterogeneity  of  PCa,  the  use  of  the  multiple  markers  is  a  reasonable  solution  to  improve  
current  diagnostic  limitations  of  the  disease.      
Conclusion  for  all  aims  
Aim  1  
The  main   aim   of   the   presented   study  was   to   assess   the   biomarker   properties   of   five  
proteins:  Serpin  B1,  Lipocalin  2,  Copine  3,  Integrin  a4  and  5LOX  using  Western  blot,  IF,  
flow  cytometry  and  ELISA  techniques.  In  the  results,  significantly  higher  levels  of  Serpin  
B1  and  Lipocalin  2,  and  lower  levels  of  Integrin  a4  were  observed  in  WBCs  of  the  BRCA  
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cohort   compared   to   healthy   donors   suggesting   their   utility   as   early   breast   cancer  
biomarkers.  Furthermore,  levels  of  Serpin  B1  and  Lipocalin  2  increase  and  Integrin  a4  
decreased   as   the   disease   advanced,   indicating   their   utility   as   biomarkers   of   poor  
prognosis.  
Aim  2  
In   the   secondary   aim   of   the   study,   the   utility   of   BORIS   as   diagnostic   marker   was  
investigated  in  plasma  of  breast  cancer  patients  and  urinary  sediment  and  exosomes  of  
prostate   cancer   patients.   In   the   result,   the   presence   of   BORIS   was   demonstrated   in  
plasma  of  breast  cancer  patients.  Furthermore,  the  highest  levels  of  BORIS  mRNA  were  
detected  in  urine  of  prostate  cancer  patient  with  the  advanced  disease.  Suggesting,  the  
potential   of   the   BORIS   for   breast   cancer   diagnosis   and   its   utility   for   prediction   of   the  
aggressiveness  in  prostate  cancer.    
Future  work  
Given  that  currently  there  are  no  ideal  biomarkers  available  for  diagnosis,  prognosis  and  
treatment  monitoring   of   breast   cancer,   the   quest   to   identify   biomarkers   for   the   above  
purposes   continues.   In   the   complex   disease   such   as   cancer   a   single   biomarker   only  
represents   a   part   of   the   disease   pathogenesis.   Therefore,   the   use   of   a   panel   of  
biomarkers  increase  sensitivity  and  specificity  of  the  test.  In  the  present  study,  the  panel  
of  differentially  expressed  WBCs  based  biomarkers  was  validated.    
In  order  for  the  most  promising  biomarkers  to  be  applied  in  the  clinical  setting  a  series  of  
human  studies  must  be  conducted  (phase  1-­4  trials).  During  phase  1  (exploratory  phase)  
of   clinical   trials   the   diagnostic   accuracy,   sensitivity   and   specificity   of   a   biomarker   is  
determined   from   the   receiver   operating   characteristic   (ROC)   curve.   ROC   is   used   to  
determine  appropriate  cut-­off  points.  During  phase  2  (challenge  phase)  the  same  group  
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of  patients  are  traditionally  used  as  in  phase  1,  but  the  given  biomarker  is  assessed  using  
the  cut-­off  points  determined  from  the  phase  1  trials.  The  third  phase  aims  to  assess  the  
performance   of   the   biomarker   in   the   target   population   across   different   geographical  
regions.  At  this  stage  the  diagnostic  value  of  the  biomarker  has  to  be  evaluated  by  several  
independent  laboratories.  Phase  4  (outcome  phase)  assesses  the  utility  of  the  biomarker  
with   regard   to   the   long-­term   health   outcome   of   patients   following   clinical   acceptance  
and/or  commercial  availability  (Rifai  et  al.  2006).          
In  addition,  clinical  assessment  of  the  protein  assay  will  need  to  be  applied  to  determine  
whether  lifestyle  factors  (e.g.  diet,  smoking,  obesity,  alcohol  intake,  exercise)  or  the  use  
of  certain  medication  influence  the  change  in  biomarker  concentration  (Rifai  et  al.  2006).    
Since  levels  of  Serpin  B1,  Lipocalin  2  and  Integrin  a4  were  significantly  altered  in  WBCs  
of  the  BRCA  cohort  compared  to  healthy  individuals,  their  utility  as  early  breast  cancer  
biomarkers   should   be   tested   in   the   cohort   of   donors  which   include   the  pre-­diagnostic  
samples  to  allow  an  unbiased  validation  approach.  Usually  diagnostic  biomarker  studies  
utilise  samples  collected  after  diagnosis,  hence  the  results  could  be  affected  by  late-­stage  
response  to  cancer.  One  of  the  examples  of  the  current  study  using  this  approach  is  the  
assessment  of  plasma  CA  125  ability  to  detect  ovarian  cancer  (Menon  et  al.  2014).  
Selected  assays  for  optimisation  of  WBCs  detection  from  whole  blood  
Immunohistological  method.  Whole   blood   smears   from   breast   cancer   patients   and  
control   group   will   be   immunostained   using   the   target   biomarker-­specufic   monoclonal  
antibodies.  This  assay  provides  information  about  cell-­sub-­populations  and  phenotype  of  
biomarker-­positive  cells.  The  disadvantage  of   this  method   is   that   it  may  not  be  easily  
adapted   for   clinical   practice   due   to   it   slow   throughput.   Nevertheless   such   cell-­based  
techniques  are  preferred  by  some  diagnostic  companies  (e.g.  DakoCytomation).  
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Immunofluorometric   method.   A   flow   cytometry   approach   can   be   applied   to   detect  
biomarkers  in  whole  blood.  The  assay  has  an  advantage  of  being  high  throughput  and  
sensitive,  however,  this  assay  system  would  require  rapid  processing  of  fresh  samples  
and  would  not  be  applicable   to   frozen  samples.  The  protocol   for  such  procedures  are  
widely   available   and   their   potential   utility   has   been   demonstrated   in   the   current  
investigation  http://www.chemicon.com/resource/ANT101/a2C.asp  
ELISA     Detection   of   biomarker   in   whole   blood   using   an   ELISA   format   has   a   clinical  
advantage   for   high   throughput   test.   Sandwich   ELISA   is   a   preferred   option   in   clinical  
immunology  and  commercial  kits  are  widely  available  (JOHNSTONE,  A.  THORPE  1987;;  
Kemeny  &  Challacombe  1988).  They  were  used  in  this  investigation  with  varied  results.  
Since  this  method  detects  solubilised  antigens  from  purified  WBCs,  it  will  be  important  to  
further  optimise  the  protocols   for  extraction  of   the  antigen   from  WBCs.  The  alternative  
method   is   to   solubilise   the  whole   blood;;   in   this   case   frozen   samples   can   be   used.   If  
commercial  kits  are  not  available,  the  ELISA  kit  will  need  to  be  developed  in  house  or  in  
collaboration  with  commercial  companies      
In  addition,  in  the  future  it  would  be  interesting  to  investigate  the  changes  in  the  functions  
of   WBCs.   This   could   be   done   by   utilising   primary   breast   cancer   tissue   and   WBCs  
samples.  The  extract  from  tumour  tissue  could  be  applied  to  WBCs  to  induce  changes  
related  to  cancer.  To  study  these  changes  migration,  apoptosis,  survival  assays  could  be  
used.  Furthermore,  the  protein  profile  of  the  components  of  the  tissue  supernatant  could  
be  determined  to  identify  molecules  responsible  for  the  induction  of  WBCs.    
In  addition,  functional  studies  on  the  deletion  of  identified  WBC-­based  protein  candidate  
biomarkers  maybe  useful  to  explain  molecular  basis  by  which  differential  expression  of  
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